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ABSTRACT 
Background and research questions 
The Dyspnoea-12 (D-12) is a short questionnaire that consists of 12 items relevant to 
assessing dyspnoea in people with a variety of cardiopulmonary diseases. It measures 
the severity of dyspnoea in terms of the quality of sensation and the emotional 
response that the dyspnoea evokes. Each item is rated ‘none’ (score = 0), ‘mild’ 
(score = 1), ‘moderate’ (score = 2) or ‘severe’ (score = 3). The total scores of the D-
12 range from 0 to 36, with higher scores representing greater severity of dyspnoea. 
The D-12 has been shown to be reliable and valid in people with chronic obstructive 
pulmonary disease (COPD), interstitial lung disease, asthma and pulmonary 
hypertension. 
In Saudi nationals, this program of research was designed to address the following 
research questions: 
1. Is the Arabic version of the D-12 reliable and valid in Saudi nationals with 
COPD? 
2. Do the quality and emotional response components of the D-12 differ between 
periods of an AECOPD and periods of clinical stability?  
3. Do physical activity and sedentary behaviour in males with COPD differ from 
those of healthy controls? 
4. Are the quality and emotional response components of the D-12 associated 
with physical activity and sedentary behaviour in males with COPD?  
Study 1 (addressing the first research question) 
Methods 
This study was a cross-sectional study comprised of two parts (A and B). Part A 
involved the translation of the D-12 into the Arabic language, through a process of 
forward-backward translation. The Arabic version developed in part A was 
administered to five participants with COPD to test whether it was easily understood 
after which a final Arabic version was produced. In part B, participants completed 
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the D-12, the COPD Assessment Test (CAT), the Chronic Respiratory Disease 
Questionnaire (CRDQ), the six-minute walk test (6MWT) and spirometric measures 
of lung function. The participants in part B repeated the D-12 two weeks after the 
first administration. An intraclass correlation coefficient (ICC) was used to assess 
test–retest reliability in the entire sample and also with participants grouped 
according to their disease severity. The weighted kappa coefficient was used to 
determine the concordance of the responses between the first and second 
administrations of the D-12. The ICC was also used to assess test-retest reliability of 
the D-12 for participants grouped according to their disease severity. Pearson’s 
correlation coefficients were performed to assess construct validity of the D-12 
scores by examining the strength of associations between the D-12 and the CAT, 
CRDQ, six-minute walk distance (6MWD) and post-bronchodilator forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC). The total scores for 
the D-12 with participants grouped according to their GOLD grades were compared 
using analysis of variance. All data are expressed as mean ± standard deviation (SD) 
unless otherwise stated. 
Results 
In part A, there were no differences between the back-translated version of the D-12 
and the original English version. Five participants (four males, 80%) aged 65.0 ± 
10.0 years with a FEV1 of 51 ± 19% predicted reported that all items of the Arabic 
version of the D-12 were easily understood and no comments were reported by the 
participants. For part B, data were collected for 40 participants (33 males, 83%) aged 
63.0 ± 9.0 years with a FEV1 % of 47 ± 16% predicted. The ICC for the Arabic 
version of the D-12 over the two administrations was 0.94 (p = 0.01), and the 
weighted kappa value was 0.83. The ICC for the reliability of the D-12 score for the 
participants grouped according to their disease severity was 0.90 for moderate 
disease, 0.97 for severe disease and 0.85 for very severe disease (all p < 0.01).  
The mean scores for 10 of the D-12 items were no different between the two 
administrations and the mean scores of the remaining two D-12 items differed by less 
than one point. Strong associations were demonstrated between the: (i) total score for 
the D-12 and the CAT, (ii) quality component of the D-12 and the CAT and (iii) 
emotional response component of the D-12 and the emotional function domain of the 
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CRDQ (r ≥ 0.6, all p < 0.01). Associations of weak to moderate strength were 
demonstrated between the (i) total score of the D-12 and both 6MWD and FEV1, (ii) 
quality component of the D-12 and the dyspnoea domain of the CRDQ, FEV1, FVC 
and 6MWD and (iii) emotional response component of the D-12 and all domains of 
the CRDQ and CAT (r ≥ 0.31, all p < 0.05). The total D-12 score differed between 
participants with moderate and very severe COPD (mean difference = 4.6 ± 4.9; p < 
0.01). 
Discussion and conclusion 
This study successfully translated the D-12 to the Arabic language. Similar results 
were found in a study that translated the D-12 into Korean. The total score for the D-
12 was reliable over a two-week period, as demonstrated by the high values of ICC 
and weighted kappa. In addition, the scores obtained on the D-12 for people who 
were grouped according to disease severity were reliable, as indicated by the ICC 
values ≥ 0.85 for those with moderate to very severe COPD. In the present study, the 
ICC value was similar to those values reported in earlier work in which the D-12 was 
administered twice over the same period in populations with COPD (ICC = 0.90), 
asthma (r = 0.93 to 0.96) and interstitial lung disease (ICC = 0.94). The Arabic 
version of the D-12 is valid in Saudi nationals with COPD, as strong associations 
were reported between the D-12 components and its total score with the scores of 
questionnaire-based assessments. The differences in the total score of the D-12 
between people with moderate and very severe COPD supports the validity of the D-
12. The weak to moderate associations between the total score of the D-12 and both 
the 6MWD and the FEV1 is consistent with previous studies undertaken in people 
with COPD 
 
and asthma,
 
and indicates that dyspnoea worsens with increased 
functional limitation and disease severity. The D-12 is likely to be a useful tool for 
assessing dyspnoea in the clinical and research setting. 
Study 2 (addressing the second research question) 
Methods 
This was a longitudinal observational study that included participants who were 
admitted to hospital with an AECOPD. Within 24 hours of hospitalisation, all 
participants completed a set of questionnaires that comprised the D-12, CAT and 
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CRDQ. This set of questionnaires was repeated every 14 days until 98 days 
following hospital admission. This resulted in a total of eight administrations for 
each questionnaire. Each time the questionnaires were completed after the first 
administration in hospital, the participants were asked a standard question to 
determine whether or not they had experienced a re-exacerbation. The standard 
question asked was: ‘Has there been any change in your symptoms over the last two 
weeks that required you to increase your medication use or to visit a doctor or the 
hospital?’ To characterise the participants, measures of spirometry were obtained at 
the time they were discharged from the hospital. 
Changes were explored in both the quality and emotional response components of 
the D-12 between the first administration in hospital and the time period during the 
98 day follow-up when the participants were deemed to have returned to clinical 
stability. For this purpose, clinical stability was defined as being when the magnitude 
of change in the dyspnoea domain of the CRDQ between consecutive administrations 
was neither statistically significant nor clinically important (i.e. change was < 0.5 
points per item [ppi]).  
Effect sizes were calculated to facilitate comparison of the magnitude of the change 
in the score of each questionnaire between first administration in hospital and the 
time when participants were deemed to have returned to clinical stability. The effect 
size for each questionnaire was calculated as the mean difference in scores reported 
during the first administration in hospital and clinical stability, divided by the 
standard deviation obtained at the first administration in hospital. 
During the first administration in hospital and also during the period when 
participants had returned to clinical stability, scores of the total, quality and 
emotional response components the D-12 were compared between participants 
grouped according to their disease severity. All data are expressed as mean ± SD 
unless otherwise stated.  
Results 
Twenty-nine participants (25 males, 86%) aged 64.9 ± 3.9 years with a FEV1 of 44 ± 
11% predicted completed the study. The group met the criteria for clinical stability 
70 days after the first administration in hospital. This was because the scores in the 
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dyspnoea domain of the CRDQ completed 70, 84 and 98 days after the first 
administration in hospital did not differ statistically and the magnitude of difference 
was below the threshold for clinical importance (mean scores 3.7 ± 0.6, 3.7 ± 0.7 and 
3.7 ± 0.7 ppi, respectively, p > 0.05). Compared with the scores reported during the 
first administration in hospital, when the group had returned to clinical stability there 
was a decrease (i.e. improvement) in the total score of the D-12 (26.3 ± 3.0 versus 
20.1 ± 2.9; p < 0.001), the quality component (15.3 ± 2.2 versus 11.8 ± 1.5; p < 
0.001), and the emotional response (11.0 ± 2.0 versus 8.3 ± 1.6; p < 0.001). 
Similarly, compared with the scores reported during the first administration in 
hospital, when the group had returned to clinical stability there was an increase (i.e. 
improvement) in the scores for the dyspnoea domain of the CRDQ (2.7 ± 0.4 versus 
3.7 ± 0.7; p < 0.001) and a decrease (i.e. improvement) in the score for the CAT 
(26.2 ± 2.0 versus 20.2 ± 3.9; p < 0.001).  
Effects sizes for the change in scores reported during the first administration in 
hospital and when the group had returned to clinical stability were larger for the CAT 
(effect size = 3.0) compared with the dyspnoea domain of the CRDQ (effect size = 
2.5), total score for the D-12 (effect size 2.1) as well as the quality component (effect 
size = 1.6) and emotional response component (effect size = 1.7).  
During the first administration in hospital, the total D-12 score differed between 
participants with moderate and very severe COPD (mean difference = 5.3 ± 1.4, p = 
0.006), and between participants with severe and very severe COPD (mean 
difference = 4.2 ± 3.4, p = 0.006). Similarly, the score of the emotional response 
component of the D-12 differed between participants with moderate and very severe 
COPD (mean difference = 3.0 ± 1.1, p = 0.002), and between participants with severe 
and very severe COPD (mean difference = 1.8 ± 0.9, p = 0.019).  
During the period when participants had returned to clinical stability, the total D-12 
score differed between participants with moderate and very severe COPD (mean 
difference = 4.4 ± 2.0, p = 0.037). Similarly, the score of the emotional response 
component of the D-12 differed between participants with moderate and very severe 
COPD (mean difference = 2.6 ± 1.8, p = 0.011). 
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 Discussion and conclusions 
This study demonstrated that overall, following hospitalisation with an AECOPD, 
recovery, in terms of no further improvement in dyspnoea during activities of daily 
living, can take up to 70 days. Scores obtained from all questionnaires improved 
significantly between when participants were hospitalised with an AECOPD and 
when they had reached a period of clinical stability. The large mean differences 
coupled with the small variability in the magnitude of these differences accounted for 
the large effect sizes demonstrated in this study. The questionnaire that was most 
responsive to change was the CAT, which demonstrated an effect size of 3.5. The 
most likely reason that the responsiveness of the CAT was greater than that of the D-
12 is that the CAT comprises items related to a broad range of factors that are likely 
to be adversely impacted during an AECOPD, such as sleep quality and energy 
levels, rather than just dyspnoea. The total score of the D-12 and the emotional 
response component of the D-12 discriminated between people with COPD grouped 
according to their disease severity during the first administration in hospital and 
when they had returned to clinical stability. This finding supports the validation of 
the D-12 in people with stable COPD. Given that the effect size for the D-12 was 
similar to the effect size for the dyspnoea domain of the CRDQ (effect size 2.1 
versus 2.5) it is possible that the D-12 will demonstrate similar responsiveness to the 
CRDQ following interventions that aim to ameliorate dyspnoea such as 
bronchodilators and pulmonary rehabilitation.  
Study 3 (addressing the third and fourth research questions) 
Methods 
This study was a cross-sectional, observational study that included males with COPD 
and healthy controls. Participants were instructed to wear the StepWatch
TM
 Activity 
Monitor (SAM) during their waking hours for eight consecutive days. The SAM 
records the number of steps taken and provides data in one-minute epochs. Measures 
of spirometry were obtained for both groups. The 6MWT was completed by 
participants with COPD. Step counts derived from the SAM were exported to 
Microsoft Excel to derive the time spent in two major domains: (i) walking based 
activity (defined as ≥ 1 step/minute [steps/min]) and (ii) sedentary behaviour 
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(defined as 0 steps/min). Thereafter, walking based activity was divided into cadence 
bands suggested by the National Health and Nutrition Examination Survey study as 
follows: 1 to 19, 20 to 39, 40 to 59, 60 to 79, 80 to 99, 100 to 119 and ≥ 120 
steps/min. Data pertaining to the time spent undertaking walking based activity and 
sedentary behaviour were averaged over the duration of the wear period (one week) 
and were compared between groups. The duration of every bout of walking based 
activity and every bout of sedentary behaviour recorded over the duration of the wear 
period were averaged and were compared between groups. For each participant, the 
peak (the one-minute epoch during which the highest cadence was recorded) and 
average 30-minute peak cadence (the average of the 30 individual one-minute 
epochs, during which the highest cadences were recorded, not necessarily 
consecutively) were obtained for each day over the entire wear period and were 
averaged. Thereafter, the following variables were compared between groups: (i) the 
peak cadence and, (ii) the average 30-minute peak cadence. The proportion of 
participants with COPD and healthy controls who met the threshold of 7,000 steps 
per day over five or more days, as suggested by the guidelines of American College 
of Sports and Medicine were compared. In participants with COPD, associations 
were examined between the scores of quality and emotional response components of 
the D-12 with time spent in walking based activity and sedentary behaviour. 
Results 
Thirty males with COPD (age 62.0 ± 5.0 years; FEV1 46 ± 15% predicted) and 29 
gender-matched healthy controls (age 63.0 ± 4.3 years; FEV1 91 ± 5% predicted) 
completed the study. No differences were seen between participants with COPD and 
healthy controls in the number of days of SAM data (6.8 ± 0.5 days [COPD 
participants] versus 6.9 ± 0.3 days [healthy participants]; p = 0.36), or in the average 
daily wear time (13.4 ± 0.8 hours/day [COPD participants] versus 13.5 ± 0.5 
hours/day [healthy participants]; p = 0.40). 
Compared with the healthy controls, participants with COPD spent a lower 
percentage of their waking hours in walking based activity (37 ± 7% versus 22 ± 8%; 
p < 0.001) and a higher percentage of time in sedentary behaviour (63 ± 6% versus 
78 ± 8%; p < 0.001).  This difference was equivalent to 131 ± 105 minutes fewer 
minutes and 109 ± 103 additional minutes a day for walking based activity and 
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sedentary behaviour, respectively. Compared with the healthy controls, participants 
with COPD spent a lower percentage and fewer minutes accumulating walking based 
activity in all cadence bands except those ≥ 100 steps/min, p > 0.05. 
Compared with the healthy controls, participants with COPD accumulated time in 
walking based activity in shorter bouts (6 ± 1 versus 3 ± 1 min/day; p < 0.01) and 
sedentary behaviour in longer bouts (9 ± 2 versus 12 ± 2 min/day; p < 0.01). The 
peak cadence was lower in participants with COPD than healthy controls (76 ± 13 
versus 93 ± 13 steps/min; p < 0.01). The average 30-minute peak cadence was lower 
in participants with COPD compared with healthy controls (47 ± 11 versus 62 ± 9 
steps/min; p < 0.01). Compared with healthy controls, the proportion of participants 
with COPD who met the criteria for participating in sufficient walking based activity 
(7,000 steps per day in five or more days) was lower (34 % versus 7%; p < 0.001). 
Moderate associations were demonstrated between the quality score of the D-12 and 
time spent in walking based activity (r ≥ -0.52, p < 0.01) and sedentary behaviour (r 
≥ 0.46, p < 0.01). Strong associations were observed between the emotional response 
score of the D-12 and time spent in walking based activity (r ≥ -0.63, p < 0.01) and 
sedentary behaviour (r ≥ 0.66, p < 0.01). 
Discussion and conclusion 
The findings of this study demonstrate that, compared to healthy controls, males with 
COPD spent less time in walking based activity and more time in sedentary 
behaviour. These findings correspond to previously reported work conducted in 
Belgium and Brazil. In the present study, males with COPD spent less time in 
cadence bands < 100 steps/min when compared with healthy controls. High cadences 
(≥ 100 steps/min) have been considered a threshold for moderate intensity physical 
activity in adults. However, neither males with COPD nor the healthy controls in this 
study participated in walking based activity at cadences ≥ 100 steps/min, which 
explains the lack of difference between them in these cadence bands. These findings 
suggest that males with COPD as well as healthy controls in Saudi Arabia may be at 
greater risk of developing chronic diseases, such as cardiovascular and metabolic 
diseases, as they do not spend time participating in daily moderate intensity physical 
activity Therefore, these findings suggest that awareness of the benefits of walking 
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based activity and physical activity needs to be promoted among the general public 
as well as people with COPD in Saudi Arabia.  
Compared to healthy controls, males with COPD accumulated time in walking based 
activity in shorter bouts and sedentary behaviour in longer bouts. It is likely that the 
exercise impairment in COPD impacts the way people distribute their time of activity 
over a day, with long bouts of sedentary behaviour and shorter bouts of walking 
based activity. These findings highlight the importance of educate people with 
COPD to spend longer duration in bouts of physical activity for the purpose of health 
benefits. The peak and average 30-minute cadence were lower in males with COPD 
compared to that observed in the healthy controls. This reduction in peak cadences of 
walking based activity in males with COPD may reflect their limitation of peak 
aerobic capacity. Compared to healthy controls, the proportion of males with COPD 
(7%) who accumulated ≥ 7,000 steps/day was lower than that observed in healthy 
controls (34%). These findings increase the importance of designing interventions 
that aim to increase daily steps in males with COPD to meet the recommended 
amount of physical activity necessary to confer health benefits.   
This study demonstrated associations of moderate strength between the quality 
component of the D-12 with the time spent in walking based activity (r ≥ -0.52) and 
sedentary behaviour (r ≥ 0.46). However, the emotional response component of D-12 
yielded somewhat stronger associations with the time accumulated in walking based 
activity (r ≥ -0.63) and sedentary behaviour (r ≥ 0.66). The associations demonstrated 
in this study extend the results reported in both Study 1 and Study 2 which pertain to 
the validity of the D-12 in people with COPD. This is the first study to examine and 
report the associations between the components of the D-12 and walking based 
activity and sedentary behaviour in males with COPD. The results of this study 
highlight the importance of targeting an intervention that aims to minimise the 
emotional response of dyspnoea, which may result in reducing the time spent in 
sedentary behaviour and optimising participation in daily physical activity. 
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CHAPTER 1  
INTRODUCTION 
This program of research focuses on the assessment of dyspnoea in people with 
chronic obstructive pulmonary disease (COPD) in Saudi Arabia. All studies were 
undertaken in Riyadh, Saudi Arabia. 
In Saudi Arabia, the prevalence of COPD was estimated at 2.4%,being more 
prevalent in males (3.5%) than females (1.0%) (1). This is similar to the prevalence 
reported for the Middle East (3.6%) (1). A Saudi study among smokers aged ≥ 40 
years found that 14.2% had COPD, similar to the prevalence in smoking populations 
in Turkey (18.1%) (2, 3).  The prevalence rate of COPD in Saudi Arabia is lower 
than that reported in many other countries: 26.1% in Austria (4), 24.0% the 
Netherlands (5), 20.8% in the Philippines (6), 16.2% in Sweden (7), 7.9% in 
Australia (8) and 8.2% in China (9). 
Smoking is the primary risk factor in the development of COPD (10). The smoking 
rate in the Saudi population is 28.0% among those aged ≥ 40 years, with a rate of 
39.0% in males and 7.0% in females (11). The prevalence of COPD is therefore 
expected to increase even further (2). Other risk factors in the development of COPD 
in Saudi Arabia include outdoor air pollution, desert dust, wars and childhood 
respiratory infections (12). 
Dyspnoea (breathlessness) is a term used to describe a sensation of breathing 
discomfort that comprises distinct sensations that vary in quality and intensity (13). 
For people with COPD, dyspnoea is often the primary symptom that limits daily 
activities and leads to a decrease in health-related quality of life (HRQoL) (10, 14). 
There are several methods used to measure an individual’s perception of dyspnoea in 
COPD. However, these measurement options are often unidimensional assessments 
and may not be available in Arabic with the result being that there is little work on 
the measurement of dyspnoea of people with COPD in Saudi Arabia.  
A plethora of tools for the measurement of dyspnoea exist and the majority of tools 
have been validated in COPD populations (15, 16). Measuring dyspnoea in people 
with COPD can be done using unidimensional tools, multidimensional tools, and 
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dyspnoea may be embedded within HRQoL questionnaires. The unidimensional 
tools can assess dyspnoea directly, using the modified Borg or visual analogue scales 
(17, 18), in people experiencing dyspnoea at rest or in response to different stimuli. 
Furthermore, the unidimensional tools can evaluate dyspnoea indirectly, using the 
Medical Research Council Questionnaire (19), by asking the respondent to report 
functional limitation resulting from dyspnoea. However, the unidimensional tools 
may not be adequate enough to capture the complexity of dyspnoea. The common 
multidimensional tools, such as the Baseline and the Transitional Dyspnoea Index, 
and the Pulmonary Functional Status and Dyspnoea Questionnaire—Modified 
version (20, 21), measure different activities that cannot be accomplished due to 
dyspnoea. Although multidimensional tools provide useful information, they do not 
measure dyspnoea components such as the emotional response to dyspnoea; they 
measure the impact of dyspnoea on activities. Using dyspnoea embedded within 
HRQoL questionnaires, like the Chronic Respiratory Disease Questionnaire (22), 
provides information about the impact of dyspnoea on HRQoL. This also means that 
they cannot quantity different components of dyspnoea. The Dyspnoea-12 
questionnaire (D-12) is a multidimensional tool that measures the severity of 
dyspnoea and considers both the quality of the sensation and the emotional response 
that it evokes (23). This questionnaire was derived following a literature search of 
the descriptors used to describe dyspnoea by people with cardiorespiratory diseases 
(23). Descriptions of the measurement of dyspnoea are provided in Chapter 2; 
Section 2.3.3. 
One of the overall purposes of this program of research was to provide clinicians and 
researchers working in Saudi Arabia with a simple and valid tool to measure 
dyspnoea in people with COPD. To achieve this purpose, the D-12 was translated 
into Arabic and the reliability and validity of this version was assessed. Further, data 
are reported which demonstrate the capacity of the D-12 to both change in response 
to a change in clinical status and discriminate between people with COPD grouped 
according to the severity of their condition. A second purpose of this program of 
research was to compare physical activity levels and the time spent in sedentary 
behaviour in Saudi nationals with COPD with healthy controls. This comparison is 
important as it will assist health professionals in Saudi Arabia to understand the 
lifestyle of their patients. In addition, data are reported which explore the 
Chapter 1: Introduction 
3 
associations between the D-12 and physical activity levels and sedentary behaviour 
in COPD. This provided further support for the validation of the D-12. It also 
assisted in determining to what extent physical activity and sedentary behaviour are 
influenced by dyspnoea in Saudis with COPD. The current chapter provides a 
rationale for the development of each research question. The significance and 
novelty of each component in the program of research are also discussed. 
1.1 Research aims 
In Saudi nationals, this program of research was designed to: (i) translate the D-12 
into the Arabic language and investigate the reliability and validity of an Arabic 
version of the D-12 in people with COPD; (ii) determine whether the quality and 
emotional response components of the D-12 differed between a period when people 
were hospitalised with an acute exacerbation of COPD (AECOPD) and when they 
had reached a period of clinical stability following hospital discharge; (iii) compare 
physical activity and sedentary behaviour in males with COPD with age and gender-
matched healthy controls and, (iv) report associations between the quality and 
emotional components of the D-12 with physical activity and sedentary behaviour in 
males with COPD.  
  
Chapter 1: Introduction 
4 
 
1.2 Research Aim 1 
To translate the D-12 into the Arabic language and investigate the reliability and 
validity of an Arabic version of the D-12 in people with COPD. 
1.2.1 Research hypotheses 
The primary hypothesis was: the D-12 will be reliable and valid in Saudi nationals 
with COPD. 
The secondary hypothesis was: the D-12 will be reliable in people with COPD 
grouped according to disease severity. 
1.2.2 Background 
For people with COPD, dyspnoea is often the most distressing symptom and main 
complaint when seeking medical assistance (24, 25). Dyspnoea refers to an 
uncomfortable and inappropriate sensation of breathing that results from the 
interaction of multiple physiological, psychological, social and environmental factors 
(13). In people with COPD, dyspnoea has been found to be a strong predictor for 
mortality (26). Similar to pain, the sensation of dyspnoea can be described in terms 
of its intensity, quality of the sensation and the emotional response to dyspnoea (27, 
28).  
The assessment of dyspnoea is usually focused on the severity or intensity of the 
sensation, and this is often evaluated using unidimensional assessment tools, such as 
the modified Borg scale (17) and the visual analogue scale (18). Currently, however, 
there is increased recognition of the importance of the quality of sensation (29-31). 
Specifically, it has been observed that the quality of dyspnoea varies between people 
with different cardiopulmonary diseases (32). For example, the descriptor ‘chest 
tightness’ is most frequently described by people with asthma (29, 32, 33), while the 
descriptors ‘increased work’ and ‘effort of breathing’ are more often used by people 
with COPD (29, 33, 34). These differences suggest that the sensations have different 
pathophysiological origins. For instance, in asthma, ‘chest tightness’ appears to result 
from bronchoconstriction (35).
 In contrast, in COPD, ‘increased work’ and ‘effort of 
Chapter 1: Introduction 
5 
breathing’ may refer to the deleterious effects of pulmonary hyperinflation, which 
serves to increase the elastic and threshold loads borne by the inspiratory muscles, 
thus reducing their mechanical advantage (36, 37). 
In addition to the differences in intensity and quality of the sensation, dyspnoea often 
evokes considerable emotional distress, such as feelings of anxiety and panic (38). 
These mood disturbances increase disability, functional impairment and reduce 
HRQoL (39). Given the complexity of dyspnoea, there is an interest in developing 
instruments that assess the intensity of dyspnoea as well as its quality and the 
emotional response to this sensation. Yorke et al (23) developed the D-12 to quantify 
these three components of dyspnoea. In people with COPD, the D-12 demonstrated 
good test–retest reliability (intra-class correlation coefficient [ICC] = 0.9, p < 0.001) 
and construct validity (23). Similar observations have been demonstrated in people 
with asthma, interstitial lung disease and pulmonary arterial hypertension (40-42). 
The D-12 is available in different languages, such as Korean and Japanese (43, 44). 
However, at the time this study was initiated, there was no Arabic version available. 
1.2.2.1 Significance and novelty of the research 
Increasing recognition that dyspnoea varies in terms of the severity, quality and 
emotional response that it evokes necessitates a valid and reliable method of 
assessing these components of the sensation. This study will be the first to translate 
the D-12 into the Arabic language and establish the reliability and validity of the D-
12 in the Arabic language. The Arabic language version of D-12 will facilitate a 
means by which clinicians and researchers can assess dyspnoea in both Saudi 
nationals with COPD, but also in any Arabic Gulf COPD population as these Gulf 
countries have a similar culture. This is an important step to promote the 
implementation of therapies in Arabic Gulf countries, including Saudi Arabia, such 
as pulmonary rehabilitation, which has achieved strong evidence for reducing 
dyspnoea in people with COPD (45). 
1.3 Research Aim 2 
To determine whether the quality and emotional response components of the D-12 
differed between a period when people were hospitalised with an AECOPD and 
when they had reached a period of clinical stability following hospital discharge. 
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1.3.1 Research hypotheses 
The primary hypothesis was that the quality and emotional response components of 
the D-12 will change between periods of an AECOPD and periods of clinical 
stability.  
The secondary hypothesis was that during an AECOPD and also a period of clinical 
stability, the quality and emotional response components of the D-12 will 
discriminate between people with COPD, grouped according to disease severity. 
1.3.2 Background 
In order to optimise the use of the D-12 in clinical practice, there is a need to 
demonstrate that it can change in response to an intervention or clinical event that 
changes dyspnoea. Simple, unidimensional tools that measure dyspnoea, such as the 
Borg scale and visual analogue scale, have been shown to change following 
interventions such as pulmonary rehabilitation, and long-acting bronchodilators, and 
clinical events such as an AECOPD (24, 46-48). At the beginning of this program of 
research, consideration was given to assessing changes in the quality and emotional 
response components of the D-12 in response to pulmonary rehabilitation or 
bronchodilator therapy. Although pulmonary rehabilitation is known to be effective 
in reducing dyspnoea in people with COPD (45), in Saudi Arabia, pulmonary 
rehabilitation is generally in its infancy (49) and is not widely available. The use of 
long-acting bronchodilator therapy was not considered to be appropriate as an 
intervention to change dyspnoea. This was because these medications are considered 
to be a standard component of care for people with COPD (10) and therefore, finding 
an adequate number of people who were naïve to these medications was deemed to 
be unrealistic in the time frame available to complete these studies. The use of short-
acting bronchodilator therapy was not considered to be appropriate as the effect of 
these medications on dyspnoea is inconsistent in people with COPD (50-52). An 
AECOPD is an event characterised by a sustained worsening of the respiratory 
symptoms of an individual, from the stable state and beyond normal day-to-day 
variations, that is acute at onset and necessitates a change in regular medication (10). 
In people with COPD, an increase in dyspnoea is often the reason for seeking 
medical attention during an AECOPD (25). Earlier work has shown that the changes 
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in dyspnoea during and following an AECOPD are large (24, 53). For example, 
Aaron et al (53) and Parker et al (24) assessed dyspnoea, using the dyspnoea domain 
of the Chronic Respiratory Disease Questionnaire (CRDQ), during and following a 
moderate to severe AECOPD. The authors showed a significant increase (i.e. 
improvement) of ≥ 1.3 points per item (ppi) in the score of the dyspnoea domain of 
the CRDQ following periods of an AECOPD. This magnitude of change in the score 
of the dyspnoea domain of the CRDQ following an AECOPD represents a large 
clinical improvement. Further, following an AECOPD, the dyspnoea domain of the 
CRDQ produced a large effect size (53). 
To date, no study has explored or reported the responsiveness of the D-12 to a 
change in clinical status that impacts on dyspnoea, such as hospitalisation for a 
severe AECOPD.  
1.3.2.1 Significance and novelty of the research 
The responsiveness of the D-12 to change in clinical status is unknown and therefore, 
this study will be the first to report whether the D-12 is responsive to a change in 
clinical status during a period of recovery following a severe AECOPD. Data 
demonstrating the capacity of the D-12 to change when dyspnoea changes is needed 
before the D-12 can be widely used to evaluate dyspnoea in clinical practice and 
research. The findings from this research will also determine which components 
(quality and/or emotional response) of dyspnoea are most affected during an 
AECOPD. If there is a difference in the responsiveness between these components 
this will be the first study to report such a finding. Furthermore, this study will report 
the responsiveness of other tools in this setting (i.e. the CRDQ and COPD 
Assessment Test [CAT]) and will therefore allow the responsiveness of the D-12 to 
be compared with these other questionnaires. The findings from this research will 
provide a basis on which clinicians and researchers can select the most responsive 
questionnaires to use in people with COPD. Finally, the results of this study will be 
the first to report data on the characteristics and pattern of recovery in Saudi 
nationals who are hospitalised with an AECOPD. This will provide insight regarding 
the expected time course of recovery and assist clinicians in providing patients and 
their families information about this.   
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1.4 Research Aim 3 
To compare physical activity and sedentary behaviour in people with COPD with age 
and gender-matched healthy controls. 
1.4.1 Research hypothesis 
The hypothesis was that physical activity and sedentary behaviour will be different 
between people with COPD and healthy controls. 
1.4.2 Background  
Guidelines from the United States of America recommend that adults need to 
participate in moderate to vigorous intensity physical activity (i.e. activities that 
require an energy expenditure ≥ 3 metabolic equivalent units [METs]) to confer 
health benefits (54). In adult populations, the health benefits of regular participation 
in moderate to vigorous intensity physical activity have been demonstrated to include 
reductions in the risk of cardiovascular and metabolic disease, weight loss, lowered 
blood pressure, greater insulin sensitivity as well as lower all-cause mortality (54).  
People with COPD perform very little physical activity (55, 56). Several studies have 
demonstrated that people with COPD participate in less physical activity when 
compared with healthy controls (55-57). Data pertaining to physical activity in 
people with COPD have demonstrated that, on average, the percentage of time 
people with COPD spent participating in physical activity, relative to healthy 
controls, was 57% (58). In people with COPD, participating in lower levels of 
physical activity has been associated with several factors (59). These factors include 
higher dyspnoea severity, greater disease severity and static lung hyperinflation, less 
autonomous motivation for exercise, lower exercise capacity, worse leg muscle 
function, using long term oxygen therapy, a higher number of exacerbations in the 
past year and greater feelings of depression (59).  
To date, most studies that have explored the health benefits of physical activity have 
focused on moderate and vigorous intensity physical activity. However, there is now 
increased recognition of the possible health benefits associated with accumulating 
time in light intensity physical activity such as reducing the risk of developing 
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cardiovascular disease and type-II diabetes (60, 61). This is likely to be particularly 
relevant to people with COPD given that they are often unable to participate in 
moderate or vigorous intensity physical activity due to intolerable dyspnoea (57).  
Although there are several methods available to quantify the intensity of physical 
activity undertaken during daily life, cadence (steps/minute) is a walking parameter 
that is considered a logical surrogate of intensity (62, 63). Several laboratory-based 
studies have reported increasing intensity with increasing cadence such that ≥100 
steps/minute seems to be a threshold equivalent to moderate to vigorous intensity 
physical activity (equivalent to ≥ 3 METs) in adults (62, 64-66). Investigators from 
the National Health and Nutrition Examination Survey proposed incremental cadence 
bands that range from 0 (i.e. sedentary) to  ≥ 120 steps/minute (i.e. vigorous 
intensity) to explore differences in the intensity of physical activity amongst the 
population of the United States of  America (67). Using these incremental bands in 
people with COPD will provide detailed information regarding their patterns of daily 
physical activity in terms of time accrued in different cadence bands.  
Sedentary behaviours are defined by activities or behaviours that require low energy 
expenditure (< 1.5 METs) throughout waking hours and undertaken in sitting or 
reclining postures (68). In the general adult population, excessive sedentary time has 
been associated with a greater risk for all-cause mortality, independent of time spent 
in moderate to vigorous physical activity (69). In people with COPD, besides 
participating in low levels of physical activity, a large amount of their waking hours 
are spent in sedentary behaviour. Compared to healthy controls, people with COPD 
spend around 40% more time of their waking hours in sitting and reclining postures 
(56, 70). In people with COPD, sedentary behaviour is associated with factors 
including lower exercise capacity, less autonomous motivation for exercise, a higher 
number of AECOPDs in the past year and using long term oxygen therapy (59). To 
date, little is known about the health consequences of sedentary behaviour in people 
with COPD. It is likely that the deleterious outcomes demonstrated in the general 
population including the risk of developing metabolic and cardiovascular diseases or 
dying prematurely also apply to people with COPD (56, 57).    
In addition to looking at the total time spent participating in physical activity and 
sedentary behaviour, there is increased recognition that the way people accumulate 
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time in these domains is also important. The guidelines of American College of 
Sports and Medicine suggest that physical activity be accumulated in bouts of ≥ 10 
minutes duration (54). For sedentary behaviour, it has been shown that regularly 
breaking up time spent in sedentary behaviour, with light intensity activity every 30 
minutes, has been beneficially associated with lower waist circumference, body-mass 
index , level of triglycerides and fasting 2-h plasma glucose level (71). To date, 
information on the way people with COPD accumulate time in both physical activity 
and sedentary behaviour is limited, and there are no data on this in a Saudi 
population. This lack of information limits the ability to design interventions to 
optimise performance of physical activity and sedentary behaviour for people with 
COPD.  
To date, studies that have measured the level of physical activity in Saudi population 
used questionnaires such as the international physical activity questionnaire (72-74). 
However, quantifying physical activity (or sedentary behaviour) using subjective 
measures (e.g., diary and questionnaires) has been shown to be inaccurate, 
particularly in older people, when compared with objective measures (e.g., 
pedometers or accelerometers) (75). Information on sedentary behaviour and 
physical activity in Saudi nationals with COPD obtained using robust objective 
methods has not been reported. 
1.4.2.1 Significance and novelty of the research 
Several studies have explored the physical activity levels of people with COPD and 
compared these data with that collected in healthy controls. These studies were 
conducted in Belgium, Brazil, Sweden, Japan, Spain, Romania and the United 
Kingdom (56, 57, 76-80). Although people with COPD are characterised by low 
levels of physical activity, these low levels are different between people from 
different countries (81). Pitta et al (81) demonstrated that, after adjusted for 
confounders such as age and disease severity, people with COPD from Brazil had 
higher levels of physical activity compared with matched people with COPD from 
Austria. Therefore, data from other countries may not be representative of Saudis 
with COPD. The findings of this research will be the first to report data on physical 
activity and sedentary behaviour as well as data on the pattern of accumulation of 
physical activity and sedentary behaviour in Arabic countries, specifically in Saudi 
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Arabia. Obtaining data on sedentary behaviour and physical activity of Saudi 
nationals with COPD and comparing these data with that collected in healthy people 
of a similar age and gender will be important to assist health professionals in Arabic 
Gulf countries, especially in Saudi Arabia, to understand the lifestyle adopted by 
their patients. The findings of this study will also help health professionals to provide 
physical activity and sedentary behaviour goals to their patients, aimed at optimising 
health outcomes in this population. Further, the results of this study have the 
potential to stimulate research in Arabic Gulf countries investigating strategies aimed 
at changing barriers to physical activity such as fear of embarrassment when 
undertaking exercise (73). 
1.5 Research Aim 4  
To report associations between the quality and emotional components of the D-12 
with physical activity and sedentary behaviour in people with COPD. 
1.5.1 Research hypothesis 
The hypothesis was that the quality and emotional response components of the D-12 
will associate with the time spent in walking based activity and sedentary behaviour 
in people with COPD. 
1.5.2 Background   
It is generally accepted that people with COPD limit their participation in physical 
activity and become more sedentary to minimise their experience of dyspnoea (10, 
57). Several studies have explored the associations between objectively measured 
physical activity and dyspnoea in people with COPD (57, 82-85) with most reporting 
significant associations that range between r = 0.15 to r = 0.57 (82, 84-86). For 
example, Watz et al (85) measured physical activity, using an accelerometer, of 163 
people with mild to very severe stable COPD. The authors demonstrated a moderate 
association between daily steps and functional limitation resulting from dyspnoea, 
using the Medical Research Council dyspnoea scale, (r = -0.57, p < 0.001), indicating 
that greater limitations due to dyspnoea impacts negatively on participating in daily 
physical activity in COPD (85). To date, no study has reported an association 
between dyspnoea and sedentary behaviour in people with COPD. In addition, 
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determining whether the quality of dyspnoea and/or the emotional response to 
dyspnoea has the most impact on sedentary behaviour and physical activity of people 
with COPD has not been explored. 
1.5.2.1 Significance and novelty of the research 
The findings of this study will extend the results of the first study in this program of 
research by providing further evidence of the validity of the D-12. To date, no 
research has identified whether it is the quality or the emotional response 
components of dyspnoea that impacts most on sedentary behaviour or physical 
activity levels. Therefore, the results of this research will demonstrate which specific 
components of dyspnoea have the greatest impact on sedentary behaviour and 
physical activity. The findings of this study may promote future research into 
ameliorating the appropriate component of dyspnoea, either the quality of the 
sensation or the emotional response to it, which seems to have the greatest adverse 
effect on participation in physical activity and the accumulation of time spent in 
sedentary behaviour. In turn, this may assist in reducing the time spent in sedentary 
behaviour and increasing the time spent participating in physical activity in people 
with COPD with the overall aim of improving health outcomes. 
1.6 Study location 
All studies were undertaken in Riyadh, the capital city of Saudi Arabia, at King 
Fahad Medical City. The estimated population of Riyadh is 4,506,321 (87). King 
Fahad Medical City is a public and a tertiary care referral centre. In addition, it is 
considered the largest and most advanced medical facility in the Middle East (88). It 
comprises four hospitals, main hospital, maternity hospital, pediatric hospital, and 
rehabilitation hospital, making up a total of 1,200 beds. King Fahad Medical City 
provides high quality of services similar to those provided in Western countries such 
as the United States of America. More than 19,171 inpatients annually and over 
238,404 outpatients are treated at King Fahad medical city. Respiratory care at King 
Fahad Medical City is provided by highly trained consultants, residents and nursing 
technicians for inpatient and outpatient departments. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 Overview 
This literature review is divided into four parts. Part 1 (Section 2.2) is an overview of 
chronic obstructive pulmonary disease (COPD) and includes information pertaining 
to its causes and risk factors and the prevalence of COPD. The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) classification for disease severity, as 
well as the impact and costs associated with COPD are also discussed in part 1. Part 
2 (Section 2.3) provides information related to dyspnoea in people with COPD. In 
addition, the relationships between dyspnoea and clinical outcomes, as well as tools 
that are used to measure dyspnoea in people with COPD are discussed. Interventions 
to reduce dyspnoea in COPD are also described. Part 3 (Section 2.4) provides a 
definition for an acute exacerbation of COPD (AECOPD) and information related to 
the causes of an AECOPD. The effects of an AECOPD on clinical outcomes and the 
economic burden of an AECOPD are also discussed. In addition, information about 
the management of an AECOPD is described. Part 4 (Section 2.5) reviews the 
literature pertaining to physical activity and sedentary behaviour and public 
recommendations on physical activity levels for health. The various methods used to 
measured physical activity and factors that are associated with the measurement of 
physical activity and sedentary behaviour in people with COPD are discussed in part 
4. 
 
Chapter 2: Literature review 
14 
Part 1 
2.2 Introduction 
Chronic obstructive pulmonary disease is a preventable and treatable disease 
characterised by expiratory airflow limitation that is not fully reversible (10). The 
airflow limitation is usually progressive and arises as a consequence of an abnormal 
inflammatory response to noxious particles or gases in the lungs (10). This disease is 
caused by a combination of small airways disease (bronchiolitis) and destruction of 
the lung parenchyma (emphysema). The relative contribution of these two 
pathological abnormalities varies between people. Chronic inflammation causes 
structural changes in the airway walls, resulting in narrowing of the airway lumen. 
The inflammation and structural changes in the peripheral airways leads to a 
decrease in the volume of air exhaled during the first second of a forced expiration 
(FEV1) (10). Destruction of the lung parenchyma results in a loss of the alveolar 
attachments to the respiratory bronchioles and a decrease in lung elasticity (89). In 
turn, these changes contribute to expiratory airflow limitation and abnormalities of 
gas exchange (89). Abnormalities in gas exchange lead to hypoxemia (low levels of 
oxygen in the blood) and hypercapnia (high levels of carbon dioxide in the blood) 
and have several mechanisms in COPD. Gas transfer for oxygen and carbon dioxide 
reduces when the disease progresses (89). Reduction in the ventilation may also be 
due to reduced ventilation drive. This reduction may lead to carbon dioxide retention 
when it is coupled with decreased ventilation because of a high work of breathing 
due to severe obstruction and hyperinflation combined with ventilatory muscle 
impairment (90). The abnormalities in alveolar ventilation and a decreased 
pulmonary vascular bed lead to further worsen ventilation-perfusion abnormalities 
(89). The presence of expiratory airflow limitation and its severity can be confirmed 
by spirometry, which provides a reliable and objective measurement of static lung 
function (10). 
The characteristic of respiratory symptoms of COPD are both chronic and 
progressive dyspnoea, cough and sputum production (10). An acute deterioration in 
the respiratory symptoms of people with COPD is known as an AECOPD (10) 
(Section 2.4). The frequency of an AECOPD is often increased with increasing 
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disease severity (91). An AECOPD is also associated with accelerated decline in 
lung function and health-related to quality of life (HRQoL) (92) (Section 2.4).  
2.2.1 Causes and risk factors of COPD 
Environmental exposure to noxious gases and genetic abnormalities are two well-
known risk factors in the development of COPD (10). Exposure to tobacco smoke is 
considered the major environmental risk factor for COPD (10). Other important 
environmental risk factors are indoor air pollution (e.g. biomass fuels used for 
cooking), outdoor air pollution, respiratory infections and occupational exposure to 
organic and inorganic dusts, fumes and chemicals (10, 93, 94). However, only 15% 
to 20% of smokers develop clinically significant airflow limitation (95), suggesting 
that genetic factors also play a role in the development of the disease. The well-
documented genetic risk factor for COPD is alpha-1 antitrypsin deficiency (10, 96). 
Other candidate genes have also been suggested in the pathogenesis of COPD, but 
these genes have not yet been identified (10). 
2.2.2 Prevalence of smoking 
The prevalence of smoking varies widely across the world (97). For example, the 
Burden of Obstructive Lung Disease (BOLD) study showed that the prevalence of 
smoking is as high as 50% in Adana city in Turkey and as low as at 14% in Sydney, 
Australia (97). In Arabic Gulf countries, the most common forms of smoking are 
cigarette smoking and shisha smoking (waterpipe) (98). The shisha is a device that 
heats tobacco by charcoal, filters the resulting smoke into a bowl of water and then 
passes it to a rubber pipe for inhalation through the mouth (99). This form of 
smoking is considered a social and popular behaviour in Arabic cultures (100). 
However, shisha smoking has been found to be associated with deleterious health 
effects such as lung cancer, respiratory illness and periodontal disease (101). The 
prevalence of shisha smoking in Arabic Gulf countries ranges from 9% in Oman to 
12% in Kuwait (11, 98, 102-104). 
The prevalence of smoking (cigarettes or shisha or both) differs among Arab Gulf 
countries (11, 102-104). In general, the overall smoking prevalence in the Saudi 
population aged ≥ 40 years is 28%, with a rate of 39% in males and 7% in females 
(11). The prevalence of smoking in the Saudi population is lower than that reported 
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in Qatar (37%), with a rate of 42% in males and 7% in females, aged ≥ 15 years 
(102). In the United Arab Emirates, the prevalence of smoking in adults aged ≥ 18 
years is 24% in males and 1% in females (overall rate of smoking was not reported in 
this study) (103). In contrast, Oman appears to have the lowest prevalence of 
smoking (7%) in adults aged ≥ 20 years, with a rate of 13% in males and 0.5% in 
females compared to the aforementioned Arabic Gulf countries (104). The 
differences in the prevalence of smoking between Arabic Gulf countries reported in 
this literature could be explained in part by different sample sizes and different ages 
included in the studies.  
2.2.3 Prevalence of COPD 
The prevalence of COPD varies considerably throughout the world (97). The 
variations in reported prevalence refer to several factors such as the diagnostic 
criteria of COPD used, the study design, the study population, proportions of age and 
gender, and the response rate. Published epidemiological studies of COPD 
prevalence defined COPD using either post-bronchodilator spirometry or a 
questionnaire based definition of COPD (1, 2, 4, 6, 8, 9, 105, 106). Using post-
bronchodilator spirometry for a diagnostic of COPD is a reliable and objective 
measurement of static lung function (10). However, using this method in 
epidemiological studies has some disadvantages that introduce the possibility of 
selection bias affecting the prevalence estimates (8). These disadvantages include 
poor response rate, and it may be difficult to apply in very large populations as it 
requires medical professionals to conduct the test and interpret data obtained, and 
may only include people seeking medical care. The questionnaire based definition of 
COPD is easy to apply in large populations. However, respondents to the 
questionnaire may not recognise the symptoms of COPD, which definitely result in 
the underestimation of the prevalence of COPD. Furthermore, COPD is not 
necessarily diagnosed until it is moderately advanced. 
Only three studies  in the Arab Gulf countries have reported the prevalence of COPD 
diagnosed using post-bronchodilator spirometry, two of them were in Saudi Arabia 
and one was in the United Arab Emirates (2, 105, 107). In Saudi Arabia, the BOLD 
study was conducted in Riyadh city and recruited 784 people (361 females, 46% of 
the total) aged ≥ 40 years by stratified multistage random sampling. All participants 
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performed post-bronchodilator spirometry and completed questionnaires related to 
respiratory symptoms and cigarette smoking history (105). The overall prevalence of 
COPD was 4.2%, being higher in males (5.7%) than females (2.5%), the 
classification of COPD severity was not reported. 
Compared to the international BOLD studies, defined by spirometric criteria among 
people aged ≥ 40 years, the prevalence of COPD in Saudi Arabia is lower than that 
reported in many countries: 26.1% in Austria (4), 24% in the Netherlands (5), 20.8% 
in the Philippines (6), 18% in Iceland (108), 16.2% in Sweden (7), 13.2% in 
Germany (109), 8.2% in China (9), and 7.9% in Australia (8). Among 11 
international sites, the international BOLD reported the prevalence of COPD in males 
and females, defined by spirometric criteria (97). The prevalence of COPD in people 
aged ≥ 40 years ranged from 8.5% in Reykjavik, Iceland, to 22.2% in Cape Town, 
South Africa, in males; and from 3.7% in Hannover, Germany, to 16.7% in Cape 
Town in females (97). The prevalence rates of COPD in Saudi males and females lie 
at the lower end of the international range for males and females. It should be noted 
that the BOLD study was limited to one city in Saudi Arabia and may not represent 
the prevalence rate of COPD in the general population. 
Another Saudi study was conducted in the three largest cities, namely, Riyadh, 
Jeddah and Dammam. The sample comprised 501 smokers (52 females, 10% of the 
total) with a smoking history ≥ one year and aged ≥ 40 years who were attending 
private healthcare clinics. All participants performed post-bronchodilator spirometry 
and completed a questionnaire related to information on smoking history and 
respiratory symptoms (2). The findings showed that 14% (68 males and three 
females) had COPD and, of these, 56% had moderate COPD and 44% had severe 
COPD (2). However, this study selected a specific population seeking health 
provider advice at primary healthcare clinics which does not show a true picture of 
prevalence of COPD in the general population. Moreover, including only smokers in 
this study are likely to overestimate the prevalence of COPD in the population, 
where smoking is the primary risk factor for the development of COPD. 
In Abu Dhabi in the United Arab Emirates, the prevalence of COPD was explored in 
520 people (234 females,45% of the total) aged between 40 and 80 years who were 
selected from the catchment population of a military hospital and recruited by 
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random phone calls. All participants performed post-bronchodilator spirometry and 
completed questionnaires related to information about their smoking history and 
bakhour and biomass exposure (107). The prevalence of COPD was 4% and, of 
these, 5% had mild COPD, 63% had moderate COPD and 32% had very severe 
COPD (107). However, the majority of participants in this study were non-smokers 
(70%), who are unlikely to have COPD. In addition, there was no difference in 
prevalence between males and females (107). This study only included participants 
from one area in one city, and therefore, it may not represent the prevalence of 
COPD in Abu Dhabi as a whole. Including a large sample from the community is 
needed in order to represent the prevalence of COPD in a population.   
A survey study, named the BREATH study, conducted in the Middle East and North 
Africa region reported that the prevalence of COPD in Saudi Arabia (n = 9,730, 35% 
females) was somewhat similar to that found in the United Arab Emirates (n = 3,494, 
48% females) was 2.4% and 1.9%, respectively, in people aged ≥ 40 years (1). The 
study showed that COPD was more frequent in males than females, 3.5% versus 
1.0% in Saudi Arabia and 2.6% versus 0.4% in the United Arab Emirates. The 
definition of COPD in the survey study was based on two criteria. First, either a 
diagnosis of COPD, emphysema or chronic bronchitis OR the presence of cough 
with sputum, breathlessness or symptoms comparable with chronic bronchitis. The 
second criterion was related to smoking exposure of ≥10 years. Compared to data 
obtained from the Confronting COPD International Survey study (106) that used a 
comparable methodology and the same COPD definition as that used in the 
BREATHE study, the prevalence of COPD in Saudi Arabia and the United Arab 
Emirates are lower than that from many countries: 12.0% in Brazil, 9.0% in 
Germany and in Mexico, 8% in the United of Kingdom, 7% in the United States of 
America and in Japan. The definition of COPD used in the survey studies could 
underestimate the prevalence of COPD as people may not be able to recognise 
COPD symptoms. In addition, the prevalence of tuberculosis is high in developing 
countries and that may cause chronic irreversible airflow obstruction which may pose 
a problem regarding the definition used for COPD. Furthermore, the diagnosis of 
COPD should be made on the basis of measuring lung functions using post-
bronchodilator spirometry (10), which was not used in the survey studies. 
Chapter 2: Literature review 
19 
Data on the prevalence of COPD in the Arab Gulf countries are virtually absent, or if 
available are often limited to one city or based on inadequate definitions. Therefore, 
studies aim to determine precise estimates of the prevalence and the burden of COPD 
in the Arab Gulf countries need to conduct post-bronchodilator spirometry and use 
validated questionnaires.  
2.2.4 Cost of COPD 
Chronic obstructive pulmonary disease places a significant burden on healthcare 
resources (110). The direct costs  of COPD in the United States of America have 
been estimated to be $15.7 billion USD per year (111). This high cost is largely 
accounted for by hospital admissions and the healthcare management of the disease 
including outpatient clinic appointments and medications (112). Equivalent data for 
costs are not available for any of the Arabic Gulf countries.  
The direct cost alone does not reflect the full burden of COPD on people and society. 
Indirect costs account for a significant proportion of the burden of the disease. These 
indirect costs associated with COPD include loss of productivity and impaired work 
performance, lost income due to premature retirement, absenteeism, disability and 
activity limitation (113). The ability to work has been shown to decrease as disease 
severity increases (113). It has been shown that family caregivers of people with 
advanced COPD experience poor psychological well-being compared to those carers 
of people with early stage COPD (114).  
2.2.5 Classification of disease severity 
A possible diagnosis of COPD should be considered for an individual (i) aged ≥ 40 
years, (ii) who reports dyspnoea, chronic cough or sputum production, and/or (iii) a 
history for exposure to risk factors for the disease, such as tobacco smoke or 
occupational dusts, for ≥10 years (10). Post-bronchodilator spirometry is essential for 
the diagnosis of COPD and assessment of disease severity. A post-bronchodilator 
ratio of FEV1/forced vital capacity (FVC) < 0.70 confirms the presence of 
irreversible airflow limitation and therefore of COPD (10). The severity of COPD is 
classified based on the measurement of post-bronchodilator FEV1 expressed as a 
percentage of the predicted value in healthy people. The most widely recognised 
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system for classifying severity is the GOLD, which classifies the severity of COPD 
into four grades (1, 2, 3 and 4) as shown in Table  2-1 (10). 
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Table ‎2-1: Classification of the severity of COPD as defined by the Global 
Initiative for Chronic Obstructive Lung Disease (10).  
Grades In people with FEV1/FVC < 0.70 
1 Mild  FEV1 ≥ 80% predicted 
2 Moderate  50% ≤ FEV1 < 80% predicted 
3 Severe  30% ≤ FEV1 < 50% predicted 
4 Very severe  FEV1 < 30% predicted 
FEV1: forced expiratory volume in one second; FVC: forced vital capacity 
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2.2.6 Impact of COPD 
Chronic obstructive pulmonary disease not only affects the lungs, but is also 
characterised by extrapulmonary effects such as cardiovascular disorders and skeletal 
muscle dysfunction (115, 116). The main symptoms experienced by people with 
COPD are exertional dyspnoea and fatigue (117). Poor HRQoL, feelings of anxiety 
and depression, decreased exercise capacity and physical activity are prevalent in 
people with COPD (56, 118, 119). Muscle weakness in the lower extremities is also 
considered to be a major problem in people with COPD, influencing exercise 
capacity (120). There is also increasing recognition of the importance of 
comorbidities in people with COPD (121). The following paragraphs describe the 
symptoms that include dyspnoea and fatigue, a reduction in exercise capacity and 
physical activity, poor HRQoL, feelings of anxiety and depression, and systemic 
manifestations and/or comorbidities in people with COPD. 
Dyspnoea is the most distressing symptom experienced by people with COPD and is 
frequently the main reason for seeking medical assistance (24). In people with 
COPD, expiratory flow limitation leads to an increase in the volume of air in the 
lungs at the end of spontaneous expiration, known as pulmonary hyperinflation 
(122). In most people with COPD, hyperinflation increases the ventilatory demand 
during exercise or physical activity as well as when airflow limitation increases 
during an AECOPD (24, 37, 123). More details on dyspnoea are provided in Section 
2.3.  
Fatigue is considered another prominent symptom experienced by people with 
COPD (124). An increase in the work of breathing and dyspnoea severity has been 
reported to lead to deconditioning of muscles and fatigue in those with COPD (125). 
Fatigue in general has been shown to be a strong predictor for the risk of 
hospitalisation, independent of COPD severity (126). During a 20 month follow-up 
period, the length of hospital stay of 83 people with mild to very severe COPD (aged 
72 ± 9 years) was demonstrated to increase by a factor of four for every unit increase 
in fatigue experienced, evaluated using an Identity-Consequences Fatigue Scale 
(126). Both dyspnoea and leg fatigue lead to the avoidance of physical activity, 
which ultimately results in functional limitation and impaired HRQoL (117, 127). 
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Impaired exercise capacity is a prominent feature of people with COPD (128). 
Compared with reference values and/or data reported in healthy people, a decline in 
exercise capacity, measured as a reduced distance walked during field walking tests 
(56, 57) or maximum work rate achieved during cycle ergometry testing (34, 129), 
has been demonstrated in people with COPD. Longitudinal data showed that the 
decline in exercise capacity occurs independent of the change in airflow limitation in 
those with severe COPD (130). In addition, exercise capacity is a stronger predictor 
of mortality than FEV1 (130, 131). This is likely to be because exercise capacity is 
influenced by skeletal muscle dysfunction and pulmonary impairment, thereby, 
reflecting the primary pulmonary and secondary systemic manifestations of COPD 
(132).  
Research on the physical activity levels of people with COPD has consistently 
demonstrated that this population have a lower level of physical activity compared to 
their healthy peers (56-58). Furthermore, a decline in physical activity levels was 
found to be related to an increased risk of hospitalisation and mortality, and 
decreased HRQoL (133, 134). More details on physical activity in people with 
COPD are provided in Section 2.5.  
Health-related quality of life is a multidimensional construct that reflects physical, 
psychological and social function as well as well-being (135). Chronic obstructive 
pulmonary disease places a significant burden on people by affecting the physical, 
psychological and social components of HRQoL and well-being (136, 137). People 
with COPD have been found to have impaired HRQoL compared to healthy people 
and others with chronic conditions such as prostate cancer, hyperlipidaemia and 
diabetes mellitus (138, 139). The magnitude of this impairment in HRQoL has a 
moderate to stronger association (r ranging from 0.40 to 0.70, all p < 0.001) with 
dyspnoea and decreased exercise capacity (135, 140).  
Feelings of anxiety and depression are common among people with COPD, with the 
prevalence rate ranging from 10% to 96% depending on the criteria used to define 
them (141). Feelings of anxiety and depression are often associated with increased 
disability and morbidity (142), and have a negative impact on the HRQoL of those 
with COPD (143, 144).  
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As mentioned earlier, COPD not only impacts on lungs, but has other consequences, 
which might be considered systemic manifestations and/or comorbid conditions. In 
people with COPD, loss of skeletal muscle mass and strength, in particular of the 
quadriceps muscles has been demonstrated (145, 146). This muscle atrophy is due to 
several factors that include chronic inflammation, malnutrition, arterial blood gas 
abnormalities, electrolyte imbalance, low physical activity, the side effects of 
medications such as statins, and compromised oxygen delivery due to right heart 
dysfunction (145). One of the main muscles used for ambulation is the quadriceps 
muscle and a significant reduction in quadriceps endurance has been demonstrated in 
people with COPD (147, 148). Computed tomography scans of the thigh muscles 
demonstrated that people with COPD had a reduction in skeletal muscle mass when 
compared with healthy people (149). Muscle weakness and leg fatigue have a 
negative impact on exercise tolerance, as it has been shown that people with COPD 
who had weaker muscles reported more leg fatigue and showed decreased peak 
exercise capacity than those with less weak muscles (150). 
In people with COPD, changes in the morphology of the quadriceps muscle have 
been demonstrated (151, 152). Compared with age-matched healthy people, the 
vastus lateralis muscle of people with COPD has a lower propotion of Type I fibers 
and a higher proportion of Type IIa and Type IIb fibers (151, 152). In addition, a 
decrease in cross sectional area across Type I, IIa and IIab fiber types has also been 
found in people with COPD compared to age-matched healthy people. Changes in 
muscle biochemistry have been demonstrated in people with COPD when compared 
to age-matched normal people (153). These changes include reductions in the 
activity of two oxidative enzymes that play a part in aerobic metabolism; citrate 
synthase and 3-hydroxyacyl CoA dehydrogenase (153). A decrease in the activity of 
citrate synthase, but not 3-hydroxyacyl CoA dehydrogenase, has been found to be 
associated with more profound impairments in aerobic capacity (153). 
The most frequently reported systemic manifestations or comorbidities in COPD 
include cardiovascular diseases, musculoskeletal conditions, psychological disorders, 
metabolic syndrome, osteoporosis and lung cancer (154). These comorbidities 
increase the risk for hospitalisation and have a major impact on HRQoL, survival and 
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health care costs associated with COPD (155-157). In addition, comorbid conditions 
can occur at any severity grade of COPD (157, 158). 
In summary, COPD results in symptoms that include dyspnoea and fatigue, poor 
HRQoL, a decline in exercise capacity and physical activity, feelings of anxiety and 
depression, and is associated with systemic manifestations and/or comorbidities. The 
burden of these symptoms and associated conditions can been seen in the daily lives 
of those with COPD. 
Part 2 
This part provides information related to dyspnoea in people with COPD. In 
addition, the relationships between dyspnoea and clinical outcomes, as well as tools 
that are used to measure dyspnoea in people with COPD are discussed. Interventions 
to reduce dyspnoea in COPD are also described. 
2.3 Dyspnoea in COPD 
The American Thoracic Society defines dyspnoea as a subjective experience of 
breathing discomfort comprising distinct sensations that vary in quality and intensity 
(13). These sensations arise from interactions between multiple physiological, 
psychological, social and environmental factors (13). Dyspnoea is often an indication 
of serious disease, and it can be extremely unpleasant and frightening for people with 
COPD (159). Dyspnoea can be severely debilitating for those with COPD (160) and 
is often the primary reason for seeking medical attention (25). 
2.3.1 Pathophysiology of dyspnoea and neuromechanical disassociation  
In the COPD population, factors that increase the demand on the ventilatory system 
are likely to lead to dyspnoea when ventilatory capacity is not adequate to meet 
increased ventilatory demands (161). Neuromechanical imbalance is a popular idea 
to explain the contribution of the respiratory muscles to the development of dyspnoea 
(13). This theory suggests that dyspnoea results from a disequilibrium between the 
respiratory motor command and the resulting afferent feedback from proprioceptive 
and other sensory receptors. Therefore, when the afferent feedback from the chest 
wall relating to intrathoracic pressure changes, respiratory muscle length and 
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movement of the lungs are interpreted as insufficient corresponding motor command, 
it gives rise to dyspnoea (161, 162). Thus, the disparity between the motor command 
from the central nervous system to breathe, and the inefficient mechanical response 
of the respiratory system results in dyspnoea in people with COPD (162). 
Although several factors have been implicated in reducing the capacity of the 
respiratory muscles to meet the increase in the ventilatory demands associated with 
exercise, the following sections will focus on the most important factors which are 
pulmonary hyperinflation, mechanical loads on the inspiratory system and gas 
exchange abnormalities in people with COPD. 
2.3.1.1 Pulmonary hyperinflation 
Pulmonary hyperinflation is one of the major contributory factors to dyspnoea in 
COPD (163). In COPD, the combined effects of peripheral airway narrowing and  
reduced elastic recoil of  the lung lead to an abnormal increase in the volume of air 
remaining in the lungs at the end of spontaneous expiration, termed pulmonary 
hyperinflation (122). These changes decrease the ability of the ventilatory system to 
accommodate increased respiratory demands (i.e. during exercise, an AECOPD), by 
increasing tidal volume. Consequently, a decrease in the time available for expiration 
occurs as respiratory rate increases, leading to further increased trapped gas in people 
with COPD (164). The worsening hyperinflation increases the overall dimensions of 
the rib cage, causing the inspiratory muscles to produce more tension to bring about 
the same pleural pressure changes to achieve the same tidal volume (165). 
Hyperinflation also results in shortening of the inspiratory muscles although 
sarcomere adaption does take place in setting of chronic hyperinflation (166).  
In addition to the effects that pulmonary hyperinflation has on COPD, it may also 
contribute to dyspnoea through other mechanisms. Acute dynamic pulmonary 
hyperinflation may cause a rapid rise in the intrathoracic pericardial pressure which 
can then mechanically compress the intra-alveolar vessels (167). This leads to 
worsening hypoxia and increased pulmonary arterial resistance and pressure causing 
severe dyspnoea (167). 
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2.3.1.2 Mechanical loads on the inspiratory system 
Various types of mechanical loads (i.e. elastic, threshold, resistive) on the respiratory 
system also contribute to the sensation of dyspnoea in people with COPD. Due to the 
loss of elastic recoil, the chest wall and lungs become stiff, imposing additional 
muscle load (168). Muscle loads that are imposed by stiffness of the chest wall and 
lungs which needs to be overcome by the inspiratory muscles to produce increased 
negative pleural pressures during inspiration, are known as elastic loads (162). 
The threshold load refers to the increased intra-alveolar pressure in the hyperinflated 
COPD lungs at the end of each expiration (169, 170). It is also called as the intrinsic 
positive end expiratory pressure (170). This increased pressure has to be overcome in 
the next inspiration, therefore requiring more effort by the inspiratory muscles (169). 
The third type of the mechanical load is a resistive load which is imposed by the 
narrowed airways (171). In COPD, due to permanent destruction of the alveolar air 
sacs, excessive mucus impaction in the bronchial lumen and fibrosis of airways there 
is fixed obstruction to the airflow resulting in a resistive load (10).  
2.3.1.3 Gas exchange abnormalities 
Gas exchange abnormalities occurring as result of ventilation/perfusion mismatch 
can contribute to the development of dyspnoea (172). An acute increase in carbon 
dioxide levels the arterial blood provokes a chemoreceptor-driven increase in 
inspiratory motor command, which leads to an in increase dyspnoea, in people with 
COPD (173). Chronic carbon dioxide retention contributes to increased dyspnoea 
during daily activities (10). In COPD, carbon dioxide retention has been associated 
with increased inspiratory muscle weakness (174). It is likely that the cause of 
increased carbon dioxide levels in the arterial blood of people with weak inspiratory 
muscles results from the gradual deterioration in the mechanical properties of the  
lung and inspiratory muscle function, which leads to a relatively high force required 
for each breath and the subsequent development of a rapid breathing pattern (175). 
Such a breathing pattern decreases inspiratory muscle fatigue and minimises 
inspiratory muscle effort and dyspnoea, but at the expense of alveolar ventilation 
(176, 177). Dyspnoea reported by people with chronic carbon dioxide retention is 
Chapter 2: Literature review 
28 
more likely to result from neuromechanical disassociation because of the imbalance 
between the load and the capacity of the inspiratory muscles (13). 
Hypoxia increases the reliance on anaerobic energy systems with consequent lactate 
production triggering increased ventilation, contributing to dyspnoea (178). 
Supporting the hypothesis of these physiological changes is the finding that 
delivering oxygen to those with COPD during exercise decreases lactate 
concentration and ventilation, which in turn, contributes to reduced dyspnoea (178).  
In summary, the pathophysiology of dyspnoea that arises in COPD due to inspiratory 
muscles dysfunction, pulmonary hyperinflation, and increased mechanical loads on 
the inspiratory system and gas exchange abnormalities. 
2.3.2 Relationship between dyspnoea and clinical outcomes 
In people with COPD, dyspnoea is considered one of the major symptoms that has a 
relationship with important clinical outcomes such as exercise capacity, HRQoL, 
feelings of anxiety and depression, lung function and mortality. 
2.3.2.1 Exercise capacity  
Dyspnoea is one of the one of symptoms that limits exercise in the majority of people 
with COPD and can lead to avoidance of activity with consequent skeletal muscle 
deconditioning (37, 167, 179). Although dyspnoea is the main symptom that limits 
the performance of people with COPD during walking-based tests, dyspnoea has also 
been reported in conjunction with fatigue as limiting exercise tolerance during cycle 
ergometry testing (180). In people with COPD, a moderate to strong association has 
been demonstrated between dyspnoea and functional exercise capacity, measured by 
a six-minute walk distance (6MWD) (r > 0.4, p < 0.05)  (23, 181). This association 
indicates that as dyspnoea severity increases, functional exercise capacity declines in 
people with COPD.  
2.3.2.2 Health-related quality of life  
In people with COPD, dyspnoea is associated with poor HRQoL (14, 140). Studies 
have explored the relationship between functional limitation due to dyspnoea, using 
the Medical Research Council (MRC) dyspnoea scale, a 5-point ordainal scale, and 
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disease specific HRQoL questionnaires such as the St. George’s Respiratory 
Questionnaire (SGRQ) (182, 183). These studies demonstrated that greater 
impairments in the HRQoL of  people with COPD were found in those who had a 
high grade of functional limitation resulting in dyspnoea of a MRC grade 4 or 5, (p < 
0.05) (182, 183).  
In general, dyspnoea is often one of the determinants of HRQoL, and has significant 
moderate to strong associations (r ≥ 0.5) with the impairments in HRQoL in people 
with COPD (182). In addition, significant moderate to strong (≥ 0.4) associations 
have been found between dyspnoea and generic measures of HRQoL, such as the 
Medical Outcomes Study Short Form 36-item questionnaire, in people with COPD 
(184, 185) 
2.3.2.3 Feelings of anxiety and depression 
Feelings of anxiety and depression are commonly experienced by people with COPD 
(10, 186). Several studies have explored the associations between dyspnoea or a 
functional limitation resulting from dyspnoea, and feelings of anxiety and depression 
(187-189). These studies found that greater dyspnoea was observed in those who had 
reported higher anxiety and depression scores on screening instruments (187-189). 
For example, in 29 people with moderate to severe stable COPD, Borges et al (190) 
assessed the relationship between feelings of anxiety and depression, measured using 
the Hospital Anxiety and Depression Scale (HADS), with a functional limitation 
resulting from dyspnoea, measured using MRC dyspnoea scale. The authors 
demonstrated that compared to those without feelings of anxiety or depression, 
people with greater feelings of anxiety (HADS score > 8) had reported 29% increase 
in their MRC scores, while those with greater feelings depression (HADS score > 9) 
had reported 30% increase in their MRC scores 
2.3.2.4 Lung function 
The FEV1 is used to determine the severity of COPD, expressed as a percentage of 
the predicted value in healthy people (10). In people with COPD, a weak association 
has been demonstrated between FEV1 and dyspnoea measures (23, 191-194). 
Therefore, FEV1 may not reflect the severity of dyspnoea in COPD as it has been 
demonstrated that changes in FEV1 were not associated with change in dyspnoea 
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during exercise (r = 0.07, p = 0.8) in people receiving short-acting bronchodilators 
(195). In COPD, it has been shown that indices related to pulmonary hyperinflation, 
such as inspiratory capacity, are more closely related to dyspnoea than FEV1 (196, 
197). After receiving a short-acting anticholinergic bronchodilator, an improved 
inspiratory capacity of 14% predicted has been shown to be associated with 
improvement in dyspnoea (11% reduction in Borg dyspnoea ratings, p < 0.05), 
during exercise (198). 
2.3.2.5 Mortality  
Dyspnoea appears to be a predictor of mortality in people with COPD. Nishimura et 
al (26) included a total of 227 people with COPD (FEV1% predicted = 41 ± 17) who 
were followed for five years and found that the relative risk of mortality increased 
with increasing dyspnoea level, measured using the MRC dyspnoea scale. 
Specifically, the authors showed that the relative risk of mortality, in comparison to 
those with MRC grade 2, was 2.21 (95% confidence interval [CI] 1 to 5) for people 
with grade 3, 8.3 (95% CI 3 to 20) for people with grade 4, and 61.3 (95% CI 13 to 
285) for people with grade 5 (26). Similarly, a recent study showed that, over five 
years, the survival rate of people with COPD increased with decreased level of 
dyspnoea, assessed using the modified MRC (mMRC) (199). The study found that 
those who had a lower grade of dyspnoea (mMRC ≤ 1) had a five-year survival of 
76%, whereas for those who had a higher grade of dyspnoea (mMRC ≥ 2) the 
survival at five years was 56% (199). 
In summary, dyspnoea in people with COPD is associated with reduced functional 
exercise capacity and HRQoL, feelings of anxiety and depression and reduced lung 
function and increased mortality. 
2.3.3 Measurement of dyspnoea 
The purposes of measuring dyspnoea are: to discriminate between people who have 
less dyspnoea and those who have more dyspnoea, to titrate exercise intensity and to 
determine whether dyspnoea has changed over time and/or as a result of treatment 
(evaluation). Numerous tools are available for measuring dyspnoea which can be 
classified as unidimensional and multidimensional tools.  The use of unidimensional 
tools is often preferred when measuring general severity of dyspnoea sensation either 
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averaged over a period of time or at a point in time, for example before, during, and 
after exercise (160, 200). Although the unidimensional tools are self-administered 
and take only a few moments to complete, it is not appropriate to be used in illiterate 
people. The unidimensional tools do not provide information pertaining to 
components of dyspnoea such as the quality and emotional response to dyspnoea 
sensation.  
The multidimensional tools provide information related the effect of dyspnoea across 
multiple domains, such as daily activities and/or emotional and mental functioning. 
In addition, it is often preferred to be used when comparing the impact of dyspnoea 
on multiple domains between different populations. The multidimensional tools are 
available either self-administered and/or interviewer-administered. Compared to the 
unidimensional tools, the multidimensional tools are lengthy and require more time 
to complete. 
It is important to note that none of the tools can be considered as a ‘gold standard’ 
demonstrating accurate, comprehensive assessment of dyspnoea in all settings (201). 
Therefore, selecting the most appropriate tool depends on the context and purpose of 
measurement. The following section presents and discusses common tools used to 
measure dyspnoea in people with COPD. 
2.3.3.1 Unidimensional tools 
The two unidimensional tools that are commonly used to quantify dyspnoea are the 
modified Borg scale (17) and the visual analogue scale (VAS) (18, 202). The Borg 
scale and the VAS are most often used to measure an individual’s perceived 
dyspnoea severity during exercise testing (160). The oxygen cost diagram (OCD) 
and the MRC dyspnoea scale are other unidimensional tools that are used to measure 
dyspnoea in people with COPD.  
2.3.3.1.1 Modified Borg scale  
The modified Borg scale is a 0 to10 categorical scale with descriptors linked to 
specific numbers with ratio properties (17). This scale was originally designed to 
measure perceived exertion during activity and was scored from 6 to 20 
(corresponding to a heart rate range of 60 to 200 beats per minute). Later, the scale 
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was modified to a 0 to 10 point scale to quantify the intensity of dyspnoea (17); this 
format of the scale is the one most widely used (203). 
The modified Borg scale is considered to be a ratio scale in whereby a rating of ‘4’ 
shows that dyspnoea is twice as severe as a rating of ‘2’, ‘8’ is twice as severe as ‘4’, 
and so on (16). In people with COPD, the modified Borg scale has been shown to be 
reliable, with coefficients of variation for the maximal Borg score and Borg score at 
two minutes of cycle exercise were 3 ± 1% and 3 ± 2% respectively (204). The Borg 
scale has also been demonstrated as valid, as shown by a strong association between 
the score of Borg scale with both minute ventilation and oxygen consumption (r > 
0.92, p < 0.01) in people with COPD during exercise (204). Besides being reliable 
and valid, the scores obtained using the Borg scale have been shown to change 
following an intervention such as pulmonary rehabilitation in COPD (46, 205), with 
a large effect size > 0.90 (206). 
2.3.3.1.2 Visual Analogue Scale  
The VAS consists of either a horizontal or a vertical line, usually 100 mm in length, 
with clear anchors defined at each end of the scale, using words such as ‘not 
breathless at all’ to ‘extremely breathless’, or ‘not breathless’ to ‘breathlessness as 
bad as it can be’ (18). The individual places a line between the anchor points to 
indicate his or her dyspnoea level, and the distance from the left side or bottom of the 
VAS is measured (18). The VAS has been shown to be reliable, with a coefficient of 
variation of 6% seen during exercise tests performed two weeks apart in people with 
COPD (207). In people with COPD, the VAS has been shown to be valid, by 
demonstration of a strong association between the scores of  the VAS with the Borg 
scale (r = 0.99, p < 0.01) (208). The VAS has been shown to change in response to 
an intervention, such as pulmonary rehabilitation or supplemental oxygen (209-211), 
and yielded a moderate to large effect size ranging from 0.48 to 1.26 (206).     
Although the VAS is easy to use, comparison between studies is difficult because of 
the use of the VAS to measure different aspects of dyspnoea, such as ‘uncomfortable 
breathing’, ‘distress due to breathlessness’ or ‘bother caused by breathlessness’ (16). 
Consistent phrasing of the question is essential because the wording may affect an 
instrument’s psychometric properties For example, Wilcock et al (212) revealed that 
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questions about ‘worst breathlessness over the past 24 hours’ (from ‘not breathless at 
all’ to ‘breathlessness as bad as you can imagine’) was associated with lower 
standard deviation (SD) of the difference between the two tests, one to eight days 
apart, when compared with questions related to breathlessness ‘right now’, ‘average 
breathlessness over the past 24 hours’ and ‘bother caused by breathlessness over the 
past 24 hours’. 
It appears that the Borg scale is more responsive to change following an intervention, 
such as pulmonary rehabilitation, than the VAS as it has demonstrated a larger effect 
size (> 0.92 versus > 0.48) (46, 205, 209, 213). It is noteworthy that the modified 
Borg scale and VAS only use one question to evaluate a particular construct, such as 
the severity of dyspnoea. Because these scales are single-item tools, it is difficult to 
evaluate internal consistency; the extent to which individual items in a questionnaire 
scale measure the same construct, using conventional methods such as Cronbach’s 
coefficient alpha (214).  
2.3.3.1.3 Oxygen Cost Diagram  
The OCD is a type of VAS consisting of a 100 mm long vertical line with descriptive 
phrases of 13 daily activities located at various points along the line corresponding to 
oxygen requirements at different activity levels (215). People indicate the point 
above which they would become breathless, with higher scores indicating fewer 
impairments due to dyspnoea (215). However, not all people engage in all the 
activities listed on the OCD (216), and people have demonstrated difficulty in 
understanding how to use the diagram (217). The OCD relies mainly on ambulatory 
activities, which makes it difficult to use for evaluating those who are dyspnoeic at 
rest. The OCD has been shown to be reliable (intra-class correlation coefficient 
[ICC] = 0.64), two weeks apart, and scores demonstrated an association of moderate 
strength with the 6MWD (r = 0.49, p < 0.5) in those with pulmonary disease (218). 
The OCD has been shown to be responsive to bronchodilators, such as salbutamol, in 
those with chronic airflow limitation (22), with a medium effect size (0.5) (206).  
2.3.3.1.4 Medical Research Council dyspnoea scale 
The MRC dyspnoea scale is a simple categorical scale that is commonly used to 
assess functional limitation resulting from dyspnoea (19). It consists of a five-point 
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scale ranging from 1 (‘Normal: only get breathless with strenuous exercise’) to 5 
(‘Very severe: too breathless to leave the house or breathless on dressing’). The 
individual selects the most appropriate item. The MRC dyspnoea scale has been 
shown to be useful when categorising people with COPD based on their level of 
functional limitation due to dyspnoea (26) and has been associated with five years 
survival (p < 0.001) (26). The MRC dyspnoea scale is one of four variables, together 
with body-mass index, FEV1 and the 6MWD, which comprise a multidimensional 
grading system, known as the BODE index (Body mass index, airflow Obstruction, 
Dyspnoea and Exercise capacity), that can be used to predict survival in people with 
COPD (219). The MRC dyspnoea scale has been shown to have strong associations 
with the OCD (r = 0.70) and the baseline dyspnoea index (BDI) (r = 0.83, all p < 
0.001) (220). The MRC has not demonstrated responsiveness (160). Because the 
MRC dyspnoea scale focuses on functional limitations due to dyspnoea, it does not 
provide a quantification of dyspnoea intensity or an assessment of associated distress 
and effort.  
2.3.3.2 Multidimensional tools 
2.3.3.2.1 Baseline Dyspnoea Index and Transitional Dyspnoea Index 
The BDI and the Transitional Dyspnoea Index (TDI) were specifically designed for 
the evaluation of dyspnoea (20). Developed as a discriminative tool, the BDI 
evaluates three dimensions of dyspnoea: functional impairment, magnitude of effort 
and magnitude of task at a single point in time (20). This tool rates an individual’s 
dyspnoea in each of these domains on a scale from 0 (‘severe or extraordinary 
impairment’) to 4 (‘no impairment’). The TDI is a companion scale used to track 
changes from baseline over time and can be used to evaluate the effect of therapeutic 
interventions (221). The TDI measures changes in dyspnoea over time in the three 
BDI domains on a scale from -3 (‘major deterioration’) to +3 (‘major improvement’) 
(20). The BDI/TDI have been reported as being a reliable tool in people with 
pulmonary disease including COPD, with interrater agreement at baseline and 
transition focal scores of 92% and 90%, as well as weighted kappa value of 0.7 and 
0.6 respectively (20). In addition, the BDI has been shown to have a moderate 
association with the 12-minute walk distance (r = 0.60) and a weak association with 
FEV1 (r = 0.41, all p < 0.01) in 38 people with respiratory diseases, of whom 32 had 
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COPD (20). The TDI has been shown to have a weak association with the change in 
12-minute walk distance (r = 0.33, p = 0.04) (20). Thus, the BDI/TDI have been 
considered as valid tools to assess dyspnoea in COPD. However, overall, the strength 
of the associations of the BDI/TDI with other measures was weak and that study is 
very old. Therefore, in order to increase the utilisation of the BDI/TDI in all settings 
it would be advantageous to re-assess the validity of the BDI/TDI in COPD 
populations with available dyspnoea tools that have been validated in people with 
COPD. The minimum clinically important difference for the TDI has been 
determined as one unit improvement from the BDI (222). This finding was reported 
in a retrospective study of 997 people with stable COPD who participated in a 
randomised controlled trial evaluating the effect of triotropium. It would be 
advantageous to repeat the analyses of clinically significance difference for the TDI 
in a prospective trial. The BDI and TDI were developed to be administered by an 
interviewer, and several studies have been performed using these versions (217, 222, 
223). Mahler et al (193) developed self‐administered BDI/TDI versions and showed 
that these versions demonstrated a strong association with the interviewer-
administered versions (BDI: r = 0.83; TDI: r = 0.94; p < 0.001 for both). Using the 
self‐administered BDI/TDI version, Mahler et al (224) found that, 36 of 65 people 
reported no change in functional limitation resulting from dyspnoea measured by the 
MRC scale following a standard therapy. These 36 people reported a clinically 
important change of > 1unit in the TDI, indicating that the BDI/TDI is more sensitive 
to change compared to the MRC scale. Although the BDI/TDI are activity 
determined that measure dyspnoea with specific activities, it does not provide an 
assessment of emotional response to dyspnoea. 
2.3.3.2.2 University California, San Diego Shortness of Breath Questionnaire 
The University of California, San Diego Shortness of Breath Questionnaire (SOBQ) 
is a self-reported scale originally designed as a clinical instrument to screen people 
for suitability to participate in pulmonary rehabilitation (225). The SOBQ comprises 
24 items that evaluate dyspnoea associated with a variety of daily activities during 
the preceding week. People are required to rate their dyspnoea when undertaking 21 
different activities on a scale ranging from 0 (‘not at all’) to 5 (‘maximal or unable to 
do because of dyspnoea’). In addition, people are required to rate three additional 
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questions related to fear of harm from over-exertion and fear of dyspnoea. In 143 
people with COPD, the SOBQ has been shown to have acceptable reliability over 
two days (r = 0.94, p < 0.01) and excellent internal consistency (Cronbach’s alpha = 
0.91) (181). The validity of the SOBQ has been shown through  a moderate 
association with the 6MWD (r = 0.47, p < 0.05) and a weak association with FEV 1% 
predicted (r = 0.28, p < 0.05) (181). However, it would be advantageous to re-assess 
the validity of the SOBQ with available tools that have already been validated in 
people with COPD, and to investigate whether this questionnaire is reliable and valid 
to be used in different cultures. The SOBQ has been shown to decrease by 20% 
following eight weeks of pulmonary rehabilitation, representing an improvement in 
dyspnoea (195). For any activities that people do not perform, they are asked to 
estimate their level of dyspnoea for that activity. it should also be kept in mind that 
some people may not have the reading skills required to complete the questionnaire 
accurately and may need help, uncontrolled factors that are not always easy to detect 
but that could affect validity. Although this questionnaire is long, it only attempts to 
address aspects of the emotional response to dyspnoea as indicated by perceived fear, 
and this is only in response to specific activities.  
2.3.3.2.3 Pulmonary Functional Status and Dyspnoea Questionnaire 
The Pulmonary Functional Status and Dyspnoea Questionnaire is a self-
administered, 164-item questionnaire that evaluates dyspnoea and activity levels 
(226). Lareau et al (21) developed a shorter version: the Pulmonary Functional Status 
and Dyspnoea Questionnaire—Modified version (PFSDQ-M). The modified version 
contains 40 items measuring dyspnoea, fatigue and functional status. It has variable 
Likert-type scales and the mean score for each subscale and total score can be 
calculated, responses with a lower score indicative of greater impairment (21). The 
dyspnoea domain evaluates the ability of an individual to perform different activities 
and any associated dyspnoea. The PFSDQ-M has been demonstrated to be reliable 
(ICC = 0.83) and have reasonable internal consistency (Cronbach’s alpha = 0.80) in 
50 people with stable COPD (21). The validity of this tool has been demonstrated via 
moderate to strong associations with the Sickness Impact Profile and 12-minute walk 
distance (r = 0.52 and r = 0.62), respectively, all p < 0.001) (21). The PFSDQ-M has 
been shown to improve one year after short-stay pulmonary rehabilitation in 34 
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people with COPD (p < 0.001) (227). However, the PFSDQ-M is lengthy and does 
not evaluate dyspnoea aspects such as the quality of dyspnoea and the emotional 
response to dyspnoea.  
2.3.3.2.4 Multidimensional dyspnoea profile  
The Multidimensional Dyspnoea Profile (MDP) is a questionnaire that measures the 
immediate intensity, immediate unpleasantness, sensory quality and emotional 
response to dyspnoea components (228). This questionnaire is proposed to refer to a 
specific event or period of time. Therefore, the user needs specify a “focus period”, 
such as “after you climb three flights of stairs”, “the last minute of breathing on the 
mouthpiece” or “right now” (229). The MDP includes 12 items: an immediate 
sensory intensity item, an immediate unpleasantness item, five items related to 
sensory qualities (e.g. work/effort, chest tightness/constriction), and five items 
addressing emotional response (e.g. anger, frustration). All items are rated on a scale 
of 0 to 10, with higher scores representing greater intensity, unpleasantness or 
distress. However, the items of MDP appear to be allocated as sensory or emotional 
components without robust testing for their psychometric properties. The use of both 
psychophysical and psychometric approaches to validate the MDP is important in the 
field of dyspnoea measurement instruments in order to increase the confidence of 
using this tool (229). 
The five items on the sensory quality component are descriptors similar to those 
found in the literature on the language of dyspnoea (29, 33, 230). The MDP 
descriptors were selected using inter-correlations between item responses from an 
earlier study involving 104 people with COPD (231). The emotional response items 
on the MDP include ‘depression’, ‘anxiety’, ‘frustration’, ‘anger’ and ‘fear’. These 
items appear to be extrapolated from pain research due to the similarity between 
dyspnoea and pain in terms of emotional response component (232-234).  
Meek et al (235) demonstrated that acceptable reliability (test-retest reliability, ICC > 
0.90) and internal consistency (Cronbach’s alpha > 0.80) of the of MDP in 151 
people with cardiopulmonary diseases, including COPD (n = 41), over a time period 
of one hour. However, this time period, one hour, between test-retest is an 
insufficient time period as it could allow respondents to recall their initial responses. 
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Approximately two weeks is often considered generally appropriate time interval 
between test-retest (236).  
The validity of the MDP was demonstrated by significant associations between both 
components of the MDP and the MRC grades (both r > 0.34). Similarly, associations 
were found between the scores for components of the MDP and the PFSDQ-M 
scores for dyspnoea and fatigue (r > 0.56) and the  scores for anxiety and depression 
components of the Brief Symptom Inventory (r > 0.66 and r > 0.54, respectively, p = 
0.01 for all) (235). Meek et al (235) also showed that the MDP was responsive to 
change following an AECOPD (a small effect size of 0.38). Given the small 
proportion of COPD participants and an insufficient time period between test-retest, 
further study testing psychometric properties of the MDP in people with COPD is 
required in order to increase the confidence of using this tool.    
2.3.3.2.5 Dyspnoea-12 questionnaire 
The Dyspnoea-12 (D-12) questionnaire measures the severity of dyspnoea (23). 
Compared with the MDP, the D-12 was derived from the large pool of dyspnoea 
descriptors assembled. More than 300 people with COPD, interstitial lung disease 
(ILD) and chronic heart failure participated in the study to develop the D-12 (237).  
The D-12 provides an overall score for the direct effect of dyspnoea and 
incorporating quality and emotional response components. The quality component 
includes items such as ‘my breathing requires more work’ and ‘my breathing is 
exhausting’. The emotional response component relates to the emotional effect of 
dyspnoea and includes items such as ‘my breathing makes me feel depressed’ and 
‘my breathing is distressing’ (23). The overall score is calculated by adding the 
responses for each item (0 = none to 3 = severe). The total D-12 score ranges from 0 
to 36, with higher scores indicating greater severity (237). This tool is simple and 
quick to use for assessing dyspnoea in clinical practice (23, 237).  
The D-12 does not rely on a reference level of activity, such as taking a bath or 
walking up stairs, or on any specific type of activity. The reference frame ‘these 
days’ reflects the current level of dyspnoea experienced by people in their daily life 
as opposed to dyspnoea experienced in response to a specific activity or on the day of 
the test (237). This time reference may be very useful in identifying and tracking 
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dyspnoea in daily life over weeks or months but is not suitable for evaluating 
dyspnoea at a specific time or with a specific activity or intervention. 
In a study of 153 people with COPD, Yorke et al (23) reported that the D-12 has 
acceptable internal reliability (Cronbach’s alpha = 0.9) and acceptable test-retest 
reliability (ICC = 0.90), with a median of 16 days for retest reliability. The validity 
of the D-12 has been demonstrated through weak to moderate associations with 
HADS (anxiety: r = 0.51 and depression: r = 44) and with FEV1 (r = -0.30), 6MWD 
(r = -0.38) and MRC grades (r = 0.48) (p < 0.05 for all) in 53 people with COPD 
(23). In addition, the D-12 has been demonstrated to be reliable two weeks apart in 
84 people with ILD (ICC = 0.94) (41), 102 people with asthma (ICC = 0.93 to 0.96) 
(40) and 176 people pulmonary arterial hypertension (ICC = 0.90) (42). The validity 
of the D-12 has been demonstrated through strong associations with total score of 
SGRQ domain (r > 0.78, p < 0.001), moderate association MRC grades (r > 0.59, p < 
0.001) and weak to moderate association with HADS (anxiety: r = 0.35 to 0.57 and 
depression: r = 0.22 to 0.59, p < 0.05) in those with ILD and asthma (40, 41). 
Furthermore, in those with pulmonary arterial hypertension, the D-12  was shown to 
be strongly associated with the Minnesota Living with Heart Failure Questionnaire –
Pulmonary hypertension modified version, measures the effects of heart failure 
symptoms, functional limitations and psychological distress on an individual’s 
quality of life (r = 0.70, p < 0.01), and moderately and strongly associated with 
anxiety and depression, measured using the HADS (r = 0.54 and r = 0.68, p < 0.001, 
respectively) (42). 
The D-12 has been successfully translated to the Korean language and is a reliable 
and valid tool for measuring dyspnoea in people with tuberculous destroyed lung and 
bronchiectasis (43). However, this instrument has not yet been tested for 
responsiveness to interventions, such as bronchodilators or pulmonary rehabilitation. 
In this thesis, given the simplicity of the D-12 in terms of assessing the intensity, 
quality and emotional response of dyspnoea and the lack of tools to measure 
dyspnoea in Saudi people with COPD, the D-12 was translated to the Arabic 
language and then tested for reliability, validity and responsiveness to change in a 
clinical condition over time.  
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2.3.3.3 Dyspnoea embedded in health-related quality of life questionnaires 
A number of questionnaires have been designed to assess the overall impact of 
COPD on an individual’s HRQoL. Disease-specific HRQoL questionnaires may 
include components that evaluate the effect of dyspnoea on quality of life. It is 
important to note that single components may not provide the same psychometric 
properties when used without the rest of the instrument. These scales often require 
the respondent to recall activities associated with dyspnoea.  
2.3.3.3.1 Chronic Respiratory Disease Questionnaire 
The Chronic Respiratory Disease Questionnaire (CRDQ) includes 20 items that 
evaluate an individual’s outcomes, with a focus on four dimensions of disease: 
dyspnoea, fatigue, emotional function and the individual’s feeling of control or 
mastery over the disease (22). This questionnaire has been widely used to quantify 
the effect of COPD on an individual’s HRQoL (200, 238). The CRDQ is available in 
four different versions for clinical use: the original interviewer-administered CRDQ 
with an individualised dyspnoea domain, an interviewer-administered CRDQ with a 
standardised dyspnoea domain, a self-administered CRDQ with an individualised 
dyspnoea domain and a self-administered CRDQ with a standardised dyspnoea 
domain. The individualised dyspnoea domain in the CRDQ requires the individual to 
identify five activities from a list of 25 common activities that they have undertaken 
during the past two weeks, which are important to them and during which they have 
experienced breathless (22). The dyspnoea severity is evaluated on a seven-point 
scale, ranging from 1 (‘most dyspnoea’) to 7 (‘least dyspnoea’) (22). An interviewer-
administered CRDQ with both individualised and standardised dyspnoea domains 
appears to be appropriate for those illiterate people with COPD.  
While an interviewer-administrated CRDQ with both individualised and standardised 
dyspnoea domains may help to avoid missing responses and errors in completing the 
CRDQ, an interviewer led questionnaire can be very time consuming (239, 240). 
This led to the development of a self-administered CRDQ with a standardised 
dyspnoea domain (241). The standardised dyspnoea domain in the CRDQ includes 
standardised activities that ask the people to indicate how much shortness of breath 
they have experienced while performing each of the activities (242). The dyspnoea 
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severity is evaluated similarly to the individualised version (242). The dyspnoea 
domain of the CRDQ can be considered on its own (221).  
In people with COPD, the individualised version of  CRDQ has been demonstrated 
to have acceptable test-retest reliability (ICC = 0.73), but the dyspnoea domain has 
shown low internal consistency (Cronbach’s alpha = 0.53) (243). This low internal 
consistency could indicate it may not have identical psychometric properties when 
used in isolation from the scale in its entirety. However, the dyspnoea domain of the 
CRDQ has been found to strongly associate with the VAS (r = 0.66, p < 0.05) (244). 
Another study (53) also showed  moderate to strong associations between scores 
from the dyspnoea domain of the CRDQ with TDI scores and FEV1 (r = 0.78, r = 
0.48, respectively; p = 0.0001 for all). The dyspnoea domain score of the CRDQ 
increased significantly by a mean of 1.6 point per item (ppi) during the recovery 
periods following an AECOPD (24) and 0.79 ppi following pulmonary rehabilitation 
compared to those who received usual care (45). A mean change of 0.5 ppi within a 
domain is considered clinically important (245). 
2.3.3.3.2 St. George’s Respiratory Questionnaire  
The SGRQ is a self-administered, 76-item questionnaire measuring disease HRQoL 
(246). This questionnaire measures three domains: symptoms, activities and impact 
on daily life. Dyspnoea is evaluated in terms of its effect on daily activities, using a 
specific ‘activity’ domain. It is also evaluated using the ‘symptoms’ domain in 
conjunction with information pertaining to coughing, sputum production and 
wheezing. However, dyspnoea is not assessed as a separate domain in the SGRQ. 
Therefore, it is difficult to identify the impact of dyspnoea on HRQoL. 
Jones et al (246, 247) reported on the reliability, validity and responsiveness of the 
SGRQ. The reliability of the SGRQ has been demonstrated over a two-week retest 
reliability period involving 40 people with stable asthma (ICC = 0.91) and 20 people 
with stable COPD (ICC = 0.92) (246). The reliability for the sub-components was 
considered acceptable (ICC = 0.91 for symptoms; ICC = 0.87 for activity; ICC = 
0.88 for impact on daily life) (246). The SGRQ has been demonstrated to be valid 
through a moderate to strong association with the MRC grades (r ≥ 0.46, p < 0.05) 
(247, 248) and with anxiety (r ≥ 0.57, p < 0.05) and depression (r ≥ 0.57, p < 0.05), 
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measured using HADS (246). A Cochrane review concluded that the SGRQ changed 
significantly by 6.89 units for the total scores following a pulmonary rehabilitation 
compared to those who received usual care (45). A mean change of 4.0 units is 
considered clinically important (45, 249). 
In summary, dyspnoea can be measured using unidimensional, multidimensional, 
and HRQoL tools that include assessment of dyspnoea. Most of the available 
dyspnoea tools focus on assessing behaviours such as activity limitation. Few tools 
attempt to quantify individual’s perception of the experience of dyspnoea and its 
direct impact on how the individual feels. Most notable, is the absence of evaluating 
the emotional response to dyspnoea in all tools except the MDP and D-12. 
2.3.4 Interventions to reduce dyspnoea in COPD 
2.3.4.1 Changing the inhaled gas 
2.3.4.1.1 Oxygen 
Supplemental oxygen is part of the standard care for the treatment of people with 
COPD who experience chronic hypoxemia, defined as partial pressure of oxygen in 
arterial blood < 55 mmHg, and its ability to relieve dyspnoea has been demonstrated 
(13, 250-252). The beneficial effect of oxygen could be associated with stimulation 
of receptors related to gas flow via the upper airway (253) and/or changes in 
chemoreceptor stimulation, leading to changes in the pattern of breathing (254, 255).  
2.3.4.1.2 Heliox 
Heliox is a helium-oxygen mixture that is known to be nontoxic, noncarcinogenic 
and have no lasting impacts on any human organ systems (256). The short-term use 
of heliox has been shown to result in reductions in dyspnoea outcome measures in 
people with stable COPD and during exacerbations (257-261). Heliox decreases the 
resistance to airflow, which may reduce the work of breathing, decrease the rate of 
hyperinflation, improve exercise capacity and decrease dyspnoea in people with 
COPD (257, 258, 262). However, there is no evidence related to the long-term use of 
heliox in people with COPD. Compared with oxygen, heliox is more expensive 
(263).  
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2.3.4.2 Pharmacological approaches 
2.3.4.2.1 Opioids medications 
Short-term administration of opioids can be used for the treatment of dyspnoea in 
people with COPD and has been demonstrated to reduce dyspnoea (264-266). 
Opioids may have multiple mechanisms of action leading to decreased dyspnoea, 
including reductions in ventilation, oxygen consumption, sensitivity to hypercapnia, 
the central perception of dyspnoea and anxiety related to dyspnoea (267). Opioids 
can be administered either in oral, parental or nebulised forms (13). Oral morphine is 
the most common prescribed opioid for decreasing dyspnoea (264). Other opioids 
medications include dihydrocodeine, diamorphine, fentanyl, hydromorphone, and 
oxycodone (264). Opioids are associated with side effects, particularly constipation, 
but the development of respiratory depression is not common with the doses used to 
treat dyspnoea (13).  
Other pharmacological agents including bronchodilators, anxiolytic medications, 
antidepressants, phenothiazines, inhaled furosemide and inhaled lidocaine are used to 
reduce dyspnoea. However, these medications have been found to be either 
ineffective or there are insufficient data to recommend their use in people with 
COPD (13, 264). 
2.3.4.3 Non-pharmacological approaches 
2.3.4.3.1 Pulmonary rehabilitation 
Pulmonary rehabilitation is defined as an evidence-based, multidisciplinary and 
comprehensive program of care for people with COPD, with exercise training 
considered the key component of pulmonary rehabilitation (268). The beneficial 
effects of pulmonary rehabilitation include reductions in exertional dyspnoea and leg 
fatigue, improved exercise capacity and HRQoL, decrease in the risk of 
hospitalisation for exacerbations and reduced mortality (45, 269, 270). Exercise 
training leads to improvements in skeletal muscle function of people with COPD 
(271, 272). Further, the increased oxidative capacity of the skeletal muscles leads to 
a decreased ventilatory demand for a given submaximal work rate; this reduces 
dynamic hyperinflation and decreases exertional dyspnoea (273, 274). A recent 
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Cochrane review included 19 randomised controlled trials that measured dyspnoea 
intensity after pulmonary rehabilitation, using the dyspnoea domain of the CRDQ, in 
people with COPD (45). The review concluded that people allocated to pulmonary 
rehabilitation who received at least four weeks of exercise training had, on average, a 
greater improvement in dyspnoea intensity compared with those allocated to control 
groups (mean difference = 0.79 ppi, 95% CI 0.56 to 1.03) (45). The mean difference 
exceeded the minimal clinically important difference (MCID) (0.5 ppi) (275). 
2.3.4.4 Other non-pharmacological approaches 
A number of strategies have been explored for their potential impact on reducing 
dyspnoea in people with COPD. Pursed-lip breathing is often a strategy used 
spontaneously by people with COPD to reduce dyspnoea (264). In addition, cool air 
provided by a fan is often reported by people with respiratory disease as means of 
reducing their dyspnoea (13). However, no studies have examined the use of fans 
and/or cool airflow for the reduction of dyspnoea intensity in people with COPD.  
Non-invasive ventilation leads to decreased work of breathing which might reduce 
dyspnoea. Studies that assessed long-term nocturnal use of non-invasive ventilation 
in people with severe COPD demonstrated a significant reduction in dyspnoea 
perception (276, 277). In people with COPD, the use of non-invasive ventilation 
during exercise improves exercise tolerance (278, 279), which may facilitate the 
achievement of high work rates and optimise training response. 
In summary, inhaled gases such as oxygen and heliox have been demonstrated to 
reduce the level of dyspnoea reported by people with COPD. Pharmacological and 
non-pharmacological approaches have also been shown to decrease the perception of 
dyspnoea in people with COPD.  
Part 3 
This part provides a definition for an AECOPD and information related to the causes 
of an AECOPD. The effects of an AECOPD on clinical outcomes and the economic 
burden of an AECOPD are also discussed. In addition, an overview of the 
management of an AECOPD is provided.    
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2.4 Definition and classification of severity of an AECOPD 
An AECOPD is an acute event characterised by a worsening of the individual’s 
respiratory symptoms that is beyond normal day-to-day variation and leads to a 
change in medication (10). The severity of an AECOPD is often classified as mild 
when the exacerbation of respiratory symptoms requires only a change of inhaled 
medication by the individual, without additional healthcare provider contact (10). An 
AECOPD is classified as moderate when the exacerbation of an individual’s 
respiratory symptoms necessitates medical assistance, including a short course of 
antibiotics and/or oral corticosteroids, without requiring hospitalisation (10). An 
AECOPD is classified as severe when the exacerbation of the individual’s respiratory 
symptoms requires hospitalisation (10). 
2.4.1 Causes of an AECOPD 
An AECOPD can be caused by infections and/or exposure to air pollutants. However 
one-third of causes of severe AECOPDs are unknown (280, 281). 
2.4.1.1 Viral infections 
An AECOPD can be triggered by upper respiratory tract infections, which are 
common during the winter months when respiratory viral infections are common in 
the community (282).Viruses have been detected in around half of those with 
exacerbations, depending on the diagnostic techniques used (283, 284). The most 
commonly isolated viruses are human rhinoviruses, coronavirus, respiratory 
syncytial virus, influenza, parainfluenza, and adenovirus (282-284). Human 
rhinoviruses can infect the lower airways and contribute to inflammatory changes 
during an AECOPD (282). In people with COPD, low-dose- experimental rhinovirus 
infection has been found to induce symptoms that are typical of an AECOPD, 
providing support that respiratory viruses can infect the lower airways (285). 
AECOPD that is caused by a viral infection is often more severe, associated with a 
prolonged recovery time and increases the risk of hospitalisation than an 
exacerbation caused by other factors (286, 287). 
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2.4.1.2 Bacterial infections 
The precise role of bacteria in an AECOPD has been difficult to clarify as the 
bacteria found in the airways of people with COPD during periods of clinical 
stability are often associated with those isolated during an exacerbation (288-290). 
An AECOPD may result from a change in the colonising strain of bacteria (291), 
although not all exacerbations are associated with a change in bacterial strain, and 
not all bacterial strain changes cause anexacerbation. The common bacterial 
organisms are Streptococcus pneumoniae, Haemophilus influenza and Moraxella 
catarrhalis, and in people with more severe COPD, Pseudomonas aeruginosa (282, 
292). The presence of lower airway bacterial colonisation in an individual during 
periods of clinical stability has been shown to be related to an exacerbation 
frequency (293). People with COPD who have their airways colonised by 
Haemophilus influenza during periods of clinical stability report more symptoms and 
increased sputum purulence during an AECOPD than those not previously colonised 
(293, 294). This suggests that lower airways bacterial colonisation in people with 
stable COPD modulates the character and frequency of an AECOPD (293, 294). 
Up to 25% of AECOPDs are caused by bacterial and viral coinfection which is 
associated with more severe disease (295). An increase in the systemic inflammatory 
response has been found in exacerbations associated with both Haemophilus 
influenzae and rhinovirus isolation (288) These findings have been confirmed in a 
further study that revealed greater impairment in lung function and longer 
hospitalisations in people with an AECOPD associated with bacterial and virus 
coinfection compared with those without coinfection (295). 
2.4.1.3 Air pollutants 
The role of air pollution in causing an AECOPD has been investigated in 
epidemiological studies that have demonstrated that increases in sulphur dioxide, 
nitrogen dioxide, particulate matter under 10 microns in diameter and black smoke 
particles are associated with worsening chronic respiratory symptoms and an 
increased mortality rate in people with COPD (296-298). These studies investigated 
the rate of hospital admission for an AECOPD at times of increased levels of 
atmospheric pollution and concluded that effects of air pollution on hospital 
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admission are significant, and could account for approximately 6 to 9% of all 
admissions for an AECOPD, depending on the time of year (299).   
2.4.2 Effects of an AECOPD on clinical outcomes 
An AECOPD can have serious clinical consequences such as worsening respiratory 
symptoms and reduced lung function, specifically a decline in the FEV1 (91). In 
addition, a decrease in HRQoL (92), functional capacity and physical activity, 
increased feelings of anxiety and depression, and higher risk of mortality have been 
demonstrated during an AECOPD (91, 92).  
2.4.2.1 Symptoms 
An AECOPD is associated with worsening dyspnoea and changes in sputum 
purulence and/or volume (25, 300). One of the first studies that tracked changes in 
respiratory symptoms, using daily diary cards, reported on 504 exacerbations 
experienced by 91 people with moderate to severe COPD over two and half years 
(25). The study found that, on the day of onset of an exacerbation, symptoms 
increased sharply with 64% of exacerbations associated with dyspnoea and 26% with 
increased sputum volume and 42% with increased sputum purulence. Increases in 
minor symptoms such as cough and wheeze ranged from 12% to 35% (25). In people 
with COPD, dyspnoea is often the primary reason for seeking medical assistance 
during an AECOPD (13). Several studies have shown that people have reported a 
higher intensity of dyspnoea during an AECOPD compared to their dyspnoea 
intensity following an AECOPD (24, 53, 301). Parker et al (24), for instance, 
assessed 20 people during an AECOPD and 60 ± 5 days following an AECOPD 
using the dyspnoea domain of the CRDQ. The authors reported that, during an 
AECOPD people were more dyspnoeic during their usual activities of daily living 
than 41 days following the AECOPD (dyspnoea domain score of the CRDQ 2.4 
versus 4.5 ppi) (24). 
The trajectory of recovery for an AECOPD is variable. Parker et al (24), 
demonstrated that, following an AECOPD, 40% of 20 people with a moderate to 
very severe AECOPD reported that their levels of dyspnoea had not returned to pre-
AECOPD levels within an average of 41 days. This suggests that the recovery period 
may be prolonged in a large proportion of people with COPD. Seemungal et al (25) 
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reported, in 101 people with a moderate to severe AECOPD, that 91% had returned 
to their pre- AECOPD levels of respiratory symptoms by 91 days following an 
AECOPD. The current evidence suggests that a follow-up period of ≥ 91 days is 
required to allow 91% of people with an AECOPD to recover following an 
AECOPD. 
Fatigue is considered to be a major symptom experienced by people with COPD and 
has also been shown to increase during an AECOPD (117, 302). Baghai-Ravary et al 
(303) used the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in 
107 people with COPD during a period of clinical stability and during an AECOPD. 
The authors found that those who had an AECOPD (n = 32) experienced a 24% 
increase in fatigue (p < 0.001) during an AECOPD (severity of an AECOPD was not 
reported) compared with a period of clinical stability (303). Furthermore, people who 
had frequent AECOPDs (≥ 2 exacerbations per year) experienced more fatigue than 
those who had infrequent AECOPDs (p = 0.002) (303). The study also demonstrated 
that only those people (53%) who had infrequent AECOPDs reported that their 
fatigue levels had returned to pre-AECOPD levels within six weeks after an 
AECOPD (303).  
2.4.2.2 Exercise capacity  
In people with COPD who have decreased functional exercise capacity, a further 
decrease in exercise capacity during an AECOPD has been reported (302, 304, 305). 
For instance, Carr et al (302) measured functional exercise capacity, using the 
6MWD, in 34 people with stable moderate to severe COPD at the completion of 
pulmonary rehabilitation, and followed up them for six months until they had an 
AECOPD. The authors found a reduction of 16% in the 6MWD two weeks following 
a moderate to severe AECOPD (302). This magnitude of reduction is similar to that 
observed between the first week of an AECOPD and at one month following hospital 
discharge (19%) (304). Furthermore, the reduction of exercise capacity following an 
AECOPD persisted over the two years of follow-up (306). In addition, people with 
frequent AECOPDs (≥ 2 exacerbations per year) had lower functional exercise 
capacity than those who had infrequent AECOPDs (p = 0.006), with a mean 
difference of 51 meters in the 6MWD (306), seen which is greater than the MCID 
(30 meters) (307). 
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2.4.2.3 Physical activity 
The level of physical activity of people with COPD reduces in response to an 
AECOPD (304, 308, 309). Consistent findings were reported by Pitta et al (304) and 
Borge et al (310) who used accelerometers (DynaPort McRoberts; The Hague, 
Netherlands) to measure the physical activity of people hospitalised for AECOPD. 
They demonstrated that a large proportion (> 86%) of people’ waking hours were 
spent sitting and lying down during hospitalisation. One month after discharge, Pitta 
et al (304) demonstrated that the time spent in sitting and lying down did not 
significantly differ than that seen during hospitalisation. Borge et al (310) reported 
that, one month after discharge, the proportion of time spent sitting and lying down 
reduced to approximately 67% of waking hours (p < 0.001). The differences in the 
findings between the two studies could be explained in part by the people included in 
the studies. Borge et al (310) included those who had less severe COPD and higher 
functional exercise capacity at one month after discharge compared to those included 
in the study by Pitta et al (304) (FEV1% predicted, 49% versus 34% and 6MWD, 373 
m versus 332 m, respectively). Decreases in FEV1 and 6MWD have been associated 
with low levels of physical activity in people with COPD (56, 85), which could 
influence the recovery of physical activity following hospital discharge. 
A reduction in physical activity has also been demonstrated in those who had an 
AECOPD without hospitalisation (i.e. a mild or moderate AECOPD). Using a 
pedometer (a Yamax Digiwalker SW-200), Alahmari et al (309) reported a reduction 
of 12% in the daily step counts of 73 people with moderate to severe COPD between 
a period of clinical stability and the first seven days of a mild to moderate AECOPD 
(p = 0.045). The same study also revealed that those with frequent exacerbations (≥ 2 
exacerbations per year) had a greater decrease in daily step counts over time than 
those with infrequent exacerbations (707 versus 337 steps per year, p = 0.002) (309). 
These data imply that people with frequent AECOPD (≥ 2 exacerbation per year) 
participated in a little physical activity than those with infrequent AECOPD (309). 
2.4.2.4 Health-related quality of life  
Studies that used disease–specific HRQoL questionnaires, such as the SGRQ and the 
CRDQ, during and following an AECOPD, showed a reduction in HRQoL during an 
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AECOPD (92, 302, 306, 311, 312). Although impairments in HRQoL have been 
reported during an AECOPD, it appears that people with frequent exacerbations have 
more impairment in their HRQoL than those with infrequent exacerbations (92, 311, 
313). Furthermore, regardless of the criteria used to define frequent AECOPDs, 
people with frequent AECOPDs tend to have greater HRQoL deterioration over time 
compared with those who had infrequent AECOPDs. Spencer et al (314), for 
instance, demonstrated that people with frequent exacerbations ( ≥ 1.65 
exacerbations per year) had more rapid deterioration in HRQoL (mean of 2.9 units 
per year), assessed by the SGRQ, compared to those with infrequent exacerbations 
(mean of 2.4 units each year) (p < 0.001) (314). 
The time course for recovery of HRQoL varies following an AECOPD (314). During 
the first month following an AECOPD, greater improvements were reported amongst 
those who had only one AECOPD compared with those who had more than one 
AECOPD (p < 0.05) over six months of follow-up (301, 314). After the first month, 
HRQoL improved for people with only one AECOPD and this improvement was 
persisted up six months (314). In contrast,  the HRQoL of those who experienced 
two or more AECOPDs, remained unchanged after the first month of improvement 
(301, 314). These results indicate that HRQoL may take several months to return to 
pre-AECOPD levels in those who experience multiple AECOPDs.  
2.4.2.5 Feelings of anxiety and depression 
Feelings of anxiety and depression are common among people with COPD and also 
appear to be associated with an AECOPD (315, 316). However, there are limited 
data on whether the feelings of anxiety or depression are altered during an AECOPD. 
Thompson et al (317) measured anxiety and depression using the HADS amongst 40 
people with a severe AECOPD on admission to the hospital. Thirty-two (80%) 
people reported feelings of anxiety (HADS scores ≥ 8) on admission. These HADS 
scores remained unchanged over a median of 14 weeks of follow-up after discharge. 
Although an improvement in the score of depression was observed over the same 
follow-up period (depression HADS scores mean difference = 2.5), this improvement 
was not statistically different to that reported on admission (p > 0.05) (317). The lack 
of statistical significance may be explained in part by the small sample size. In 
addition, feelings of anxiety and depression may require a longer time frame to 
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return to pre-AECOPD levels. Quint et al (318) used the Center for Epidemiologic 
Studies Depression Scale in 169 people with moderate COPD to assess depression. 
Over a one year follow-up, the authors demonstrated that feelings of depression 
during an AECOPD increased compared to that reported during a period of clinical 
stability (20.3 ± 10.4 versus 14.6 ± 11.8, p < 0.001) (318). In addition, people with 
frequent exacerbations (≥ 3 exacerbations per year) had more feelings of depression 
than those without frequent exacerbations (p = 0.03) (318). 
2.4.2.6 Lung function 
Several studies have investigated the effect of an AECOPD, regardless of severity, 
on lung function (91, 312, 319, 320). Specifically, these studies showed a 
relationship between accelerated decline in the FEV1 and an AECOPD. Compared to 
the FEV1 value obtained during a period of clinical stability, FEV1 has been shown to 
be reduced by approximately 20% in people during a moderate to severe AECOPD 
(24). A similar decrease in the FEV1 (16%) during a moderate to severe AECOPD 
was reported by Cote et al (306). The authors reported that this decrease persisted 
and did not return to pre-AECOPD levels over two years of follow-up.  
The FEV1 of people with more frequent AECOPDs has been shown to deteriorate 
more quickly than that of people who had infrequent AECOPDs (91, 320, 321). 
Donaldson et al (91) demonstrated that the decline in the FEV1 over four years was 
25% higher in people with moderate to severe COPD who experienced frequent 
exacerbations (> 2.92 exacerbations per year) than those with less frequent 
exacerbations. 
2.4.2.7 Mortality 
Several studies have revealed a high mortality rate in people with COPD who were 
hospitalised for an AECOPD (322-324). In people with a severe AECOPD, the 
mortality rate during hospitalisation was 8% (325) and increased to 23% after one 
year of follow-up (325, 326). Sprooten et al (326) demonstrated that those who were 
re-hospitalised early (within 49 days) had a mortality rate of 40%. The mortality rate 
for people with a severe AECOPD increases over time (327). Over a 17-year follow-
up, the rate of mortality for people who had experienced a severe AECOPD was 50% 
at 3.6 years, 75% at 7.7 years and 96% by 17 years (327). In addition, the risk of 
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mortality has been show to increase with increasing frequency of AECOPD, 
regardless of other prognostic factors such as age, body mass index, FEV1 and 
comorbidities (324). Thus, people with frequent AECOPDs (≥ 3 exacerbations per 
year) had the highest rate of mortality, with a 4.1 times higher risk of death (95% CI, 
1.80 to 9.45) (324) than people with infrequent AECOPDs or those with 1 to 2 
AECOPDs per year. 
In summary, an AECOPD is associated with worsening symptoms and greater 
impairments in exercise capacity, physical activity, HRQoL and lung function. 
Increased feelings of anxiety and depression as well as increased rate of mortality are 
also associated with an AECOPD.  
In people with a severe AECOPD, the mortality rate during hospitalisation was 8% 
(325) and increased to 23% after one year of follow-up (325, 326). The latter study 
(326) demonstrated that those who were re-hospitalised early (within 49 days) had a 
mortality rate of 40%. The mortality rate for people with a severe AECOPD 
increases over time (327). Over a 17-year follow-up, the rate of mortality for people 
was 50% at 3.6 years, 75% at 7.7 years and 96% by 17 years (327). In addition, the 
risk of mortality increased with increasing frequency of AECOPD, regardless of 
other prognostic factors such as age, body mass index, FEV1 and comorbidities 
(324). Thus, people with frequent AECOPDs (≥ 3 exacerbations per year) had the 
highest rate of mortality, with 4.1 times higher risk of death (95% CI, 1.80 to 9.45) 
(324) than people with infrequent AECOPD or those with 1 to 2 AECOPDs per year. 
In summary, an AECOPD is associated with worsening symptoms and greater 
impairments in lung function, HRQoL, exercise capacity and physical activity. 
Increased feelings of anxiety and depression as well as increased rate of mortality.  
2.4.3 Economic burden of an AECOPD 
A significant portion of COPD treatment costs are associated with an AECOPD 
(112). Furthermore, the severity and frequency of an AECOPD influences health care 
costs (112, 328). A retrospective study carried out in the United States of America 
and published in 2012 (329) included 8,554 people with COPD (329). The study 
showed that the annual total expense for health care (i.e. hospital admissions, 
emergency room, physician office visit and medications) was $4,720 USD for people 
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who had one or more AECOPDs compared with $1,425 USD for people who had no 
AECOPD. The annual cost for people with a severe AECOPD was approximately 
four times higher than those with a moderate AECOPD ($12,765 USD versus $3,356 
USD). Equivalent data for costs associated with an AECOPD in Saudi Arabia are not 
available. 
The burden of an AECOPD is not only reflected in direct costs, but also in indirect 
costs (113). Indirect costs including lost wages of the individual, lost wages of family 
caregivers, and employer-borne costs such as absenteeism and sick leave, disability 
and impaired work performance. The indirect costs of lost work days associated with 
an AECOPD have been estimated to account for 14% of the total AECOPD 
treatment cost (330).  
2.4.4 Management of an AECOPD 
The goals of management for an AECOPD are to reduce the impact of the current 
exacerbation and prevent subsequent exacerbations from developing (10). Depending 
on the severity of an AECOPD, people can be managed at home or at hospital (10). 
Home management of an AECOPD is common for people with less severe 
exacerbations and includes increasing the dose or frequency of existing 
bronchodilator therapy (10, 331). Hospital management of an AECOPD involves 
oxygen therapy, pharmacological therapy and may include ventilatory support. 
2.4.4.1 Hospital management 
2.4.4.1.1 Pharmacological therapy 
There are three classes of medications commonly used for an AECOPD, namely 
bronchodilators, corticosteroids and antibiotics (10, 331). 
Bronchodilators: Despite there being no controlled trials, short-acting inhaled β2-
agonists (e.g. salbutamol and terbutaline) with or without short-acting 
anticholinergics (ipratropium) are often the preferred bronchodilators for treatment of 
an AECOPD in order to minimise respiratory symptoms and to maximise 
bronchodilation (331-333). Inhaled bronchodilators can be delivered by nebulisers 
and metered dose inhalers with spacer device. Nebulisers and meter dose inhaler 
have been found to have equal efficacy in relieving an AECOPD, with no significant 
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difference in duration of hospitalisation (334). The dose of 5mg of salbutamol 
delivered by nebuliser is equivalent to 8 to 10 puffs of 100 mcg salbutamol delivered 
by metered dose inhaler and spacer (331). High doses of β2-agonists may lead to a 
decrease in the level of serum potassium (hypokalaemia) and predispose to irregular 
heartbeats (cardiac arrhythmias) (331). In the case of a severe AECOPD and 
insufficient response to short-acting bronchodilators, oral or intravenous 
methylxanthines (theophylline or aminophylline) can be considered (10). 
Glucocorticosteroids: Oral, inhaled or intravenous glucocorticosteroids are beneficial 
in treating people with an AECOPD (10, 331, 335). In addition to bronchodilator 
therapy (plus oxygen therapy), glucocorticosteriods are recommended for the 
management of an AECOPD (10, 336, 337) as they decrease recovery time and 
improve FEV1 (336, 337). A dose of 30 to 50 mg of oral prednisolone per day for 10 
to 14 days is a reasonable compromise between efficacy and safety (331). However, 
the optimal dose of glucocorticosteriods has not been established. A prolonged 
course and high dose of glucocorticosteriods can provide a long anti-inflammatory 
effect. However, glucocorticosteriods are associated with adverse effects, such as 
hyperglycemia, bone fractures, and osteoporosis, especially with the increasing doses 
due to the re-exacerbation of an AECOPD (331). A meta-analysis reported that use 
of glucocorticosteriods in COPD was associated with a modest but statistically 
significant increase in fracture risk. Each 500μg increase in glucocorticosteriod dose 
was associated with a 9% increase in fracture risk (338). Therapeutic guidelines 
(331, 339) reported that prolonged use of glucocorticosteriods (> 7.5 mg daily for 
more than 6 months) increases the risk of developing osteoporosis (331). it appears 
that lower doses of glucocorticosteriods are associated with fewer side effects and 
more benefit than higher doses in hospitalised people with an AECOPD (340).  
Antibiotics: Given that bacteria are associated with a substantial proportion of 
episodes of AECOPD, the use of antibiotics is more effective when increased sputum 
purulence and volume is present (331). Oral antibiotics are preferred, for ease of 
administration, despite intravenous antibiotics can be given if there is difficulty in 
swallowing. A meta-analysis of 11 studies found that using antibiotics decreases the 
risk of short-term mortality by 78% and sputum purulence by 44% in people with an 
AECOPD (341). Therapeutic guidelines (331, 339) recommend the use of oral agents 
Chapter 2: Literature review 
55 
of antibiotics such as doxycycline or amoxicillin is recommended. In case of people 
with an AECOPD do not respond or resistant organisms are suspected, amoxycillin–
clavulanate must be prescribed (331). Although the use of antibiotics are 
recommended for seven to 10 days, optimal duration of antibiotics use has not been 
established (331, 339, 342). 
2.4.4.2 Controlled oxygen therapy 
During an AECOPD, oxygen administration is one of the primary therapies for 
people with hypoxaemia (10, 331). Controlled oxygen needs to be titrated to provide 
adequate levels of oxygenation (percutaneous oxygen saturation > 90%) (10).When 
oxygen is administered, arterial blood gases should be regularly checked in order to 
ensure there is adequate oxygenation without carbon dioxide retention or acidosis 
(10).  
2.4.4.3 Ventilatory support 
In people with a severe AECOPD who require ventilatory support, the primary 
objectives of mechanical ventilatory support are to reduce mortality and morbidity 
and to relieve symptoms (10). Mechanical ventilatory support during an AECOPD 
can be delivered non-invasively using positive pressure devices (by nasal or facial 
mask) or invasively (by endo/naso-tracheal tube or tracheostomy). 
Findings of randomised controlled trials using non-invasive ventilation in acute 
respiratory failure have consistently produced success rates of 80% to 85% (343-
345). Non-invasive ventilation has been shown to reduce respiratory acidosis 
(increases pH and decreases partial pressure of carbon dioxide in arterial blood) and 
reduce the severity of dyspnoea in the first four hours of treatment, and shorten the 
length of hospitalisation (331, 343, 346).  
There are several indications for using invasive ventilation during an AECOPD of 
which one is the failure of an initial trial of noninvasive ventilation (10). However, 
there are major risks associated with invasive ventilation including the risk of 
ventilator-acquired pneumonia (especially when multiresistant organisms are 
prevalent), barotrauma, and failure to wean to spontaneous ventilation (10).  
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In summary, depending on the severity of an AECOPD, people can be managed at 
home or in hospital. Hospital management includes controlled oxygen therapy, 
pharmacological therapy and ventilatory support. 
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Part 4 
This part reviews the literature pertaining to physical activity and sedentary 
behaviour, and public health recommendations on physical activity and sedentary 
behaviour for health. Various methods that are used to measured physical activity 
and sedentary behaviour, and factors associated with the measurement of physical 
activity and sedentary behaviour in people with COPD are also discussed. 
2.5 Physical activity and sedentary behaviour 
Physical activity can be defined as any bodily movement produced by skeletal 
muscles that results in energy expenditure above resting (basal) levels (54). When 
physical activities are planned, structured, repetitive and purposive in the sense that 
optimisation or maintenance of one or more components of physical fitness is the 
objective, it is known as exercise (347). Physical activity includes sport, exercise and 
physical activities performed as a part of people’s daily living, occupation, 
transportation or leisure activities. Physical activity is often categorised as light, 
moderate or vigorous intensity, based on the level of energy expenditure required 
(348). For instance, light intensity physical activity includes energy expenditure ≥ 
1.5 and < 3 metabolic equivalent units (METs). One MET represents the energy 
expenditure used during quiet rest and is frequently defined in terms of an oxygen 
uptake of 3.5 ml·kg
-1
·min
-1 
(348). Light intensity physical activity involves activities 
such as ironing, slow walking, washing dishes and cooking food (348). Moderate 
intensity physical activity includes energy expenditure ≥ 3 and < 6 METs, and 
involves activities like dancing, brisk walking and sweeping the floor (348). 
Vigorous intensity physical activity requires an energy expenditure ≥ 6 METs and 
includes activities such as running, swimming, playing soccer, walking uphill and 
playing volleyball (348, 349).  
Sedentary behaviour is characterised by low energy expenditure (< 1.5 METs) while 
in a sitting or reclining posture during waking hours (68, 350). It can occur 
throughout the waking day in different domains (i.e. across work, leisure, commuting 
and entertainment) (351). The most common sedentary behaviours are reading, 
sitting time, using the computer and television viewing (352). 
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2.5.1 Public recommendations on physical activity for health 
The American College of Sports and Medicine (ACSM) guidelines recommend that 
adults undertake at least a minimum of 150 minutes of moderate intensity physical 
activity or 75 minutes of vigorous intensity physical activity each week, to maintain 
health benefits such as a reduction in cardiovascular and metabolic disease, and all-
cause mortality (54). These beneficial effects have been proposed to be mediated by 
several physiological adaptations (54). These adaptations include improvement in 
endothelial function, production, expression and release of myokines by skeletal 
muscle, cardiovascular fitness and insulin sensitivity, maintenance of a healthy body 
weight, preservation of fat free mass, reduction in systemic inflammation and 
adiposity and/or improvements in immune function (54, 353). It appears that people 
who participate in regular prolonged periods of moderate to vigorous physical 
activity are more likely to have many of these physiological adaptations. This is 
supported by the current ACSM guidelines that recommend that adults perform at 
least 30 of daily moderate intensity physical activity, accumulated in bouts of at least 
10 minutes in duration (54). It can be also achieved by performing a total of 75 
minutes per week of vigorous intensity aerobic physical activity (54).  
Daily step counting is a simple measure that is easily and directly translatable from 
the research to the clinical setting. In addition, it appears that it is meaningful for 
people trying to maintain or increase their physical activity, compared with other 
measures of physical activity such as METs. Therefore, there has been a growing 
interest in translating the current recommendation by the ACSM for moderate 
intensity physical activity into steps per day (62, 354, 355). Data pertaining to an 
appropriate translation of 30 minutes of moderate intensity physical activity in terms 
of daily steps were reviewed by Tudor-Locke et al (355), who concluded that 30 
minutes of daily moderate intensity physical activity taken in addition to habitual 
daily activities in healthy older people is equivalent to accumulating at least 7,000 
steps per day. These findings are consistent with the recommendation by the ACSM 
for adults to accrue at least 7,000 steps daily to confer health benefits (54). The 
review by Tudor-Locke et al (355) concluded that to meet the current 
recommendation for moderate intensity physical activity, steps can be also 
accumulated in a minimum of 3,000 steps in 30 minutes per day, which can be split 
Chapter 2: Literature review 
59 
into 3 daily bouts of 1,000 steps for at least 10 continuous minutes for healthy older 
people (355). 
2.5.2 Importance of reducing sedentary behaviour 
Among those who participate in the recommended amount of physical activity, the 
proportion of total waking hours spent participating in physical activity is low, with a 
high proportion of time spent in either sedentary behaviour or light intensity physical 
activity (70). In the general adult population, a higher proportion of time in sedentary 
behaviour has been associated with a greater risk for all-cause of mortality (69, 356). 
This association is independent of the amount of time spent in moderate-to-vigorous 
intensity physical activity (69). The mechanisms for the association found include 
the minimal muscular contractions in the large postural muscles occurring during 
sitting (357), with the lower energy expenditure when compared with sedentary 
behaviours (358).  
The manner in which sedentary time is accumulated appears to be important. 
Specifically, it has been shown that, regardless of the total time spent in sedentary 
behaviour, people who accumulated sedentary behaviour in prolonged unbroken 
bouts are at greater risk of developing cardiovascular and metabolic diseases 
compared to those who interrupted their sedentary time with either light or moderate 
intensity physical activity (71, 359). Despite a lack of sufficient evidence to provide 
firm recommendations about how often should we get up, a practical message may 
be to sit less throughout the day, and stand up at least every 30 minutes.  
2.5.3 Quantifying physical activity and sedentary behaviour 
Physical activity and sedentary behaviour can be measured using subjective methods 
(e.g. self-reported questionnaires) or objective methods (physical activity monitors 
such as pedometers and accelerometers).  
2.5.3.1 Subjective methods 
Subjective methods of measuring physical activity and sedentary behaviour include 
the use of questionnaires, diaries or logs, and surveys or interviews (360). These 
subjective methods are often inexpensive and easy to apply. However, the 
information they provide appears to be inaccurate (361), since people with COPD are 
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likely to overestimate the time spent walking and underestimate the time spent 
standing and sitting (362), reflecting recall and social desirability bias. Garfield et al 
(363) conducted the first study that simultaneously evaluated the validity of four 
physical activity questionnaires (the Baecke questionnaire, the Zutphen Physical 
Activity Questionnaire, the Stanford 7-day Physical Activity Recall Questionnaire 
[PAR], and the Physical Activity Scale for the Elderly Questionnaire) against a 
multi-sensor accelerometer in people with moderate to severe COPD (363). They 
found that only the score of the PAR was significantly associated with time spent 
engaging in ≥ 3 METs obtained by a multi-sensor accelerometer (r = 0.54; p < 0.001) 
and the PAR also predicted active people (≥ 30 minutes at ≥ 3 METs) (363). 
However, the PAR cannot accurately measure the amount of physical activity and 
sedentary behaviour for people, nor can it provide information pertaining to the 
domain in which the physical activity and sedentary behaviour were performed 
(363).  
Although measures obtained by subjective methods may show inaccuracies because 
of a long recall time period (364), detailed questioning related to physical activity for 
recent time periods (i.e. two days) has been shown to increase the reliability of the 
information gathered from people with COPD (365). The Multimedia Activity Recall 
for Children and Adults (MARCA) is a computer-based time instrument that, 
through a structured interview format, records and constructs detailed daily physical 
activity information (365). The MARCA has been demonstrated to be reliable (intra-
class correlation coefficients [ICC] for test-retest ≥ 0.9) (365). This instrument also 
has been demonstrated to be valid (r = 0.47 to 0.80) when compared to two physical 
activity monitors in people with COPD, for measuring time and energy expenditure 
associated with physical activities and sedentary behaviours (365). However, it 
should be noted that that data provided using the MARCA are not as accurate as 
motion sensors in terms of recording actual movements (365). Despite these 
limitations, these subjective methods provide detailed information on the type of 
activities performed during daily life, which can be useful in setting targets and goals 
for participation in daily physical activity, depending on people’s preferences (70). 
The low cost and simplicity of using subjective methods has led to their widespread 
use in clinical practice and epidemiological research (70). 
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2.5.3.2 Objective methods  
Objective methods for quantifying physical activity and sedentary behaviour 
commonly use motion sensors, such as pedometers or accelerometers, to capture 
body movement (361). The measurement properties of motion sensors and their 
outcomes differ considerably. Most motion sensors necessitate technical expertise to 
collect, download, and interpret the data. The selection of a physical activity motion 
sensor requires careful consideration of the device’s cost, validity, reliability, 
convenience, research and clinical goals, responsiveness and the population being 
studied (366).  
2.5.3.2.1 Pedometers 
Pedometers are considered the simplest motion sensors as they are small, 
inexpensive, and easy to use. Most models are worn on the waist and contain a 
horizontal spring-suspended lever arm that deflects with the up and down motion 
(vertical acceleration) of the hips during walking (367). However, one of the 
limitations of pedometers is that any vertical movement, such as vibrations while 
seated in a moving car, may trigger the device to count the movement as a step (368). 
Moreover, pedometers do not provide data related to the pattern of physical activity 
and sedentary behaviour, nor the intensity of the activities performed (369). 
Pedometers are often less sensitive to the steps of people who have a slow or 
shuffling gait, and therefore tend to undercount-steps in the COPD population (370-
373). For instance, the study by Furlanetto et al (373) which included people with 
COPD, found that, compared to steps counted by direct observation, pedometers 
under-estimated the number of steps at slow speed of 1.4 ± 0.3 km/h (79 ± 17 versus 
26 ± 26 steps; p < 0.05). 
Despite the limitations of pedometers, these motion sensors appear to be useful tools 
for those aiming to optimise their physical activity (374). For example, Mendoza et 
al (375), whose study included people with mild COPD, reported a 56% increase in 
steps per day in those people who wore a pedometer for three months and were 
encouraged to increase their daily physical activity.  
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2.5.3.2.2 StepWatchTM Activity Monitor 
The StepWatch
TM
 Activity Monitor (SAM) (OrthocareInnovations, Seattle, 
Washington, USA) has the ability to record steps accurately at fast and slow walking 
speeds (376, 377). This monitor is a small (75 × 50 × 20 mm) microprocessor-linked 
sensor enclosed within a lightweight (38 g), pager-sized, durable casing. This 
monitor is worn on the right ankle and secured in place using a Velcro strap and can 
be covered by clothing. It uses a combination of position, timing, and acceleration to 
detect steps (378). The SAM has a sampling frequency of 128 Hertz (Hz) and records 
the number of steps taken every minute (378). This monitor costs approximately 
$525 AUD and $2500 AUD for the computer interface docking station. Several 
studies have established the accuracy of the SAM in measuring steps in populations 
characterised by their slow walking speeds (376, 378). In people with COPD, the 
SAM has been demonstrated to have an excellent capacity to accurately detect steps, 
irrespective of walking speed or use of a wheeled-walker, when compared to direct 
observation (377). 
Given the advantages of the SAM and the fact that Saudi nationals tend to wear 
traditional long dress, the SAM appears to be suitable for use in this population, and 
therefore the SAM was selected for the study described in Chapter 5 of this thesis. 
2.5.3.2.3 Accelerometers 
Accelerometers have been developed with increasingly advanced motion sensors that 
measure the acceleration of body movements in one (uniaxial), two (biaxial) or three 
(triaxial) planes (379, 380). One of the advantages of most accelerometers is their 
ability to accurately determine the quantity and intensity of movement over a specific 
period of time (381). Depending on the type of accelerometer, these monitors can be 
worn on the waist, hip, wrist, back, and upper or lower limbs. The percentage of time 
spent active and performing specific activities can be calculated, depending on the 
type of accelerometer. The output from some accelerometers can be used to divide 
waking time into sedentary behaviour, and light, moderate and vigorous intensity of 
physical activity (359). Moreover, some of them have the capacity to distinguish 
brisk walking from other activities of daily life (382). However, accelerometers are 
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often more expensive than pedometers and most need technical expertise to collect, 
download and analyse the data (70). 
2.5.3.3 Other methods for measuring physical activity 
There are other methods that can be directly and indirectly used to measure physical 
activity. Direct observation is considered the gold standard method to measure 
physical activity. It is undertaken by observers who watch or videotape activities 
performed by people and quantify them (361). However, this method is very time 
consuming, intrusive and inappropriate for large populations (383).  
The assessment of energy expenditure using doubly labelled water is an indirect 
method used to estimate physical activity. This method is a standard technique for 
measuring energy expenditure that uses a quantity of water containing both stable 
oxygen and hydrogen isotopes. This method is based on the principle that after 
drinking a quantity of oxygen and hydrogen isotopes, oxygen is eliminated as carbon 
dioxide and water, and deuterium is eliminated from the body as water. The 
difference between the two isotope elimination rates is used to calculate the total 
energy of the body (384). The high cost of materials and expertise needed to analyse 
the isotope concentrations using mass spectrometry limits the use of doubly labelled 
water as a measurement technique in large population studies (384, 385). 
2.5.4 Factors associated with the measurement of physical activity and 
sedentary behaviour 
Generally, the measurement of physical activity and sedentary behaviour appears to 
be highly variable in amount, intensity and type, and is influenced by many factors 
related to sampling (386). These factors include the number of hours per day and the 
number of days of monitoring (387, 388), whether measurements are obtained over 
weekdays versus weekend days (389) and the impact of seasonal variation (390). 
Determining the minimum number of hours per day and number of days of activity 
monitoring is required to minimise the burden for participants but still reflect the 
habitual activity of people (387, 391). A review by Masse et al (387) concluded that 
wearing motion sensors for 10 hours or 60% of waking time a day in the adult 
population is required to accurately reflect their daily physical activity levels. In the 
Chapter 2: Literature review 
64 
healthy adult population, habitual level of activity varies considerably, and therefore, 
three to five days of activity monitoring has been recommended to obtain a measure 
of physical activity (386, 388). In older populations, it has been found that two valid 
days of monitoring physical activity are considered the minimum number of required 
days to assess physical activity (ICC ≥ 0.8) (392, 393). This finding is consistent 
with that reported by Pitta et al (56), who found that measurement for only two 
weekdays was required to produce an acceptable reliability (ICC ≥ 0.7), for the time 
spent in various body positions (lying down, sitting, standing and walking). 
However, Watz et al (85) found that at least three days were necessary to reliably 
(ICC ≥ 0.7) measure average daily physical activity in people with mild to severe 
COPD. These authors found that only two days of physical activity monitoring were 
required for people with very severe COPD (85). Steele et al (82) found that three 
days of physical activity monitoring were required to reliably (ICC ≥ 0.70) quantify 
physical activity for those with moderate to severe COPD. Pooling the results of 
these studies, it would seem that at least three days of physical activity monitoring 
would be appropriate to adequately measure the average daily activity for people 
with COPD.  
Although most of the studies mentioned above recommended a minimum of three 
days for monitoring, it is important to determine whether these three days need to be 
consecutive or whether a combination of any three days of monitoring is acceptable 
in order to provide a reliable measurement of physical activity. Studies that included 
healthy adult people have shown that a decrease in physical activity occurred on 
Sundays when compared to other days of the week (355, 389). However, an earlier 
study demonstrated less day-to-day variability in physical activity, when measures 
were collected over seven consecutive days in people with COPD (368). Lorse et al 
(78) measured physical activity over seven consecutive days using an accelerometer 
in 23 people with moderate to very severe COPD and found that accelerometer 
activity counts for people with COPD did not differ between three within-week 
measurement periods or between weekdays and weekend days (r > 0.97; p < 0.001) 
(78). Given the results of these studies, it would appear that a combination of any 
three days of physical activity measurement are sufficient to accurately quantify 
physical activity in people with COPD. 
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Seasonal variation appears to impact on physical activity and sedentary behaviour, 
with lower levels of physical activity seen during winter than summer (p = 0.02) 
(390). Sewell et al (390) showed that people with COPD who commenced a 
pulmonary rehabilitation program in winter attained a greater improvement in daily 
physical activity compared to those who started the program in summer (p = 0.04). In 
line with the influence of seasonal variation, Moy et al (369) demonstrated that 
people with COPD, who had their baseline measurement of physical activity in 
winter and follow-up in spring, had an increase in daily steps, whereas those who had 
their baseline visit in autumn and follow-up in winter experienced a decline in daily 
steps, after controlling for baseline step count (p = 0.013). In Saudi Arabia, data 
pertaining to the impact of seasonal variation on physical activity and sedentary 
behaviour are unavailable. 
2.5.5 Impact of COPD on physical activity and sedentary behaviour 
There is strong evidence demonstrating that people with stable COPD walk less 
compared with age and gender-matched healthy people (55-58, 76, 78). Specifically, 
it appears that people with stable COPD walk for a shorter duration and more slowly 
than their healthy counterparts (55-58). One of the first studies reporting this 
difference was conducted by Pitta et al (56), who used an accelerometer (DynaPort 
Activity Monitor) to provide detailed information on time spent in different activities 
and positions by people with mild to very severe COPD compared with healthy 
controls. They demonstrated that, compared with healthy controls, during waking 
hours, people with COPD spent less time standing (191 ± 99 versus 295 ± 109 
min/day, p < 0.001) and walking (44 ± 26 versus 81 ± 26 min/day, p < 0.001) (56). 
Vorrink et al (58) reviewed data related to physical activity in people with COPD 
compared with healthy controls. This review concluded that the proportion of time 
people with COPD spent engaging in physical activity each day was only 57% of the 
time spent by healthy controls (58). Furthermore, people with COPD walked around 
25% slower than their healthy counterparts (56, 58). Pitta et al (56) found that people 
with COPD walked at a slower intensity when compared with age and gender 
matched healthy people (1.8 ± 0.3 versus 2.4 ± 0.5 m/s
2
; p < 0.0001). These data 
were similar to that reported by Hernandes et al (57) who demonstrated that people 
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with COPD walked with lower movement intensity when compared with their 
healthy controls (1.9 ± 0.4 versus 2.3 ± 0.6 m/s
2
; p = 0.004). 
There are some data related to the way in which physical activity is accumulated by 
people with COPD demonstrating that people with COPD walk in short interrupted 
bouts instead of long continuous walking (394, 395). For example, Pitta et al (394), 
included 29 people with COPD, demonstrated that before and after pulmonary 
rehabilitation, time spent in walking in daily life was accumulated in very short bouts 
(up to one minutes in length). Similarly, Jehn et al (395) found that walking time 
spent by people with COPD each day was accumulated in short interrupted bouts of 
less than five minutes.  
Besides participating in lower levels of physical activity during waking hours, people 
with COPD also spend larger proportions of time in sitting and lying positions 
compared to healthy controls (56). For example, one study found that people with 
COPD spent 52% and 12% of their waking hours in sitting and lying positions, 
compared to 42% and 4% in healthy controls (56). These findings indicate that 
people with COPD participate in less physical activity and spend much of their day 
in sedentary behaviour, such as sitting or lying down, when compared with healthy 
people of a similar age and gender. 
2.5.6 Factors associated with physical activity and sedentary behaviour in 
COPD 
Dyspnoea and fatigue are frequently reported by people with COPD during daily 
activities, and the adoption of a sedentary lifestyle by this population is presumably a 
strategy to minimise these symptoms during daily activities (10, 56). People with 
COPD who participate in low levels of physical activity are likely to experience 
deconditioning of both the cardiovascular system (115, 396) and muscles of 
locomotion (147, 397), which can lead to deterioration in their exercise capacity and 
HRQoL (398). Several factors have been demonstrated as being associated with low 
levels of physical activity in COPD, including increased dyspnoea, COPD severity, 
functional disability and exercise capacity, extrapulmonary manifestations and risks 
of hospitalisation and mortality (56, 85, 115, 134, 399, 400). 
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Research has supported the importance of subdividing walking time based on the 
METs levels defined earlier, showing that time spent engaged in moderate to 
vigorous physical activity is associated with higher functional exercise capacity and 
lower all-cause mortality in people with stable COPD (56, 133). Moreover, time 
spent engaged in light intensity physical activity may decrease the risk of developing 
cardiovascular diseases and type 2 diabetes in healthy people (359). Further, 
sedentary behaviour has been identified as a risk factor for metabolic diseases and 
premature death in the general population (359, 401). Prolonged sedentary behaviour 
is associated with factors including lower exercise capacity, less autonomous 
motivation for exercise, use of long term oxygen therapy and a higher number of 
exacerbations in the past year (59). 
2.5.6.1 Dyspnoea 
Low levels of physical activity have been associated with dyspnoea in people with 
COPD (57, 84). For example, a study by Watz et al (85) measured physical activity 
using a multi-sensor armband, and assessed dyspnoea using the mMRC dyspnoea 
scale in 163 people with stable COPD. This study showed that those people who 
reported feeling too breathless to leave the house (mMRC grade 4) were sedentary as 
they had a low energy expenditure (1.26 METs), which is considered slightly greater 
than a chair-or bed-bound patient (402). The authors also found that increasing levels 
of dyspnoea were associated with fewer steps and less time spent in moderate 
intensity physical activity (> 3 METs) (85). Data pertaining to the relationship 
between dyspnoea and sedentary behaviour in COPD are lacking. 
2.5.6.2 Functional disability and exercise capacity 
In people with COPD, low levels of physical activity have been associated with 
increased functional disability and decreased exercise capacity (399, 403). A 
population-based cohort study included 206 people with COPD and used the 
Community Healthy Activities Model Program for Seniors Physical Activity 
Questionnaire, and the Valued Life Activities scale to measure physical activity and 
disability, respectively (399). The results of the study demonstrated that a low level 
of physical activity at baseline was a strong predictor of a prospective increase in 
disability over the following year (odds ratio [OR] 2.5, 95%; CI 1.1 to 5.3) (399) 
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A moderate to strong association has been demonstrated between daily physical 
activity, expressed as walking time, and exercise capacity, measured as the 6MWD (r 
> 0.42, p < 0.01) (56, 57). This corroborates the associations demonstrated by Watz 
et al (85), who showed that the 6MWD had a strong association with the steps 
accumulated and a moderate association with the number of minutes spent 
performing moderate intensity physical activity each day (r = 0.63 and 0.47 
respectively; both p < 0.001).  
In 113 people with mild to moderate stable COPD, a strong association has been 
found between functional exercise capacity, measured using the 6MWT, and sitting 
time (r = 0.74,  p < 0.001), measured using a triaxial accelerometer (DynaPort), 
indicating that functional limitations increase with prolonged time spent in sedentary 
behaviour (59). 
2.5.6.3 Health related quality of life  
Reduced levels of physical activity have been demonstrated to be associated with 
poor HRQoL in people with COPD (134, 404). Jehn et al (134) demonstrated that the 
time spent in fast walking (5km/h measured using an accelerometer) was associated 
with HRQoL, measured using the Medical Outcomes Study 36-Item Short Form 
Health Survey (SF-36) and SGRQ. Specifically, a moderate association was found 
between the time spent walking at more than 5km/h and the score of the physical 
function component of the SF-36 (r = 0.4, p < 0.05). Similarly, a moderate 
association was demonstrated between the time spent walking at more than 5km/h 
and the score of the activity domains of the SGRQ (r = -0.40, p < 0.05) (134). These 
results suggest that people with COPD who had the lowest daily intensities of 
physical activity had the worst HRQoL. However, a study by Coronado et al (405) 
showed no association between physical activity, measured using an accelerometer, 
and HRQoL, assessed using the SGRQ. This study measured physical activity on the 
first day and last day of a three-week pulmonary rehabilitation program for 15 people 
with COPD. The lack of association in this study may be due to their small sample 
size and a large range seen in the total score of SGRQ (42 ± 11 for the first day and 
31 ± 12) for the last day). In addition, walking activity in this study was assessed in 
the rehabilitation centre environment, which does not reflect a normal pattern of 
daily activities, whereas the SGRQ assesses HRQoL in the individual’s usual 
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environment. Data pertaining to the association between HRQoL and sedentary 
behaviour are not available. 
2.5.6.4 Disease severity 
Although decrements in physical activity have been demonstrated in people with 
COPD, it appears that these decrements increase with increased disease severity (55, 
85, 395, 406). One of the largest early studies, which used a multisensor armband 
monitor (SenseWear Armband, Bodymedia, Pittsburgh, PA) to investigate physical 
activity levels in 70 people with stable mild to very severe COPD and in 30 healthy 
people, showed that daily steps and time spent in moderate activities decreased with 
increased COPD severity (55). That is, compared to the values obtained in healthy 
controls, the number of steps per day accumulated by people with COPD was 87% ± 
34% for those with mild disease, 71% ± 32% for moderate, 49% ± 34% for severe, 
and 29% ± 20% for those with very severe disease. The same study showed that the 
time spent in moderate intensity physical activity (3.6 ≥ METs) was 53% ± 48%, 
41% ± 45%, 31% ± 48%, and 22% ± 33% of the values seen in healthy controls for 
those with mild, moderate, severe and very severe COPD respectively. These 
differences were statistically significant for those with moderate to very severe 
COPD when compared with that seen in healthy controls (p < 0.05) (55). This 
finding is consistent with that reported by Jehn et al (395), who used an 
accelerometer to measure physical activity in 107 people with stable COPD. This 
study found that the number of steps per day decreased with increasing severity of 
COPD (moderate: 5075 ± 2753, severe: 4318 ± 2272, very severe: 3189 ± 2238; p < 
0.05). In addition, Jehn et al (395) demonstrated that daily walking time was 
accumulated in short, intermittent bouts of less than five minutes. This is consistent 
with Pitta et al (394), who demonstrated that walking time during daily life 
accumulated in very short bouts of walking (up to 1 minute in length) before and 
after pulmonary rehabilitation. In contrast to data on physical activity, Hartman et al 
(59) demonstrated, using a triaxial accelerometer (DynaPort), that sedentary time 
accumulated by people (n = 113) with mild to very severe COPD dids not differ 
across their disease severities. 
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2.5.6.5 Extrapulmonary manifestations 
It appears that reduced physical activity is associated with the presence of 
extrapulmonary manifestations of COPD (115). Watz et al (115) investigated the 
associations between the extrapulmonary effects of COPD and decreased levels of 
physical activity of 170 people with stable COPD, measured using an accelerometer. 
They found that high levels of left cardiac dysfunction and systemic inflammation, 
specifically N-terminal pro– B-type natriuretic peptide levels and high-sensitivity C-
reactive protein, were associated with decreased physical activity, independent of 
COPD severity according to the GOLD or the multidimensional BODE index. 
Parker et al (407) objectively measured sedentary time using the ActiGraph in 223 
people with COPD. The authors demonstrated that no significant differences in 
sedentary time between those with and without metabolic syndrome. Sedentary time 
was associated with a large waist circumference and high blood glucose levels (all r 
= 0.2, p < 0.05), indicating greater cardio-metabolic risk.  
2.5.6.6 Hospitalisation  
In people with COPD, low physical activity has been associated with hospitalisation 
for an AECOPD (408) and mortality (133, 400). A cohort study of 2,386 people with 
COPD demonstrated that those who reported performing a minimum of two hours 
walking or cycling a week, measured using a self-reported questionnaire, had a 30% 
to 40% reduced risk of both hospitalisation due to an AECOPD and mortality over a 
20 year period (133). This is similar to the findings of by Benzo et al (408), who 
showed that less than two hours of physical activity per week, assessed by a self-
reported questionnaire, was a significant predictor (OR 0.60, 95%; CI, 0.41 to 0.88) 
of hospitalisation for an AECOPD in 610 people with COPD. Esteban et al (409) 
followed 391 people with COPD for more than two years. They showed that those 
who maintained a low level of physical activity, where physical activity was assessed 
using a questionnaire, demonstrated an increased rate of hospitalisation for an 
AECOPD compared to those who were more active (OR 1.90; 95% CI 1.09 to 3.32). 
This study also found that those who had the highest level of physical activity at 
baseline and had a reduction in their physical activity during the follow-up period 
demonstrated an increased rate of hospitalisation (OR 2.134; 95% CI, 1.15 to 3.98).  
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It has been shown, in 113 people with mild to very severe stable COPD, that 
prolonged time spent in sitting is associated with a higher number of exacerbations in 
the past year (r = 0.31, p < 0.05) (59). It appears that those who had been hospitalised 
due to an AECOPD experienced a prolonged impact on their physical activity and 
sedentary behaviour levels. Compared to people with stable COPD, those who were 
hospitalised for an AECOPD spent more time sitting and less time walking and 
standing, up to one month following hospital discharge (304).  
2.5.6.7 Mortality 
A decline in physical activity levels is associated with an increased risk of all-cause 
mortality in people with COPD (400, 410). The prognostic value of physical activity, 
measured using an accelerometer, was evaluated in 173 stable people with COPD by 
Garcia-Rio et al (411). They demonstrated that for every 10 vector magnitude units 
that daily physical activity increased, the risks of mortality and hospitalisation 
reduced by 14% and 11%, respectively, after adjusting for relative confounders such 
as age, gender, Body Mass Index, current smoking, Charlson co-morbidity index, 
and treatment with long term oxygen therapy or inhaled corticosteroids (411). 
Waschki et al (400)  measured daily physical activity of 170 people with stable 
COPD using a multi-sensor armband. They demonstrated that physical activity was 
the best predictor of all causes of mortality (400). The authors demonstrated that 
every 0.5 SD increase in the number of daily steps (equivalent to 1,845 steps) was 
associated with a lower risk of death (hazard ratio 0.49, 95% CI, 0.34 to 0.69) after 
standardisation and adjustment for age and gender (400). Pooling the results of these 
studies, it appears that regular participation in physical activity reduces the risk of 
mortality in people with COPD. No data are available for the relationship between 
sedentary behaviour and mortality in people with COPD.  
In summary, people with COPD are characterised by low levels of physical activity, 
with worsens with increasing dyspnoea and disease severity. In addition, physical 
activity and sedentary behaviour appear to be associated with lower exercise capacity 
and disability, and risk of hospitalisation and mortality (only with physical activity 
level). However, little is known about the impact of sedentary behaviour on health 
outcomes in people with COPD. In addition, there is there no information about 
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physical activity and sedentary behaviour in people with COPD in Arabic Gulf 
countries.
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CHAPTER 3  
RELIABILITY AND VALIDITY OF AN ARABIC 
VERSION OF THE DYSPNOEA-12 
QUESTIONNAIRE FOR SAUDI NATIONALS 
WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE 
3.1 Overview 
Dyspnoea is a multidimensional and subjective experience of a difficult or 
uncomfortable sensation of breathing. It originates from an interaction between 
physiological, psychological, social and environmental factors (412). For people with 
chronic obstructive pulmonary disease (COPD), dyspnoea is often the most 
distressing symptom and is frequently the primary reason for seeking medical help 
(412). The sensation of dyspnoea leads to disability and a negative effect on the 
health-related quality of life (HRQoL) for those with COPD (221). Dyspnoea is 
perceived and expressed similarly to pain in terms of its severity, quality of the 
sensation and the emotional response that it evokes (27, 413). The quality of the 
sensation may assist in determining the underlying cause of dyspnoea (414). The 
emotional response to dyspnoea induces distress and is commonly observed in 
clinical and laboratory settings (31, 228). Increases in the emotional response to the 
sensation of dyspnoea in people with COPD leads to functional impairment during 
their activities of daily living and greater reductions in their HRQoL (39). Tools that 
are commonly used to evaluate perception of dyspnoea in people with COPD at rest 
or during exertion include the modified Borg scale and visual analogue scales (17, 
415). These tools are unidimensional and may not reflect different components of 
dyspnoea, such as quality of the sensation and emotional response to dyspnoea. A 
multidimensional tool, the Dyspnoea-12 questionnaire (D-12) was developed to 
quantify the severity of both the quality of the sensation and the emotional response 
to dyspnoea, using descriptors associated with various cardiopulmonary diseases 
(23). The English version of the D-12 has been demonstrated to be reliable and valid 
in people with  pulmonary diseases such as COPD and asthma (23, 40). Further, the 
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D-12 has been translated into different languages such as Korean and Japanese (43, 
44). In Arabic Gulf countries, there is limited work in COPD and that results in a 
lack of tools used to measure dyspnoea in people with COPD. Therefore, it is 
important to develop and validate a tool such as the D-12 to assess dyspnoea in an 
Arabic Gulf COPD population, specifically in Saudi Arabia.  
The study presented in this chapter has been published in the Annals of Thoracic 
Medicine (416). However, additional data pertaining to the reliability of the D-12 
obtained for people who were grouped according to their disease severity have been 
added to this chapter.  
3.1.1 Overall aim  
The primary aim of this study was to translate the D-12 into the Arabic language and 
investigate the reliability and validity of an Arabic version of the D-12 in people with 
COPD. The secondary aim was to explore the reliability of the D-12 for people with 
COPD grouped according to disease severity. 
3.1.2 Research hypotheses 
The primary hypothesis for this study was: The D-12 will be reliable and valid in 
Saudi nationals with COPD. 
The secondary hypothesis for study was: The D-12 will be reliable in people with 
COPD grouped according to disease severity. 
3.2 Methodology 
This study comprised two parts (A and B). Part A involved translating the D-12 from 
English into Arabic and part B examined the reliability and validity of the Arabic 
version of the D-12. The study was approved by the Institutional Review Board at 
King Fahad Medical City, Saudi Arabia (approval number 12/038) and the Human 
Research Ethics Committee of Curtin University, Australia (approval number HR 
106 /2012). Participants provided written, informed consent prior to data collection. 
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3.2.1 Participants 
3.2.1.1 Recruitment  
People with COPD were recruited from the outpatient pulmonary clinics at King 
Fahad Medical City in Riyadh, Saudi Arabia. During the clinic visit, consecutive 
patients with COPD were asked by their respiratory physician whether they were 
interested in being told about the study. Those who expressed an interest were 
contacted by the primary investigator (MA) who provided all necessary information 
related to the study. Participants provided written, informed consent prior to data 
collection. 
3.2.1.2 Inclusion criteria   
To meet inclusion criteria for both parts of the study, participants needed a 
spirometric diagnosis of COPD, in accordance with the criteria established by the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) (10).
 
In addition, 
participants were required to be clinically stable (defined as no change in medication 
use over the past four weeks) and to be able to read and write Arabic. 
3.2.1.3 Exclusion criteria 
For part B, participants were excluded if they had a comorbidity that limited 
mobility, such as severe musculoskeletal impairment and/or symptomatic 
cardiovascular disease.  
3.2.2 Protocol  
3.2.2.1 Part A 
This part of the study used a process similar to that described previously for 
translating questionnaires into a different language (417, 418).
 
First, the English 
version of the D-12, presented in Appendix A, was translated into Arabic by two 
independent certified professional translators. Second, these two Arabic versions of 
the D-12 were reviewed by an expert panel that comprised three respiratory 
physicians, one respiratory therapist, one respiratory health educator and one 
physical therapist. The panel compared the two translations with the original D-12 
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and suggested alternative words for any ambiguous items. A single version of the 
Arabic D-12 was produced via consensus. Third, the Arabic version of the D-12 was 
translated back into English by two other independent, certified translators, who were 
not aware of the original English version. These versions were compared to the 
original English version to confirm concordance. The comparison of the back 
translated versions with the original English version was performed by the expert 
panel and the translators to identify any discrepancy encountered during the 
translation process. Finally, the Arabic version of the D-12 was presented to five 
participants with COPD to ensure that all items were easily understood. This was 
done by asking the five participants to complete the Arabic version of the D-12 and 
then to answer the following question ‘Was each item of this questionnaire easily 
understood? If not, please determine the item’. In addition, participants were asked to 
write any comment related to the questionnaire, if they had. 
3.2.2.2 Part B 
This part of the study was a cross-sectional study with measures collected during two 
assessment sessions, completed two weeks apart. During the first session, 
participants completed three questionnaires. Specifically, they completed Arabic 
versions of the D-12 first. Thereafter, participants performed two six-minute walk 
tests separated by a 30-minute rest period. During the rest period, the COPD 
Assessment Test (CAT) (419, 420) and the Chronic Respiratory Disease 
Questionnaire (CRDQ) were completed (239, 421). Measures were collected of 
airflow obstruction. Age, gender, weight and height were recorded. During the 
second assessment session, participants again completed the Arabic version of the D-
12. In order to optimise the completeness of the Arabic version of the D-12 on the 
second assessment, each participant was contacted by telephone both before and after 
the scheduled second assessment. One week before the second assessment, a copy of 
the Arabic version of the D-12 was posted to every participant with a reply-paid 
registered post envelope in which to return the completed questionnaire. Specifically, 
participants were contacted by the primary investigator (MA) to ensure that they had 
received the questionnaire. During the same phone call, participants were reminded 
to complete the questionnaire and asked a standard question to identify whether or 
not they had experienced a re-exacerbation. The standard question asked was: ‘Has 
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there been any change in your symptoms over the last two weeks that required you to 
increase your medication use or to visit a doctor or the hospital? Thereafter, a time 
within 24 hours of the scheduled assessment was arranged to speak with each 
participant and go through the questionnaire to ensure its completion. 
3.2.3 Measurements 
3.2.3.1 Dyspnoea 
Dyspnoea was measured using the Arabic version of the D-12, which comprises 12 
items: seven related to the quality of the sensation of dyspnoea and five related to the 
emotional response to this sensation. Each item is graded in terms of its severity on a 
scale of none (score = 0), mild (score = 1), moderate (score = 2), or severe (score = 
3). The D-12 produces a total score ranging from 0 to 36, with higher scores 
indicating greater severity (23). 
3.2.3.2 Health status 
Health status was measured via the CAT. The CAT consists of eight items and 
addresses cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity 
limitation at home, confidence leaving home, sleep and energy. Each item was 
scored on a six-point scale, with higher scores indicating poorer health status (419). 
3.2.3.3 Disease-specific health-related quality of life 
Health-related quality of life was measured using the self-administered CRDQ with 
the standardised dyspnoea domain (241, 421). This questionnaire consists of 20 items 
grouped into four domains; dyspnoea, fatigue, emotional function and mastery. Each 
item was scored on a seven-point scale, with higher scores indicating better HRQoL 
(241). 
3.2.3.4 Lung function  
Post-bronchodilator measures of forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC) were obtained using an Easy One Spirometer (NDD 
Medical Technologies, Massachusetts, USA), according to the guidelines of the 
American Thoracic Society (422).
 
The spirometer device was calibrated in 
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accordance with the manufacturer’s recommendations. Measures were expressed as a 
percentage of the predicted values previously established in a local population (423). 
3.2.3.5 Functional exercise capacity 
Participants performed the 6MWD on a 45-meter straight course within an enclosed 
corridor, in accordance with the European Respiratory and American Thoracic 
Societies technical standards (307). To account for improvements resulting from 
familiarisation with the tests (424),
 
two tests were conducted, separated by 30 
minutes of rest, and the best distance was reported as the test result. The 6MWDs 
were expressed as a percentage of the predicted values previously established in an 
international sample (425). 
3.3 Statistical analyses 
3.3.1 Sample size calculations 
Sample-size calculations were conducted using published data (23). Specifically, the 
weakest association reported between D-12 scores and clinical measures was seen 
with the FEV1 (r = 0.30) (23). Therefore, in order to establish construct validity, a 
sample size of 44 participants with COPD was required to detect an association of at 
least this strength between the D-12 and the clinical measures used in this study (α = 
0.05, 1-β = 0.8). 
3.3.2 Statistical analyses 
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS version 21.0, Armonk, NY: IBM Corp, USA). The distribution of the data was 
examined using the Shapiro–Wilk test. Test–retest reliability of the D-12 was 
assessed using an intraclass correlation coefficient (ICC) (426). The weighted kappa 
coefficient was used to determine the concordance of the responses between the first 
and second administrations of the D-12. The ICC was also used to assess test-retest 
reliability of the D-12 for participants grouped according to their GOLD grades. 
Construct validity of the D-12 scores attained at the first administration was assessed 
by examining the strength of the associations between the D-12 and the CAT, 
CRDQ, 6MWD, FEV1 and FVC using Pearson’s correlation coefficients. Differences 
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in the D-12 scores, with participants grouped according to their GOLD grades, were 
compared using analysis of variance (ANOVA). Data are presented as mean ± 
standard deviation (SD) unless otherwise stated. A probability (p) value less than 
0.05 was used to denote statistical significance. 
3.4 Results 
3.4.1 Participants 
From October 2012 to May 2013, sixty-five people with COPD were screened for 
possible inclusion into the study, of whom 22% (n = 14) did not meet the study 
criteria. Of these 14 people, seven people (50%) were excluded due to inability to 
read and write Arabic. Five and two of the 14 people (36%) who were not included 
because were not clinically stable and had a comorbidity that limited mobility, 
respectively. 
In this study, 78% (n = 51), who met the study criteria, were approached regarding 
participation. Of these 51 people, a total of 48 participants were recruited (consent 
rate of 94%). The three people who declined participation did so because of 
disinterest. Four of the 48 (8%) participants who consented withdrew before the 
second assessment, two of them because of travelling overseas and one due to 
personal issues. Ultimately, data from 44 participants were included in the final 
analysis. 
Four (80%) males and one (20%) female with a mean age of 65 ± 10 year and a 
mean FEV1 of 1.45 ± 0.61 L (51 ± 19% predicted) participated in part A of the study. 
Forty participants (33 [82.5%] males) participated in part B of the study (Table  3-1). 
No participants reported any changes in their symptoms, clinical status or medication 
use during the study period. 
3.4.2 Part A 
The back-translated versions of the questionnaire were remarkably similar to the 
original English version with the exception of a few words. Specifically, for the first 
back-translated version of the D-12, the words ‘requires’ and ‘work’ for item two in 
the original English version were back-translated from the final Arabic version to 
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words ‘needs’ and ‘effort’, respectively, Appendix B. For the second back-translated 
version of the D-12, the word ‘agitated’ for item 11 in the original English version 
was back-translated from the final Arabic version to word ‘ nervous’, Appendix C.  
After the comparison between the back-translated versions with the original English 
version, both translators agreed that the words that were not identical to those in the 
original English version had the same meanings and therefor, they could be replaced 
to be identical to those in the original English version. All participants reported that 
all items of the Arabic version of the D-12 were easily understood and no comments 
were reported by the participants. Appendix D presents the Arabic version of D-12.  
3.4.3 Part B 
3.4.3.1 Reliability 
The Arabic version of the D-12 was completed at the two administrations with no 
missing values. The ICC for the reliability of the D-12 score was 0.94 (p = 0.01). The 
mean D-12 score for the first administration was 22.5 ± 3.7 and 22.2 ± 3.3 at the 
second administration (mean absolute difference = 0.3 ± 1.7). Figure  3-1 illustrates 
the mean scores for each item of the D-12 over the two administrations. Excellent 
agreement in test scores was observed between the two administration times 
(weighted kappa = 0.83; p = 0.001). The ICC for the reliability of the D-12 score 
with the participants grouped according to their GOLD grades was 0.90 for GOLD 
grade 2, 0.97 for GOLD grade 3 and 0.85 for GOLD grade 4 (all p < 0.01). 
3.4.3.2 Validity 
Table  3-2 presents the associations between the D-12 total score and its components 
obtained at the first administration with the CAT, CRDQ domains, FEV1, FVC and 
6MWD. Strong associations (r ≥ 0.6) were demonstrated between (i) the total score 
for the D-12 and the CAT, (ii) the score for quality component of the D-12 and the 
CAT and, (ii) the score for the emotional response component of the D-12 and the 
emotional function domain of the CRDQ. The mean total scores of the D-12 differed 
between participants in GOLD grades 2 and 4 (mean difference = 4.6 ± 4.9; p < 
0.01). Figure  3-2 illustrates the mean D-12 scores for participants grouped according 
to GOLD grades.
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Table ‎3-1: Characteristics of the participants who completed part B (n = 40). 
 
Data are expressed as mean ± standard deviation (SD) or number (%). BMI: body 
mass index; CAT: COPD Assessment Test; CRDQ: Chronic Respiratory Disease 
Questionnaire; D-12: Dyspnoea-12; FEV1: forced expiratory volume in one second; 
FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung 
Disease (2: moderate, 3: severe and 4: very severe); kg: kilograms; L: liters; m: 
meters; ppi: points per item, 6MWD: six-minute walk distance; yr: year. 
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Figure ‎3-1: Mean scores obtained for each item of the Dyspnoea-12 questionnaire (D-12) on the first administration (closed 
triangles) and second administration (open squares). On both administration points, the mean scores for items 2, 4, 5, 6, 7, 8, 9, 
10, 11 and 12 were identical 
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Table ‎3-2: Associations between the D-12 scores from the first administration and CAT, CRDQ, FEV1, FVC and 6MWD 
conducted on the same day 
  
CAT: COPD Assessment Test; CRDQ: Chronic Respiratory Disease Questionnaire; D-12: Dyspnoea-12; FEV1: forced expiratory 
volume in one second; FVC: forced vital capacity; L: liters; m: meters; ppi: points per item; 6MWD; six-minute walk distance. **p < 
0.01; *p < 0.05 
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Figure ‎3-2: Total score for the Dyspnoea-12 questionnaire with participants 
grouped according to their disease severity, using grades defined by the Global 
Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Data are mean 
and standard error, calculated from the first administration. *Statistically 
significant difference (p < 0.05). 
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3.5 Discussion 
This study successfully translated the D-12 into the Arabic language and 
demonstrated that the Arabic version of this questionnaire was reliable and valid in a 
population of Saudi nationals with COPD. This is consistent with earlier work that 
has translated questionnaires from English into the Arabic language (420, 421).
  
Although the D-12 is likely to be useful in clinical practice for assessing dyspnoea, in 
terms of its severity, quality of sensation and emotional response to dyspnoea, further 
work is required to determine whether this questionnaire is responsive to 
interventions aimed at reducing dyspnoea, such as the use of bronchodilators and 
pulmonary rehabilitation. The Arabic version of the D-12 could be used in Arabic 
speaking people with COPD in more than 22 countries of the Middle East. 
Using the methodology previously described to translate the English version of the 
CRDQ and the CAT into different languages (417, 418),
 
the D-12 was translated into 
the Arabic language. The back-translation demonstrated good concordance with the 
original English version and the Arabic version was easily understood. Similar 
results were found in a study that translated the D-12 into Korean (427). 
The D-12 scores obtained in this study were reliable over a two-week period, as 
demonstrated by the high ICC value and the excellent weighted kappa score. In 
addition, the scores obtained on the D-12 for people who were grouped according to 
GOLD grades were reliable, as indicated by the ICC values ≥ 0.85 for GOLD grades 
2 to 4. It is noteworthy that the mean scores for 10 of the D-12 items were no 
different between the two administrations and the mean score for the remaining two 
D-12 items differed by less than one point. In this study, there were no missing data 
over the two administration points for the D-12, demonstrating evidence of its utility. 
In the present study, the ICC value was similar to those values reported in earlier 
work in which the D-12 was administered twice over the same period in populations 
with COPD (ICC = 0.90), asthma (r = 0.93 to 0.96) and interstitial lung disease (ICC 
= 0.94) (23, 40, 428). The high ICC value indicates that the D-12 provides a stable 
measure of dyspnoea in people with moderate to very severe COPD, which serves to 
increase confidence that any change in scores following an intervention is unlikely to 
simply reflect variability in responses to the questionnaire items.  
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Construct validity was demonstrated as the D-12 total score and its components 
scores associated significantly and in the expected direction with questionnaire-based 
assessments. Specifically, data from this study revealed a moderate to strong 
relationship between the D-12 total score and both the CAT score and the CRDQ 
total score. In addition, significant relationships were demonstrated with the scores of 
components of the D-12 and both the CAT and many of the domains of the CRDQ. 
Earlier work in people with COPD has used the Medical Research Council dyspnoea 
scale and the Hospital Anxiety and Depression Scale to examine construct validity of 
the D-12 (23).
 
In contrast, we chose to use the CAT and the CRDQ to establish 
validity of the Arabic version of the D-12, as both have been validated in the Arabic 
language (420, 421)
 
and comprise items related to the impact of dyspnoea on the 
daily life of people. Despite the different questionnaires used, our data were 
consistent with a previous study in people with COPD (23),
 
showing that scores for 
the D-12 were associated with dyspnoea during daily life as well as emotional 
function. Further, the strong association between the D-12 total score and the CAT is 
consistent with data obtained in adults with asthma, interstitial lung disease and 
pulmonary hypertension (40, 428, 429) showing a strong relationship between the D-
12 total score and a measure of health status. Our data confirm that in Saudi nationals 
with COPD the perception of dyspnoea contributes significantly to health status and 
mood.  
Associations of weak to moderate strength were demonstrated between the total 
score of the D-12 and both the 6MWD and the FEV1. This is consistent with earlier 
work undertaken in people with COPD (23)
 
and asthma (40),
 
and suggests that 
dyspnoea worsens with increased functional limitation and disease severity. It is 
noteworthy that the association between the D-12 total score and both the 6MWD 
and FEV1 appears to be driven by the score from the quality component of the 
questionnaire rather than the score from the emotional response component. This 
indicates that as COPD increases in severity, people experience a greater severity of 
various types of dyspnoea sensation, but the emotional response shows a less 
consistent response pattern. This highlights the value of using a multi-dimensional 
tool to quantify dyspnoea in this population. 
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There is lack of tools available to measure dyspnoea in the Arabic speaking 
populations, in people with COPD or other respiratory diseases. The D-12 focuses on 
distress associated with dyspnoea as oppose to the tools that are available in the 
Arabic language, such as the CRDQ and CAT, which they form a part of HRQoL or 
health status measures only (241, 419-421). Although the CRDQ has a dyspnoea 
domain, this domain only measures dyspnoea related to specific daily activities and 
provides no direct measure to dyspnoea sensation in terms of the quality and 
emotional response to this sensation. The other tool that is available to use in the 
Arabic COPD population is the CAT (420). However, this tool measures health 
status and is not designed to measure dyspnoea. People with COPD can be extremely 
sensitive to dyspnoea, which they may find emotionally overwhelming. 
Approximately 50% of people with COPD have been found to have anxiety and 
depression (430). Emotional distress is linked to the severity of dyspnoea. The brain 
structures involved in the perception of dyspnea have been identified using brain-
imaging techniques (431). These images demonstrate evidence for the activation of 
emotional and cognitive structures similar to that found in other unpleasant 
experiences. Therefore, emotions appear to play an important role in a person’s 
perception of, and reaction to, dyspnoea. Using the D-12 in the Arabic populations 
will provide health practitioners and researchers with information about the 
experience of dyspnoea sensation in terms of the quality and the emotional response 
to this sensation. This may lead to greater advocacy for programs such as pulmonary 
rehabilitation which aim to reduce dyspnoea in people with COPD. In addition, the 
use of D-12 will allow researchers from Arabic speaking countries to compare the 
experience of dyspnoea of their populations with others such as Western populations.  
The mean scores reported by males and females for the quality and the emotional 
response of the D-12 appear to be similar. This indicates that both genders 
experienced a similar quality of dyspnoea sensation as well as the same emotional 
response to dyspnoea. In the present study, it is noteworthy that 50% of people who 
did not meet the study criteria were illiterate. Therefore, this highlights the 
importance of developing an interviewer-administered version of the D-12 in order to 
increase its utilisation for assessing dyspnoea in COPD population.  
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3.6 Limitations 
There are limitations to this study. The size of the sample might be seen as a 
limitation, the present study used an adequate statistical power and the highly 
significant statistical results clearly show that it was possible to assess the reliability 
and the validity of the D-12 with the sample. The participants were only recruited 
from one centre and included a small proportion of female participants. However, the 
proportion of females in the sample (7 out of 40 participants; 17.5%) is not profound 
as the overall prevalence of COPD in females (1.0%) is lower than that reported in 
males (3.5%) (22.2%) in Saudi Arabia (432). In addition to the study limitations, all 
participants had a diagnosis of COPD. These factors may limit the generalisability of 
our results. Further studies with a large sample size, including females, from 
different regions in Saudi Arabia are needed to increase the generalizability for using 
the Arabic version of the D-12 in clinical and research settings. Further studies are 
also required to investigate the responsiveness of the Arabic version of the D-12 to 
therapeutic interventions, such as pulmonary rehabilitation, or in response to a 
change in clinical status such as recovery following an acute exacerbation of COPD. 
3.7 Conclusions 
The Arabic language version of the D-12 is a reliable and valid instrument for 
assessing dyspnoea in Saudi nationals with COPD and is likely to be a useful tool for 
assessing dyspnoea in research and clinical settings. 
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CHAPTER 4  
CHANGES IN THE DYSPNOEA-12 
QUESTIONNAIRE FOLLOWING AN ACUTE 
EXACERBATION OF CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
4.1 Overview 
An acute exacerbation of COPD (AECOPD) is an event characterised by a 
worsening of respiratory symptoms that is beyond the normal day-to-day variations 
and results in a change in medication of people with COPD (10). Dyspnoea is often 
the most distressing sensation and the primary reason people with COPD seek 
medical care (25). Following an AECOPD, some people remain dyspnoeic for up to 
60 days (24), which may contribute to a greater activity limitations and poor 
perceived health status (92).  
The Dyspnoea-12 questionnaire (D-12), is a self-reported outcome measure that was 
developed using 12 descriptors of dyspnoea and is relevant to people with a variety 
of cardiopulmonary disease, including COPD (23). This questionnaire measures the 
severity of dyspnoea, incorporating two components; the quality of the sensation and 
the emotional response to the sensation (23). The D-12 has been demonstrated to be 
reliable and valid in people with COPD (23). However, the capacity of the 
components of the D-12 to change in response to an intervention or clinical event 
that changes dyspnoea has not been determined. Data demonstrating the 
responsiveness of the D-12 are important to optimise its utilisation in both the 
clinical and research setting. 
4.1.1 Overall aim 
The primary aim of this study was to determine whether the quality and emotional 
response components of the D-12 differed between a period when people were 
hospitalised with an AECOPD and when they had reached a period of clinical 
stability following hospital discharge. 
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The secondary aim was to determine whether the quality and emotional response 
components of the D-12 discriminated between people with COPD, grouped 
according to disease severity, during an AECOPD and when they were clinically 
stable. 
4.2 Methodology 
4.2.1 Study design  
A longitudinal observational study was conducted during which data for each 
participant were collected every 14 days after hospitalisation for an AECOPD for a 
total of 98 days. Data collection was undertaken between January 2013 and March 
2014 at King Fahad Medical City in Riyadh, Saudi Arabia. This study received 
approval from the Institutional Review Board at King Fahad Medical City, Saudi 
Arabia (approval number 12/281E) and the Human Research Ethics Committee of 
Curtin University, Australia (approval number HR 14/2013).  
4.2.2 Participants 
4.2.2.1 Recruitment  
Participants with a severe AECOPD, defined as an AECOPD which required 
hospitalisation (10), who were hospitalised within the respiratory ward of King 
Fahad Medical City were identified by their respiratory physician. Within 24 hours 
of admission, consecutive people with AECOPD were asked by their respiratory 
physician whether they were interested in being told about the study. Those who 
expressed an interest were contacted by the primary investigator (MA), who 
provided them with all required information related to the study. Written, informed 
consent was obtained from all participants prior to data collection. 
4.2.2.2 Inclusion criteria   
The inclusion criteria comprised participants with a diagnosis of moderate to very 
severe COPD, defined as a post-bronchodilator FEV1/ forced vital capacity (FVC) < 
0.7 and an FEV1 of < 80% of the predicted value in a healthy adult (i.e. grades 2 to 4 
of the Global Initiative for Chronic Obstructive Lung Disease [GOLD]) (10). 
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4.2.2.3 Exclusion criteria 
Participants were excluded from the study if they had; (i) a severe psychotic disorder 
documented in their medical record; (ii) a severe cognitive disorder documented in 
their medical record; (iii) an inability to read and write in the Arabic language and/or 
(iv) no home phone or mobile to enable contact post-discharge. 
4.2.3 Protocol  
Participants with an AECOPD completed a set of questionnaires within 24 hours of 
hospitalisation. Specifically, they completed Arabic versions of the D-12 (416), the 
Chronic Respiratory Disease Questionnaire (CRDQ) (239, 421) and the COPD 
Assessment Test (CAT) (419, 420). The participants again completed the D-12, 
CRDQ and CAT on days 14, 28, 42, 56, 70, 84 and 98 after hospital admission. This 
resulted in a total of eight administrations for each questionnaire. A follow-up- 
interval of 14 days was selected as the recall period for the CRDQ is 14 days (24, 
25). Monitoring participants every 14 days allowed the trajectory of symptom 
recovery to be examined. Post-bronchodilator spirometry was performed for 
participants within 24 hours prior to discharge from the hospital. 
To optimise the completeness and accuracy of response to all questionnaires 
completed after hospital discharge, each participant was contacted by telephone both 
before and after each scheduled follow-up assessment. Specifically, one week before 
each follow-up assessment, the participants were posted a copy of the questionnaires 
with a reply-paid registered post envelope in which to return the completed 
questionnaires. Further, they were contacted to ensure that they had received the 
questionnaires. During the same phone call, participants were reminded to complete 
all questionnaires and asked a standard question to determine whether or not they had 
experienced a re-exacerbation. The standard question asked was: ‘Has there been any 
change in your symptoms over the last two weeks that required you to increase your 
medication use or to visit a doctor or the hospital?’ Thereafter, a time within 24 
hours of each follow-up assessment was arranged to speak with each participant and 
go through each questionnaire to ensure their completion.      
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4.2.4 Measurements 
4.2.4.1 Dyspnoea 
Dyspnoea was quantified using the D-12, which consists of 12 items that assess 
dyspnoea severity. Of these 12 items, seven items pertain to the quality of the 
sensation of dyspnoea and five items relate to the emotional response to this 
sensation (23). Each descriptor item is rated in terms of its intensity using a scale 
ranging from none (score = 0) to severe (score = 3). The D-12 provides a total score 
from 0 to 36, with higher scores representing greater severity of dyspnoea (23). This 
questionnaire has been demonstrated to be reliable and valid in COPD (23, 416). It is 
available in the Arabic language (see Chapter 3) (416). 
4.2.4.2 Disease-specific health-related quality of life 
The self-administered CRDQ with the standardised dyspnoea domain was used to measure 
HRQoL (241). The CRDQ comprises 20 items grouped into four domains; dyspnoea (five 
items), fatigue (four items), emotional function (seven items) and mastery (four items). Each 
item was rated using a seven-point Likert scale, with higher scores representing better 
HRQoL (241). The standardised dyspnoea domain within the CRDQ includes a list of five 
standard activities. Respondents were asked to rate how much shortness of breath they had 
experienced while performing each of the five standards activities. This questionnaire has 
been demonstrated to be reliable, valid and responsive in COPD (241, 433-435). It is 
available in the Arabic language (421). 
4.2.4.3 Health status 
Health status was measured using the CAT. The CAT comprises eight items that 
assess cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity 
limitation at home, confidence leaving the home, sleep and energy. Each item is 
rated on a six-point scale, with higher scores representing poorer health status (419). 
The scores of CAT are categorised into severity bands: low impact (CAT scores 1 to 
10), medium impact (11 to 20), high impact (21 to 30) and very high impact (31 to 
40) (436). The CAT has been demonstrated to be reliable, valid and responsive in 
COPD (437). It is available in the Arabic language (420). 
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4.2.4.4 Lung function  
Post-bronchodilator FEV1 and FVC were measured using an Easy One Spirometer 
(NDD Medical Technologies, Massachusetts, USA), in accordance with the 
guidelines of the American Thoracic Society (422).
 
The spirometer was calibrated 
according to the manufacturer’s recommendations. Measures were expressed as a 
percentage of the predicted values established in a local population (423). 
4.3 Statistical analyses 
4.3.1 Sample size calculations  
In clinically stable people with COPD, a previous study demonstrated a difference of 
2.73 ± 9.97 points between two administrations of the D-12 conducted 16 days 
(median) apart (438). As dyspnoea dramatically increases during an AECOPD (24), a 
difference in the D-12 scores between the period of hospitalisation for an AECOPD 
and return to clinical stability was expected to be at least double this difference 
previously reported between repeated administrations. Therefore, sample size 
calculations were performed to ensure adequate power (1-β = 0.8, α = 0.05) to detect 
a difference of 5.46 ± 9.97 points in the scores of D-12 between periods of an 
AECOPD and clinical stability. To detect this change, a minimum of 28 participants 
were required. 
4.3.2 Data management 
4.3.2.1 Criteria used to define clinical stability 
Changes were explored in both the quality and emotional response components of 
the D-12 between the first administration in hospital and the time period during the 
98 days follow-up when the participants were deemed to have returned to clinical 
stability. For this purpose, clinical stability was defined as when the change in the 
score of the dyspnoea domain of the CRDQ between consecutive administrations 
was neither statistically significant nor clinically important (i.e. change was < 0.5 
points per item [ppi] (245). 
The duration of the follow-up period, being 98 days, was chosen for this study as 
earlier work has reported that, following a moderate to severe AECOPD, the severity 
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of dyspnoea returns to pre-exacerbation levels by 91 days for more than 80% of 
people with COPD (24, 25). 
4.3.3 Statistical analyses  
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS version 21.0, Armonk, NY: IBM Corp, USA). The assumption of normality 
was assessed by graphical (frequency histograms and box plots) and statistical 
methods (Shapiro-Wilk test). Data that did not follow a normal distribution were 
analysed using non-parametric statistical tests. All data are expressed as either mean 
 SD or median (interquartile range [IQR]). A p value ≤ 0.05 was considered 
statistically significant.  
4.3.3.1 Establishing clinical stability  
A one-way repeated measured analysis of variance (ANOVA) was used to compare 
the scores of the CRDQ, D-12 and CAT at each administration over the 98 days 
follow-up. To determine the scores for the CRDQ, D-12 and CAT during the period 
of clinical stability, the scores obtained for each questionnaire between consecutive 
administrations that were not statistically significantly different were averaged. 
4.3.3.2 Comparing measures between AECOPD and clinical stability  
Comparisons of continuous data obtained between the first administration in hospital 
and when the participants had returned to clinical stability were performed using 
either paired t-tests or Wilcoxon tests for parametric and non-parametric data 
respectively.  
To compare changes in the scores of the D-12 components with changes in other 
questionnaires, the effect size for each questionnaire was calculated as the mean 
difference in the scores reported during the first administration in hospital and when 
clinical stability was achieved, divided by the SD obtained at the first administration 
(439). This method for calculating the effect size has been widely used in studies 
measuring the responsiveness of the CAT and CRDQ in COPD populations (437, 
440, 441) . The strength of the effect size was classified using Cohen’s d effect sizes 
with, > 0.2 being small, > 0.5 moderate and  > 0.8 large (442).  
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4.3.3.3 Sub-analyses to explore the confounding effect of re-exacerbation 
In a sub-analysis, those who had re-exacerbated during the follow-up period were 
excluded from the analysis to determine whether or not including them in the original 
analyses had impacted on the effect sizes of the questionnaires. 
4.3.3.4 Exploring the capacity of the Dyspnoea-12 questionnaire to discriminate 
between participants, grouped according to disease severity  
Total scores as well as scores for the quality and emotional response components of 
the D-12 were compared between participants grouped according to the GOLD 
grades and compared using ANOVA. 
4.4  Results 
4.4.1 Participants  
Sixty people were hospitalised for an AECOPD and were screened for possible 
inclusion in the study. Ten people (48%) were excluded because they did not have 
home phone or mobile to enable contact post-discharge and were not able to read and 
write Arabic. Eight (38%) and three (14%) of the 21 people were not included due to 
their inability to read and write Arabic and a severe cognitive disorder, respectively. 
Thirty-nine (65%) were deemed eligible and approached to participate. Of these 39 
people, a total of 31 participants were recruited (consent rate of 79%). The eight 
people who declined participation did so because of lack of interest. Two of the 31 
(6%) participants who consented withdrew before they were discharged from the 
hospital due to personal issues. Ultimately, data from 29 participants were included 
in the final analysis. Baseline characteristics of the participants are presented in 
Table  4-1.
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Table ‎4-1: Characteristics of the study participants (n = 29) 
 
Data are expressed as mean ± standard deviation (SD) or number (%) or 
median interquartile range (IQR). BMI: body mass index; CAT: COPD 
assessment test; CRDQ: Chronic Respiratory Disease Questionnaire; D-12: 
Dyspnoea-12; FEV1: forced expiratory volume in one second; FVC: forced 
vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung 
Disease (2: moderate, 3: severe and 4: very severe); kg: kilograms; L: liters; 
m: meters; ppi: points per item. 
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4.4.2 Clinical stability following AECOPD 
The sample met the criteria for clinical stability 70 days after the first administration 
of the questionnaires in hospital. This was because the score of the dyspnoea domain 
of the CRDQ completed 70, 84, 98 days after the first administration in hospital did 
not differ statistically from each other and the magnitude of the difference was below 
the threshold for clinical importance (< 0.5 ppi) (mean scores 3.7 ± 0.6, 3.7 ± 0.7 and 
3.7 ± 0.7 ppi respectively, p > 0.05) (Figure  4-1). 
4.4.3 Changes between AECOPD and clinical stability  
4.4.3.1 Dyspnoea-12 
Figure  4-2 displays the total scores for the D-12 as well as the scores for the quality 
and emotional response components of the D-12 reported over the 98 days follow-up. 
Compared with the scores found during the first administration in hospital, when the 
group had returned to clinical stability there was a decrease (i.e. improvement) for 
the total score of the D-12 (26.3 ± 3.0 versus 20.1 ± 2.9; p < 0.001), the quality 
component (15.3 ± 2.2 versus 11.8 ± 1.5; p < 0.001) and the emotional response 
(11.0 ± 2.0 versus 8.3 ± 1.6; p < 0.001) (Table  4-2). 
4.4.3.2 Chronic Respiratory Disease Questionnaire 
Figure  4-1 illustrates the scores for the dyspnoea domain of the CRDQ over the 98 
days follow-up. Compared with the scores reported during the first administration in 
hospital, when the group had returned to clinical stability there was an increase (i.e. 
improvement) in the scores for the dyspnoea domain of the CRDQ (2.7 ± 0.4 versus 
3.7 ± 0.7; p < 0.001), (Table  4-2). Scores for the fatigue, emotional function and 
mastery domains of the CRDQ are presented in Error! Reference source not 
found.. 
4.4.3.3 COPD assessment tool 
Figure  4-3 shows the scores for the CAT over the 98 days follow-up. Compared with 
the scores reported during the first administration in hospital, when the group had 
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returned to clinical stability there was a decrease (i.e. improvement) in the scores for 
the CAT (26.2 ± 2.0 versus 20.2 ± 3.9; p < 0.001) (Table  4-2). 
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Figure ‎4-1: Scores for the dyspnoea domain of the Chronic Respiratory Disease 
Questionnaire during the study period. Data are mean and standard error. 
*Statistically significant difference (p < 0.05) from the final administration (day 
98).‎†‎No‎significant‎difference‎in‎the‎score‎across‎administrations‎on‎days‎70,‎
84 and 98. Therefore, participants were considered clinically stable across these 
administrations and, for all questionnaires, scores obtained across these last 
three time points were averaged and used as the score obtained during a period 
of clinical stability. 
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Figure ‎4-2: A) the total scores of the Dyspnoea-12 questionnaire, B) the score 
for the quality component of the Dyspnoea-12 questionnaire and C) the score 
for the emotional response component of the Dyspnoea-12 questionnaire. Data 
are mean and standard error. *Statistically significant difference (p < 0.05) from 
the‎final‎administration‎(day‎98).‎†‎No‎significant‎difference‎in‎the‎scores‎across‎
administrations. 
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Figure ‎4-3: Scores of COPD Assessment Test during the study period. Data are 
mean and standard error. *Statistically significant difference (p < 0.05) from the 
final‎administration‎(day‎98).‎†‎No‎significant‎difference‎in‎the‎score‎across‎
administrations 56, 70, 84 and 98.
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Table ‎4-2: Scores obtained for the D-12, the dyspnoea domain of the CRDQ and CAT during periods of an AECOPD and 
clinical stability for the group 
 
Abbreviations: AECOPD: acute exacerbation of COPD; CAT: COPD Assessment Test; CRDQ: Chronic Respiratory Disease 
Questionnaire; D-12: Dyspnoea-12; ppi: points per item; SD: standard deviation. *Statistically significant difference..
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4.4.4 Sub-analyses after removal of participants with re-exacerbation 
4.4.4.1 Clinical stability following an AECOPD for participants who did not have 
re-exacerbations 
During the follow-up period, 22 (76%) of the 29 participants (FEV1% predicted, 44 ± 
10) had no further exacerbations during the follow-up period. The remaining seven 
participants experienced a further exacerbation during the follow-up period. Six of 
these seven participants experienced only one exacerbation: five out of these six 
participants had experienced a mild AECOPD (10) and one had experienced a severe 
AECOPD. Only one participant experienced two exacerbations which were classified 
as a mild and severe AECOPD. Participants who had a mild AECOPD were 
managed at home by increasing their medication use. Those who had a severe 
AECOPD were hospitalised for a period between four to six days. 
The participants who did not have re-exacerbations met the criteria for clinical 
stability 70 days after the first administration of the questionnaires in hospital. That 
is, the score of the dyspnoea domain of the CRDQ completed 70, 84, 98 days after 
the first administration in hospital did not differ statistically from each other and the 
magnitude of the difference was below the threshold for clinical importance (< 0.5 
ppi) (mean scores of 3.9 ± 0.6, 3.9 ± 0.6 and 4.0 ± 6 ppi respectively, p > 0.05) 
(Figure  4-4). 
4.4.4.2 Changes between AECOPD and clinical stability for participants who did 
not have re-exacerbations  
4.4.4.2.1 Dyspnoea-12 
Figure  4-5 shows the total score for the D-12 as well as the scores for the quality and 
emotional response components of the D-12 reported by the participant who did not 
have re-exacerbations over the 98 days follow-up. Compared with the scores 
reported during the first administration in hospital, when the group had returned to 
clinical stability there was a decrease (i.e. improvement) for the total score of the D-
12 (25.1 ± 2.6 versus 19.0 ± 1.9; p < 0.001), the quality component (14.9 ± 2.3 
versus 11.0 ± 1.4; p < 0.001) and the emotional response component (10.2 ± 1.1 
versus 8.0 ± 1.0; p < 0.001) (Table  4-3).   
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4.4.4.2.2 Chronic Respiratory Disease Questionnaire 
Figure  4-4 demonstrates the scores for the dyspnoea domain of the CRDQ over the 
98 days follow-up. Compared with the scores reported during the first administration 
in hospital, when the group had returned to clinical stability there was an increase 
(i.e. improvement) in the scores for the dyspnoea domain of the CRDQ (2.8 ± 0.4 
versus 3.9 ± 0.6; p < 0.001), (Table  4-3). Scores for the fatigue, emotional function 
and mastery domains of the CRDQ are presented in Error! Reference source not 
found.. 
4.4.4.2.3 COPD assessment tool 
Figure  4-6 illustrates the scores for the CAT over the 98 days follow-up. Compared 
with the scores reported during the first administration in hospital, when the group 
had returned to clinical stability there was a decrease (i.e. improvement) in the scores 
for the CAT (26.1 ± 1.9 versus 19.4 ± 2.2; p < 0.001) (Table  4-3).
Chapter 4: Responsiveness of the D-12 
105 
 
Figure ‎4-4: Scores for the dyspnoea domain of the Chronic Respiratory Disease 
Questionnaire for the participant who did not have re-exacerbations during the 
study period. Data are mean and standard error. *Statistically significant 
difference (p < 0.05) from‎the‎final‎administration‎(day‎98).‎†‎No‎significant‎
difference in the score across administrations on days 70, 84 and 98. Therefore, 
participants were considered clinically stable across these administrations and, 
for all questionnaires, scores obtained across these last three time points were 
averaged and used as the score obtained during a period of clinical stability. 
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Figure ‎4-5: A) total scores of the Dyspnoea-12 questionnaire, B) the score for 
the quality component of the Dyspnoea-12 questionnaire and C) the emotional 
response component of the Dyspnoea-12 questionnaire for the participant who 
did not have re-exacerbations during the study period. Data are mean and 
standard error. *Statistically significant difference (p < 0.05) from the final 
administration‎(day‎98).‎†‎No‎significant‎difference‎in‎the‎scores‎across‎
administrations.
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Figure ‎4-6: Scores of COPD Assessment Test for the participant who did not 
have re-exacerbations during the study period. Data are mean and standard 
error. *Statistically significant difference (p < 0.05) from the final administration 
(day‎98).‎†‎No‎significant‎difference‎in‎the‎score‎across‎administrations‎on‎days‎
56, 70, 84 and 98.
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Table ‎4-3: Scores obtained for the D-12, the dyspnoea domain of the CRDQ and CAT during periods of an AECOPD and 
clinical stability for the participant who did not have re-exacerbations 
Abbreviations: AECOPD: acute exacerbation of COPD; CAT: COPD Assessment Test; CRDQ: Chronic Respiratory Disease 
Questionnaire; D-12: Dyspnoea-12; ppi: points per item; SD: standard deviation. *Statistically significant difference.
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4.4.5 Scores of the Dyspnoea-12 questionnaire with participants grouped 
according to Global Initiative for chronic Obstructive Lung Disease 
grades  
4.4.5.1  Data obtained during the first administration in hospital 
With all participants included in the analyses, the total D-12 score differed between 
participants grouped according to their GOLD grades (p = 0.006) (Figure  4-7). 
Differences were demonstrated between GOLD grades 2 and 4 (mean difference = 
5.3 ± 1.4, p = 0.006) and between GOLD grades 3 and 4 (mean difference = 4.2 ± 
3.4, p = 0.006). No differences were observed in the score of the quality component 
of the D-12 between participants grouped according to GOLD grades (Figure  4-7). 
The score of the emotional response component of the D-12 differed between 
participants grouped according to their GOLD grades, with differences demonstrated 
between GOLD grades 2 and 4 (mean difference = 3.0 ± 1.1, p = 0.002) and between 
GOLD grades 3 and 4 (mean difference = 1.8 ± 0.9, p = 0.019) (Figure  4-7).  
4.4.5.2 Data obtained during the period when participants had returned to 
clinical stability 
With all participants included in the analyses, the total D-12 score differed between 
participants grouped according to their GOLD grades (p = 0.006) (Figure  4-8). 
Differences were demonstrated between GOLD grades 2 and 4 (mean difference = 
4.4 ± 2.0, p = 0.037). No differences were observed in the score of the quality 
component of the D-12 between participants grouped according to GOLD grades. 
The score of the emotional response component of the D-12 differed between 
participants grouped according to their GOLD grades, with differences demonstrated 
between GOLD grades 2 and 4 (mean difference = 2.6 ± 1.8, p = 0.011) (Figure  4-8).
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Figure ‎4-7: A) total score, B) the quality component and C) emotional response 
component of the Dyspnoea-12 questionnaire with participants grouped 
according to their disease severity, using grades defined by the Global Initiative 
for Chronic Obstructive Pulmonary Disease (GOLD), at the first administration 
in hospital. Data are mean scores and standard error. *Statistically significant 
difference (p < 0.05).
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Figure ‎4-8: A) total score, B) the quality component and C) emotional response 
component of the Dyspnoea-12 questionnaire with  participants grouped 
according to their disease severity, using grades defined by the Global Initiative 
for Chronic Obstructive Pulmonary Disease (GOLD), when participants had 
returned to clinical stability. Data are mean scores and standard error. 
*Statistically significant difference (p < 0.05).
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4.5 Discussion 
This is the first study to determine whether the scores for the total, the quality 
component and emotional response component of the D-12 differ between periods of 
an AECOPD and clinical stability for people with COPD. The results of this study 
have demonstrated that, on average, people with COPD return to clinical stability, 
defined as no further improvement in dyspnoea during daily life, 70 days following 
hospitalisation for an AECOPD. The scores for the total, quality and emotional 
response components of the D-12, as well as the dyspnoea domain of the CRDQ and 
the CAT, improved significantly between when the participants were hospitalised 
with an AECOPD and when they had reached a period of clinical stability. The 
improvement in the quality and emotional response components and total score of D-
12 yielded large effect sizes (all ≥ 1.5), according to Cohen’s classification (442). 
The total score of the D-12 and the emotional response component of the D-12 
discriminated between people with COPD grouped according to their disease 
severity, recorded during the first administration of the questionnaires in hospital, 
and when they had returned to clinical stability. 
4.5.1 Time course of recovery following hospitalisation for an AECOPD  
The magnitude of the difference in the score of the dyspnoea domain of the CRDQ 
between the last three consecutive administrations taken during the 98 day follow-up 
period was below the threshold for clinical importance (< 0.5 ppi) (245). This 
indicates that, on average, people would not notice any difference in the severity of 
their dyspnoea during activities of daily living after 70 days from hospitalisation. 
Therefore, this demonstrates that following hospitalisation with an AECOPD, 
recovery in terms of no further improvement in dyspnoea during activities of daily 
living can take up to 70 days. 
Previous studies have shown that the trajectory of recovery of symptoms following 
an AECOPD is quite variable (24, 25). Parker et al (24) demonstrated that 40% of 
people with a moderate to severe AECOPD had not returned to pre-exacerbation 
levels of dyspnoea within an average of 41 days following an AECOPD. This 
suggests that the recovery period may be prolonged in a large proportion of people 
with COPD. In the present study, a follow-up period of 98 days following 
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hospitalisation appeared to be appropriate as the majority of people achieved their 
clinical stability 70 days after hospitalisation for an AECOPD. The long follow-up 
period used in this study is similar with that reported by Seemungal et al (25) who 
found that by 91 days following an AECOPD, 91% of people with a moderate to 
severe AECOPD had returned to their pre-exacerbation levels of respiratory 
symptoms. 
Regarding the time course of recovery, Figure 4.2 shows that the scores for the 
quality component of the D-12 plateaued two weeks earlier than that observed for the 
emotional response component of the D-12. This observation indicates that the 
quality of dyspnoea seems to recover before the emotional response to the sensation 
of dyspnoea. The measures of the emotional response to dyspnoea recovered over the 
same administration days as dyspnoea during daily activities, measured using the 
dyspnoea domain of the CRDQ. These findings suggest that the emotional response 
to dyspnoea and overall perception of its severity during activities of daily living are 
associated with each other. This contention is supported by the association 
previously reported between the emotional response component of the D-12 and the 
dyspnoea domain of CRDQ (r = 0.31, p < 0.05) (Chapter 3) (416). 
Although the definition of clinical stability used in this study was based on dyspnoea 
during activities of daily living, this definition appears to be appropriate as the 
measures of health status plateaued over the same administration days seen when the 
clinical stability of dyspnoea was achieved. Taken together, these findings can assist 
clinicians in providing Saudis with an AECOPD and their families’ information 
regarding the expected time course of recovery for dyspnoea and health status 
following a severe AECOPD. 
4.5.2 Changes in the questionnaires between an AECOPD and clinical stability 
Significant improvements in the scores, coupled with large effect sizes, were 
observed for all the questionnaires used in this study between when participants were 
hospitalised for an AECOPD and when they had reached a period of clinical 
stability. The large effect sizes were the result of both large mean changes, coupled 
with the small variability in the magnitude of these differences. The questionnaire 
most responsive to change during this study was the CAT, which had an effect size 
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of 3.0. The most likely reason that the CAT was more responsive than the D-12 is 
that the CAT comprises items relating to a broad range of factors that are likely to be 
adversely impacted during an AECOPD, such as sleep quality and energy levels, 
rather than just dyspnoea. The effect size reported in this study is greater than that 
reported by Jones et al (437) for the CAT following a moderate to severe an 
AECOPD. Jones et al (437) demonstrated a small effect size (0.19) for the CAT 
between the first administration (during an AECOPD) and 14 days after an 
AECOPD. This discrepancy in the effect sizes between the current study and that of 
Jones et al (437)  is likely to have been due to the severity of an AECOPD, as Jones 
et al (437) did not exclusively include only those with a severe AECOPD.  
The magnitude of change seen in the dyspnoea domain of the CRDQ between when 
people were hospitalised for an AECOPD and when they had returned to clinical 
stability was 1.0 ± 0.6 ppi. Using Jaeschke et al’s (245) definition, in which the 
clinical improvements in scores of the CRDQ domains were classified as small (≥ 
0.5 ppi), moderate (≥ 1.0 ppi) and large (≥ 1.5 ppi), the magnitude of change seen in 
this study for the dyspnoea domain of the CRDQ following an AECOPD (1.0 ppi) 
indicates a moderate clinical improvement. The magnitude of change demonstrated 
in the current study for the dyspnoea domain of the CRDQ is similar to that reported 
for the dyspnoea domain of the CRDQ (0.79 ppi) on completion of a program of 
pulmonary rehabilitation (45). Further, it is also similar to that reported by Aaron et 
al (53) who explored changes in the dyspnoea domain of the CRDQ following an 
AECOPD. Aaron et al (53) demonstrated a magnitude of change of 1.3 ± 0.2 ppi 
between the first administration of the dyspnoea domain of the CRDQ (during an 
AECOPD) and 10 days following an AECOPD. Thus, the effect size of 2.5 for the 
dyspnoea domain of the CRDQ reported in the present study is greater than that 
calculated by Aaron et al (53), who reported an effect size of 1.3. A possible 
explanation for this discrepancy is, in the present study, there was smaller variability 
in the scores reported at the first administration (SD at baseline = 0.4 ppi) compared 
to that obtained by Aaron et al at the first administration (SD at baseline = 1.0 ppi) 
(53). The magnitude of change in the dyspnoea domain of the CRDQ seen in the 
current study seems to be less than what has been reported in a previous study (24). 
Parker et al (24) assessed dyspnoea, using the individualised dyspnoea domain of the 
CRDQ, in 22 people with moderate to severe AECOPD. The authors demonstrated a 
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magnitude of change in the dyspnoea domain of the CRDQ between the first 
administration (during AECOPD) and the final administration (60 days following an 
AECOPD) of 1.6 ± 0.4 ppi. However, a people in the current study had a severe 
AECOPD, whereas in the study by Parker et al (24), only seven out of 20 people had 
a severe AECOPD. Therefore, the discrepancy in the magnitude of change in 
dyspnoea between the present study and that of Parker et al (24) may reflect the 
differences in the severity of an AECOPD as well as differences in the versions of 
the CRDQ that were used (i.e. standardised dyspnoea domain vs individualised 
dyspnoea domain). 
Regarding the changes seen in the D-12, similar effect sizes were obtained for the 
quality and emotional response components of the D-12 (effect sizes 1.6 and 1.7, 
respectively), which shows that both components of the D-12 have a similar capacity 
to change following a severe AECOPD. Further work is needed to determine the 
threshold for the minimal clinical important difference of the D-12. Using the D-12 
for assessing dyspnoea recovery following an AECOPD will provide health 
professionals information related to the severity of both the quality of dyspnoea 
sensation and emotional response to dyspnoea. In addition, the D-12 could be used to 
provide people who have been hospitalised with a severe AECOPD, and their 
families, information regarding the time course recovery of dyspnoea.  
Given that the effect sizes for the total score for the D-12 was a similar to the effect 
size for the dyspnoea domain of the CRDQ (effect size 2.1 vs 2.5), it is possible that 
the total score for the D-12 will demonstrate similar responsiveness to the CRDQ 
following interventions that aim to ameliorate dyspnoea, such as bronchodilators and 
pulmonary rehabilitation.  
4.5.3 The impact of an AECOPD on dyspnoea, HRQoL and health status 
Although the proportion of females in the present study is very small, it appears that 
females and males experience the same quality of dyspnoea sensation and emotional 
response to dyspnoea at an AECOPD period. In addition, during the period of an 
AECOPD, both genders seem to experience the same perception of dyspnoea during 
their activities of daily living and poor health status.   
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This is the first study to assess dyspnoea in both components during the period of a 
severe AECOPD. The findings of this study demonstrated that people with COPD 
appeared to experience worse dyspnoea in both the quality and the emotional 
response to dyspnoea sensation when compared to their severity of dyspnoea 
reported during the period of clinical stability. This finding, overall, is similar to that 
reported in different studies that showed people with COPD had worse dyspnoea 
during an AECOPD, dyspnoea was measured using different tools such as the 
modified Medical Research Council and Borg scale (440, 443, 444). The results of 
this study highlight the importance of targeting an intervention that aims to reduce 
the severity of both components of dyspnoea during an AECOPD. 
During an AECOPD, people in the present study reported worse dyspnoea related to 
daily activity and poor health status compared to that reported during the period of 
clinical stability. These findings of this study are the first to report dyspnoea related 
to daily activities, using the dyspnoea domain of the CRDQ, and health status, using 
the CAT, during an AECOPD in the Gulf countries, especially in Saudi Arabia. 
Parker et al (24)  assessed dyspnoea, using the individualised dyspnoea domain  of 
the CRDQ, in 20 people with COPD from Canada during an AECOPD. The authors 
reported a similar score (2.4 ± 0.3 ppi) for the dyspnoea domain of the CRDQ to that 
obtained in the present study (2.7 ± 0.4 ppi). This indicates that, during an AECOPD, 
people with COPD from Saudi Arabia and Canada experience similar severity of 
dyspnoea during their daily activities. Due to different tools that are available to 
measure HRQoL in people with COPD it was not possible to compare dyspnoea 
related daily activities during an AECODP in Saudi population with other 
international findings. 
Poor health status was observed in Saudi people with COPD during an AECOPD. 
The score of the CAT (26.2 ± 2.0) reported in this study is similar to the CAT scores 
reported in 224  people with COPD from Spain (22.2 ± 8.4)  (440) and in 75 people 
with COPD from United Kingdom (24.1 ± 7.3) during severe AECOPDs (445). 
These findings demonstrate that severe AECOPDs lead to poor health status as 
observed in those populations. 
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4.5.4 The impact of a re-exacerbation 
When the analyses were limited to the participants who did not have re-exacerbations 
(i.e. those who did not experience a second exacerbation during the recovery period), 
the results were similar to those presented in the main analyses, in terms of the time 
period required to reach clinical stability. This similarity is because the majority of 
the participants (76%) in this study did not have-re-exacerbations. However, the 
effect sizes for the questionnaires for the participants who did not have re-
exacerbations appeared to be greater than those obtained for the main analyses which 
included all participants. Although both components of the D-12 demonstrated large 
effect sizes in the participants who did not have re-exacerbations, the emotional 
response component seemed to change more than the quality component (effect size 
of 2.0 versus 1.6).     
4.5.5 Capacity of the Dyspnoea-12 questionnaire to discriminate between 
people grouped according to disease severity 
The current study demonstrated that during hospitalisation with an AECOPD, people 
with very severe COPD experienced greater emotional response to dyspnoea 
compared to those with moderate or severe COPD. Compared to people with 
moderate COPD, the greater severity of emotional response to dyspnoea in people 
with very severe COPD was still evident even when the people had returned to 
clinical stability. The difference in the mean scores of the D-12 between people with 
moderate and those with very severe COPD when they had returned to clinical 
stability is concordance with that observed between those with stable moderate and 
very severe COPD (Chapter 3) (416). This suggests that interventions which target 
the emotional response to dyspnoea, such as cognitive behavioural therapy, may be 
of more value in those with more severe disease. The lack of differences between 
people grouped according to their disease severity in the quality of dyspnoea during 
periods of an AECPD and clinical stability indicates that people with different 
disease severity have a similar quality of dyspnoea sensation during both an 
AECOPD and periods of clinical stability. 
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4.6  Limitations 
This study had some limitations. The small sample size with the small proportion of 
females in this study can be a limitation. However, the present study had an adequate 
power and recruited the minimum number of participants to demonstrate the 
sensitivity of the D-12 to change following an AECOPD. In addition, the proportion 
of females to males in the sample (4 out of 29 participants; 13.8%) is lower than the 
proportion of females (1.0%) to males (3.5%) with COPD in the population in Saudi 
Arabia (22.2%) (432). This may limit the generalisability of the results especially in 
females. A large study, including females, from different regions in Saudi Arabia is 
required to increase the generalisability of the Arabic version of the D-12.  
Furthermore, illiteracy in the older adult Saudi population should also be considered. 
This was the main reason for those who did not meet the study criteria. Therefore, 
developing an interviewer-administered version of the D-12 is recommended. The 
results of this study are restricted to those who experienced a severe AECOPD that 
required hospitalisation. Therefore, the results may not be generalisable to changes 
seen following a mild or moderate AECOPD. Changes in the scores of D-12 were 
not tested by administering a given intervention that is known to change dyspnoea. 
Instead, this study investigated changes in the D-12 scores in response to clinical 
status. Therefore, further research is required to investigate the ability of the D-12 
detect changes in response to therapeutic interventions, such as pulmonary 
rehabilitation. Finally, the capacity to detect changes in the D-12 between 
participants grouped according to their disease severity is likely to have been 
comprised by the limited number of people in GOLD grades 2 and 4. 
4.7 Conclusions 
This study has demonstrated that overall, following hospitalisation with an 
AECOPD, recovery, in terms of no further improvement in dyspnoea during 
activities of daily living, can take up to 70 days. Scores from all questionnaires 
improved significantly between when people were hospitalised with an AECOPD 
and when they had reached a period of clinical stability. The effect size of the D-12 
was similar to that obtained for the dyspnoea domain of the CRDQ. In addition, the 
D-12 was able to discriminate between people grouped according to disease severity. 
Chapter 4: Responsiveness of the D-12 
119 
Therefore, it appears that the D-12 is suitable to use in the clinical setting for 
evaluating changes in dyspnoea. 
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CHAPTER 5  
PHYSICAL ACTIVITY AND SEDENTARY 
BEHAVIOUR OF SAUDI MALES WITH 
CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE: A COMPARISON WITH AGE AND 
GENDER MATCHED HEALTHY CONTROLS 
5.1 Overview  
In both healthy and diseased populations, health benefits of regular participation in ≥ 
30 minutes of moderate intensity physical activity (activities that require and energy 
expenditure ≥ 3 metabolic equivalent units [METs]), on at least five days each week, 
are well documented (54). Walking is a common form of physical activity that is 
generally safe, convenient and inexpensive (369). In adults, work has shown that 
walking at a cadence ≥ 100 steps/min appears to be equivalent to moderate intensity 
physical activity (62, 64-66). Compared with healthy controls, people with chronic 
obstructive pulmonary disease (COPD) spend less time of their waking hours 
participating in physical activity (i.e. walking) and more time in sedentary behaviour 
(i.e. sitting) (56, 57). This higher proportion of time spent in sedentary behaviour can 
have deleterious health outcomes including the risk of developing diabetes, 
cardiovascular disease and premature mortality (401). Although people with COPD 
have lower levels of physical activity when compared with healthy controls, these 
low levels have been shown to vary between people from different countries (81). 
Therefore, data obtained in one country may not be representative of the time spent 
in physical activity and sedentary behaviour of people from other countries, due to 
factors such as different ethnicity, culture, geographical location, environment and 
socioeconomic factors (81, 446). 
Data on physical activity from different countries in the world have shown that males 
are more active than females (447-451).  Similar findings have been reported that, 
compared to males, females in the Gulf region are more inactive (74, 452-454). The 
reasons for the low levels of physical activity and sedentary behaviour among Saudi 
females compared with both Saudi males and females from different countries are 
Chapter 5: Physical activity and sedentary behaviour 
121 
poorly explored. There are certain sociocultural factors in the Gulf region that seem 
to be barriers to females’ physical activity such as wearing an abaya (a long dress) 
outside the house, limited freedom of movement outside of the house, depending on 
a driver, and employing domestic helpers (455, 456). In addition, the hot climate is 
an important barrier for both males and females for exercising outdoors. Males also 
experience significant barriers such as employing domestic helpers, and regular use 
of automobiles. However, compared to females, males have more freedom of 
movement outside of the home. 
In people with COPD, dyspnoea, or the sensation of breathing discomfort that occurs 
during exertion, is generally believed to be the main limitation to participating in 
physical activity (10, 56). This belief is supported by the associations demonstrated 
between dyspnoea and physical activity (57, 82, 84). Information on physical activity 
and sedentary behaviour in people with COPD from Saudi Arabia has not been 
reported to date. In addition, it is unknown whether the quality of dyspnoea or the 
emotional response to dyspnoea has the greatest negative impact on participating in 
physical activity and accumulating time in sedentary behaviour in people with 
COPD.  
Data presented in this chapter are only for males. It was not possible to recruit 
females to this study. In Saudi culture, it is not acceptable for a man to talk to women 
in public areas unless they are a family. Therefore, the male primary investigator 
(M.A) could not recruit female participants and as he did not have a female colleague 
available to assist with the study it was not possible to include females in the study. 
5.1.1 Overall aim  
The primary aim of this study was to compare physical activity and sedentary 
behaviour of Saudi males with COPD with that of healthy age and gender-matched 
controls. 
The secondary aim was to investigate the associations between the quality and 
emotional response components of the Dyspnoea-12 questionnaire (D-12) with the 
time spent in walking based activity and sedentary behaviour in males with COPD. 
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5.1.2 Research hypotheses  
The primary hypothesis for this study was that physical activity and sedentary 
behaviour will differ between males with COPD and healthy controls. 
The specific hypotheses are; 
i. Males with COPD will spend less time in walking based activity and more 
time in sedentary behaviour during waking hours compared with healthy 
controls. 
ii. The way in which time spent in walking based activity and sedentary 
behaviour were accumulated will differ during waking hours between males 
with COPD and healthy controls. 
iii. Males with COPD will have lower peak and average 30-minute peak cadence 
compared to healthy controls. 
iv. Males with COPD will have a smaller percentage of males who participated 
in sufficient physical activity when compared to healthy controls.  
The secondary hypothesis for study was that the quality and emotional response 
components of the D-12 will be associated with the time spent in walking based 
activity and sedentary behaviour in males with COPD.  
5.2 Methodology 
5.2.1 Study design  
This study was cross-sectional in design. Data collection was undertaken between 
February 2013 and March 2014. Approval to conduct the study was granted by the 
Institutional Review Board at King Fahad Medical City, Saudi Arabia (approval 
number 12/312) and the Human Research Ethics Committee of Curtin University, 
Australia (approval number HR 24/2013).  
5.2.2 Participants  
Two groups were recruited. These were males with COPD and healthy controls. 
Chapter 5: Physical activity and sedentary behaviour 
123 
5.2.2.1 Males with COPD 
5.2.2.1.1 Recruitment  
Males with COPD were recruited from the outpatient pulmonary clinics at King 
Fahad Medical City in Riyadh, Saudi Arabia. During the clinic visit, consecutive 
males with COPD were asked by their respiratory physician whether they were 
interested in being told about the study. Those who expressed an interest were 
contacted by the primary investigator (MA) who provided all necessary information 
related to the study. Written, informed consent was obtained from the participants 
prior to data collection.  
5.2.2.1.2 Inclusion criteria  
The inclusion criteria were; (i) males, (ii) a diagnosis of COPD defined as post-
bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity 
(FVC) < 0.7 and post-bronchodilator FEV1< 80% predicted (10), (iii) a stable 
condition for at least two months and (iv) aged ≥ 40 years. Further, only those who 
were retired (i.e. no longer undertaking paid employment) were included. This 
decision was made in order to minimise any confounding influence the nature of 
someone’s work may have had on their participation in daily physical activity and 
sedentary behaviour. 
5.2.2.1.3 Exclusion criteria  
Exclusion criteria comprised; (i) presence of any comorbid condition thought to 
adversely affect the capacity to participate in physical activity, such as uncontrolled 
cardiovascular disease or severe musculoskeletal condition, (ii) use of supplemental 
oxygen, (iii) use of a gait aid and, (iv) inability to read and write the Arabic 
language. 
5.2.3 Healthy controls 
5.2.3.1 Recruitment   
A sample of convenience of healthy males was recruited through the distribution of 
flyers. The first sources were mosques and the relatives of people with COPD. Two 
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mosques in Riyadh were approached every two months. The capacity of these 
mosques was approximately 2,500 persons each. Flyers were distributed to males 
attending these mosques. The second source was family members of participants 
with COPD. Participants with COPD were asked if they had family members who 
would like to participate in the study. Written, informed consent was obtained from 
the participants prior to data collection.  
5.2.3.1.1 Inclusion criteria  
Inclusion criteria were; (i) males who were free from a serious health condition, (ii) 
normal spirometry and, (iii) retired. In order to optimise the likelihood that the 
COPD and healthy controls were balanced in terms of age, males with COPD were 
recruited first and their mean age and standard deviation (SD) were determined. 
Thereafter, healthy people were recruited if they were aged within ±1 SD of the 
mean age of the COPD group. 
5.2.3.1.2 Exclusion criteria 
Exclusion criteria comprised; (i) smoking history of ≥ 10 years, (ii) presence of any 
co-morbid condition thought to adversely affect the capacity to participate in 
physical activity such as uncontrolled cardiovascular disease or severe 
musculoskeletal condition, determined by an interview and screening of current 
medications, (iii) use of a gait aid and, (iv) inability to read and write the Arabic 
language. 
5.2.4 Protocol 
Participants with COPD were required to attend, at King Fahad Medical City, one 
session of two-hours duration. During this session, measures were obtained of post-
bronchodilator FEV1, FVC, dyspnoea using the D-12 and six-minute walk distance 
(6MWD). Also, participants’ characteristics such as age, height and weight were 
recorded. At the completion of this session, each participant was fitted with a 
Stepwatch Activity Monitor (Stepwatch, Cyma Corporation, Seattle, WA, USA; 
[SAM]). Participants were required to wear the SAM during waking hours for eight 
consecutive days. They were instructed to remove the monitor while showering and 
during swimming activities as well as sleeping overnight. Participants were requested 
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to maintain their usual daily physical activity while wearing the SAM. All 
participants were given a reply-paid registered-post envelope in which to return the 
SAM after completion of their participation in the study. 
The protocol for the healthy control group was similar to that used for the COPD 
group. However, participants in this group were not required to complete the D-12 or 
perform the six-minute walk test. 
5.2.5 Measurements 
5.2.5.1 Physical activity  
Physical activity was measured using the SAM, which is a microprocessor-linked 
sensor enclosed within a lightweight (38 g), pager-sized, durable casing, which 
responds to time, acceleration and position. It has been shown to have an excellent 
capacity to accurately detect steps in healthy elderly people, as well as males with 
COPD regardless of walking speed or the use of walking aids (e.g. wheeled-walker) 
(377, 457, 458). The SAM was attached to the participant’s right ankle using a 
Velcro strap. This device has a sampling frequency of 128 Hz and data were 
available in one-minute epochs. The data correspond to the number of steps taken by 
the right leg and therefore the step count was doubled to provide the total number of 
daily steps. The SAM was initialised for each participant prior to data collection. 
During this initialisation procedure, the height of each participant was entered into 
the SAM software, and the settings related to ‘range of walking speed’ and ‘leg 
motion’ were selected as ‘moderate’ and ‘normal’ respectively. For each participant, 
the first 40 steps taken while wearing the SAM were observed to ensure that the 
device was detecting steps correctly, as indicated by a flashing light emitting diode 
upon heel strike (459).  
Wearing the SAM over eight consecutive days was considered unlikely to affect 
participants’ daily routines as the monitor was small, light and provided no feedback 
(460).  
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5.2.5.2 Dyspnoea  
Dyspnoea was measured using the Arabic D-12, which comprises 12 items that 
assess dyspnoea severity. Each item is graded in terms of its severity using a four-
point scale ranging from none (score = 0) to severe (score = 3) (23). The D-12 
produces a total score from 0 to 36, with higher scores indicating greater severity of 
dyspnoea. Of the 12 items seven relate to the quality of dyspnoea, with scores 
ranging from 0 to 21, and five related to the emotional response to dyspnoea, with 
scores ranging from 0 to 15. The D-12 has been shown to be reliable and valid in 
Saudi nationals with COPD (Chapter 3) (416).  
5.2.5.3 Lung function 
Post-bronchodilator FEV1 and FVC were measured using an Easy One Spirometer 
(NDD Medical Technologies, Massachusetts, USA), according to the guidelines of 
the American Thoracic Society (422).
 
The spirometer device was calibrated in 
accordance with the manufacturer’s recommendations. Measures were expressed as a 
percentage of the predicted values previously established in a local population (423). 
5.2.5.4 Functional exercise capacity 
Functional exercise capacity for participants with COPD was evaluated using the 
6MWD, which was undertaken according to a protocol based on recommendations 
made by the European Respiratory and American Thoracic Societies (307). The 
6MWD was performed over a 45-meter level straight course within an enclosed 
corridor. Standardised instructions were read to each participant prior to the 
commencement of the test, and standardised encouragement was given at the end of 
every minute. To account for improvements resulting from familiarisation (424),
 
two 
tests, separated by a 30-minute rest period, were conducted and the best distance 
achieved was recorded as the test result. The 6MWD was expressed in absolute 
values and as a percentage of the predicted values previously established in an 
international sample (425). 
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5.3 Statistical analyses 
5.3.1 Sample size calculations  
A previous European study that measured walking time in people with COPD and 
healthy controls reported that those with COPD participated in walking for (mean ± 
SD) 44 ± 26 minutes/day and healthy controls participated in walking for 81 ± 26 
minutes/day (56). Using these data, it appears that people with COPD were, on 
average, 46% less active than their retired healthy age and gender-matched 
counterparts (56). For the current study, a more modest difference (i.e. a 25% 
reduction in physical activity) was expected between Saudi nationals with COPD and 
their healthy controls. This was because it was expected that the general population 
of Saudis would be less active than those living in Western countries (74). 
Specifically, the weather in Saudi Arabia tends to be very hot in the summer and cold 
in the winter which limits the capacity to participate in outdoor physical activity. 
Data from an earlier study that measured the level of physical activity in Saudi 
nationals using the International Physical Activity Questionnaire revealed that they 
generally participate in little physical activity (72). As a European study 
demonstrated that healthy people walked for 81 ± 26 minutes each day, a 25% 
reduction is equivalent to 20 minutes (25% of 81 minutes = 20 minutes). Assuming 
the same SD as reported in the European study, it was calculated that to detect of 
difference in walking time of 20 ± 26 min/day between the COPD and healthy 
control groups (α = 0.05, 1-β = 0.8), a sample size of 28 was needed for each group.  
5.3.2 Data management 
Data recorded by the SAM were exported to Microsoft Excel™ (version 2010, 
Microsoft, Redmond, USA). Data collected on the day that the SAM was first fitted 
were discarded from analyses as data for this day were incomplete. Overnight sleep 
time, which would have been included in the output and recorded as 0 steps/min, was 
also discarded from analyses. This was because sleep is not considered as sedentary 
behaviour (350), and also to optimise the accuracy of the time spent in sedentary 
behaviour. Therefore, waking hours were defined in accordance with earlier work 
that used the same monitor to measure physical activity in people with knee 
osteoarthritis (461). That is, waking hours were defined as the period between when 
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the first step was registered in the morning to when the last step was registered in the 
evening. 
5.3.2.1 Defining minimal acceptable wear time for the stepwatch activity monitor 
data required to be included in the analyses 
5.3.2.1.1 Number of measurement days 
The minimum number of acceptable days of wearing a physical activity monitor 
varies between studies (see discussion). Consistent with earlier work a minimum of 
five days of wear time was required to include the data in this study’s analyses (85). 
5.3.2.1.2 Number of measurement hours per day 
The minimum wear time for a physical activity monitor in terms of number of hours 
per day varies between studies. Consistent with earlier work done in elderly people, a 
pragmatic option of a minimum of 10 hours a day was used to define the minimum 
acceptable wear time needed to be included in analyses (388). 
5.3.2.1.3 Weekdays versus weekends 
Outcomes of monitoring physical activity in people with moderate to very severe 
COPD was found to not differ between weekdays and weekends (78). Therefore, this 
study chose to include a minimum of five days of wear time, regardless of weekdays 
or weekends.  
5.3.2.2 Exploring the time spent in walking based activity and sedentary 
behaviour 
Walking based activity was defined as ≥ 1 step/min and sedentary behaviour was 
defined as 0 steps/min. Time spent in walking based activity and sedentary behaviour 
was expressed as absolute minutes and also as a percentage of total wear time (i.e. to 
account for differences in wear time between participants). Total daily steps count 
were calculated for both groups. 
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5.3.2.3 Exploring the time spent in walking based activity undertaken at 
difference cadences 
Wear time was divided into cadence categories, using the same thresholds described 
in the National Health and Nutrition Examination Survey (NHANES) (67). 
Specifically, walking cadences were categorised into the following domains: 1 to19 
steps/min (i.e. incidental movement), 20 to 39 steps/min (i.e. sporadic movement), 40 
to 59 steps/min (i.e. purposeful steps), 60 to 79 steps/min (i.e. slow walking), 80 to 
99 steps/min (i.e. medium walking), 100 to 119 steps/min (i.e. brisk walking), and ≥ 
120 steps/min (i.e. fast locomotor movements) (67). Time in each of these cadence 
bands was expressed as absolute minutes and also as a percentage of total wear time 
(i.e. to account for differences in wear time between participants).  
5.3.2.4 Exploring patterns of accumulation for both walking based activity and 
sedentary behaviour 
To explore the way in which time was accumulated for both walking based activity 
and sedentary behaviour, the duration of each bout of time spent in walking based 
activity (defined as any one-minute period during which ≥ 1 step/min was recorded) 
and sedentary behaviour (defined as any one-minute period during which 0 steps/min 
were recorded) was determined. This was achieved using a three-step process. First, 
SAM data were scanned for walking based activity. Second, the duration of each 
bout of walking based activity that occurred during waking hours was derived by 
summing the number of consecutive cells in which ≥ 1 step/min were recorded. That 
is, for the pattern of one-minute epochs of SAM data outlined below, a bout duration 
for walking based activity was recorded as one minute as only one of the one-minute 
epochs had ≥ 1 step/min recorded. 
0, 0, 0, 0, 0, 0, 24, 0, 0, 0 
Similarly, for the pattern of one-minute epochs of SAM data outlined below, a bout 
duration for walking based activity was recorded as five minutes as five of the one-
minute epochs had ≥ 1 step/min recorded.  
0, 0, 0, 0, 30, 10, 24, 28, 50, 0 
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Third, for each measurement day included in analyses, the duration of all bouts of 
walking based activity were averaged.   
This process was then repeated for sedentary behaviour. That is, SAM data were 
scanned for sedentary behaviour. Second, the duration of each bout of sedentary 
behaviour that occurred during waking hours was derived by summing the number of 
consecutive cells in which 0 steps were recorded. That is, for the pattern of one-
minute epochs of SAM data outlined below, a bout duration for sedentary behaviour 
was recorded as one minute. 
10, 24, 28, 50, 50, 24, 0, 10, 24, 28 
Similarly, for the pattern of one-minute epochs of SAM data outlined below, a bout 
duration for sedentary behaviour was recorded as five minutes. 
10, 24, 0, 0, 0, 0, 0, 10, 24, 28 
Third, for each measurement day included in analyses, the duration of all bouts of 
walking based activity were averaged. 
5.3.2.5 Exploring peak and 30-minute peak cadences for walking based activity 
Stepwatch Activity Monitor data were sorted in descending order of cadence. 
Thereafter, the peak (the one-minute epoch during which the highest cadence was 
recorded) and average 30-minute peak cadence (the average of the 30 individual one-
minute epochs, during which the highest cadences were recorded, not necessarily 
consecutive) were obtained for each day. The method used in this study for analysis 
of the peak intensity of walking abased activity is the same method reported by 
NHANES (462). 
5.3.2.6 Exploring the proportion of participants who met the criteria for 
participating in sufficient walking based activity 
There is controversy in the literature regarding the number of steps that are required 
to meet the current recommendations for participation in physical activity that will 
produce health benefits (54). Tudor-Locke et al (355) reviewed the results of studies 
that used an accelerometer to translate the current physical activity recommendations 
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into daily steps in older adults. These authors concluded that accumulating 7,000 to 
10,000 steps/day is equivalent to performing 30 minutes per day of moderate to 
vigorous intensity physical activity. These findings are similar to those reported in 
the guidelines of the American College of Sports and Medicine (ACSM) who 
recommend that adults should accumulate at least 7,000 steps daily (54). Based on 
these data, participants in this study who had SAM data for seven days and 
accumulated at least 7,000 steps/day in five days or more, were deemed to have met 
the criteria for participating in sufficient walking based activity. 
5.3.3 Statistical analyses 
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS version 21.0, Armonk, NY: IBM Corp, USA). The distribution of data was 
examined by graphical (frequency histograms and box plots) and statistical methods 
(Shapiro-Wilk test). Data that did not follow a normal distribution were analysed 
using non-parametric statistical tests. Prior to undertaking the comparisons of data 
between the participants with COPD and healthy controls, for each group, 
differences in walking based activity and sedentary behaviour variables were 
compared across the days that SAM data were available. These within-group 
analyses were needed to show that there were minimal differences between days and 
therefore, that data could be averaged across days for the purpose of the between-
group comparisons. Within-group comparisons of walking based activity and 
sedentary behaviour variables were performed using a one-way repeated measures 
analysis of variance (ANOVA) or Friedman’s ANOVA for parametric or non-
parametric data respectively.  
In the absence of any large differences between days within groups, all walking 
based activity and sedentary behaviour variables were averaged across the days that 
the SAM data were available. Thereafter, data were compared between the 
participants with COPD and healthy controls using either independent-samples t-tests 
or Mann-Whitney U tests for parametric or non-parametric data, respectively. The 
Chi-squared statistic was used to compare the proportion of participants who 
accumulated ≥ 7,000 steps/day.  
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Associations between the quality and emotional response components of the D-12 
and time spent (expressed as percentage of total wear time and minutes) in walking 
based activity and sedentary behaviour in participants with COPD were examined 
using Pearson or Spearman’s correlations for parametric or non-parametric data, 
respectively. For all analyses, a p value ≤ 0.05 was considered significant. Data are 
expressed as mean  SD unless otherwise stated. 
5.4 Results 
5.4.1 Participants  
Seventy-two males with COPD were screened for possible inclusion into the study. 
Twenty males (28%) were not eligible to participate in the study, of whom ten (50%) 
were not clinically stable for the last two months. Seven (35%) of the 20 males who 
did not meet the study criteria were not retired. The remaining three (15%) of the 20 
males were on supplemental oxygen and, therefore, were not eligible for 
participation in the study.  
Fifty-two (72%) were eligible and approached to participate. Of these 52 males, a 
total of 34 consented to participate (consent rate of 65%). The reasons for not 
participating are outlined in Figure  5-1. Four of the 34 (12%) were not included in 
the analyses pertaining to walking based activity and sedentary behaviour because of 
hospitalised with an acute exacerbation of COPD during the monitoring period (n = 
1), insufficient wear time ≤ 10 hour/day (n = 1) or were SAM data were not unable to 
be retrieved as they did not return the device (n = 2) (Figure  5-1).   
Of the 30 participants in the COPD group who had their walking based activity and 
sedentary behaviour data analysed, 21 (70%) wore the SAM for ≥ 12 hours/day on 
all seven days, nine (30%) wore the monitor for ≥ 12 hours/day for six days and one 
(3%) wore the monitor for ≥ 12 hours/day for five days. Their characteristics are 
presented in Table  5-1. 
Forty healthy controls were screened for possible inclusion into the study. Eight 
males (20%) did not meet the criteria of the study. Five males (62%) of the eight 
were not retired and the other three (38%) had abnormal spirometry data. 
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Thirty-two (80%) were eligible and approached to participate. These 32 males 
consented to participate (consent rate of 100%) in this study. Three of the 32 (9%) 
were excluded from the analyses pertaining to walking based activity and sedentary 
behaviour because they did not return the activity monitors.  
Of the 29 healthy controls who had their walking based activity and sedentary 
behaviour data analysed, 26 (90%) wore the SAM for ≥ 12 hours/day for all seven 
days, and three (10%) wore the monitor for ≥ 12 hours/day for six days (Figure  5-1). 
Their characteristics are presented in Table  5-1.
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Figure ‎5-1: Study flow diagram 
Abbreviations: Abbreviations: D-12, Dyspnoea-12 questionnaire; SAM, 
StepWatch
TM
 Activity Monitor; 6MWD, six-minute walk distance. 
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Table ‎5-1: Characteristics of participants 
Data are expressed as mean ± SD: standard deviation or number (%). BMI: body 
mass index; D-12: Dyspnoea-12; FEV1: forced expiratory volume in one second; 
FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung 
Disease (2: moderate, 3: severe and 4: very severe), GORD: gastro-oesophageal 
reflux disease and 6MWD: six-minute walk distance. * Significant difference 
between groups. 
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5.4.2 Number of measurement days and number of measurement hours per 
day 
There were no differences between the COPD and healthy participants in the number 
of days of SAM data included in the analyses (6.8 ± 0.5 days versus 6.9 ± 0.3 days; p 
= 0.36), or in the average daily wear time (13.4 ± 0.8 hours/day versus 13.5 ± 0.5 
hours/day; p = 0.40).  
5.4.3 Within group comparisons of walking based activity and sedentary 
behaviour variables  
5.4.3.1 COPD participants 
There were no differences between days in the time spent in walking based activity 
and sedentary behaviour expressed as minutes (Table  5-2) or in the percentage of 
total wear time (Figure 5-2). No differences were observed between total daily step 
counts between days (Table  5-2). Figure  5-3 and Figure  5-4 illustrate the percentage 
of waking hours spent in walking based activity when divided into cadence bands. 
When walking based activity was divided into cadence bands and expressed in 
minutes, there was no difference between days (p > 0.05) (Table  5-2). When walking 
based activity was divided into cadence bands and expressed as a percentage of total 
wear time, there was a significant difference in the percentage of waking hours 
accumulated at a cadence between 1 and 19 steps/min (p = 0.047) (Figure  5-3). Post-
hoc analyses revealed that the percentage of waking hours accumulated at a cadence 
between 1 and 19 steps/min on Sunday (11.0 ± 4.7) was lower than that measured on 
Wednesday (15 ± 6.3, p = 0.011) and Thursday (14.2 ± 5.8, p = 0.014). 
There were no differences between days in the average bout duration for time spent 
in walking based activity (p > 0.05); Figure  5-5), the average bout duration for time 
spent in sedentary behaviour (p > 0.05; Figure  5-5) peak cadence (p > 0.05; 
Figure  5-5) or the average 30-minute peak cadence (p > 0.05; Figure  5-5). 
Given that there were very few differences between days, and that the one difference 
which was demonstrated was small, these variables were averaged across days 
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Table ‎5-2: Time spent in walking based activity and sedentary behaviour across each day that the SAM was worn, expressed in 
minutes, for participants with COPD (n = 30). 
 Data are presented as mean ± standard deviation or *median (interquartile range). min: minutes; SD: standard deviation
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Figure ‎5-2: Time spent in walking based activity and sedentary behaviour 
across each day that the SAM was worn, expressed as a percentage of total wear 
time, for participants with COPD A) walking based activity and B) sedentary 
behaviour. Data are expressed as mean ± standard deviation. 
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Figure ‎5-3: Time spent in walking based activity cadence of A) 1 to 19, B) 20 to 
39 and C) 40 to 59 steps/day across each day that the SAM was worn, expressed 
as a percentage of total wear time, for participants with COPD A). Data are 
expressed as mean ± standard deviation. *Statistically significant difference (p < 
0.05). 
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Figure ‎5-4: Time spent in walking‎based‎activity‎cadence‎of‎A)‎60‎to‎79,‎B)‎80‎to‎99,‎C)‎100‎to‎119‎and‎D)‎≥‎120‎steps/day‎across‎
each day that the SAM was worn, expressed as a percentage of total wear time, for participants with COPD. Data are expressed 
as mean ± standard deviation.
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Figure ‎5-5: (A) Average bout durations for walking based activity and 
sedentary behaviour and (B) the peak and average 30-minute peak cadence 
across each day that the SAM was worn for participants with COPD. Data are 
expressed as mean ± standard deviation.
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5.4.3.2 Healthy controls 
There were no differences between days in the time spent in walking based activity 
and sedentary behaviour expressed as minutes (Table  5-2). There was a significant 
difference between days in the percentage of waking hours accumulated in walking 
based activity ≥ 1step/min (p = 0.040) (Figure  5-6). Post-hoc analyses revealed that 
the percentage of waking hours accumulated in walking based activity on Friday 
(32.0 ± 9.6) was lower than that measured on Sunday (34.8 ± 13.5, p = 0.047), 
Monday (36.8 ± 9.3, p = 0.026), Tuesday (37.4 ± 10.7, p = 0.002), Wednesday (39.8 
± 10.3, p = 0.002) and Thursday (36.8 ± 9.6, p = 0.026). 
In healthy controls, there was a significant difference between days in the percentage 
of waking hours accumulated in walking based activity ≥ 1step/min (p = 0.048) 
(Figure  5-6). Post-hoc analyses revealed that the percentage of waking hours 
accumulated in walking based activity on Friday (32.3 ± 9.6) was lower than that 
measured on Sunday (35.0 ± 13.5, p = 0.044), Monday (36.8 ± 9.3, p = 0.047), 
Tuesday (37.4 ± 10.7, p = 0.026), Wednesday (38.8 ± 10.3, p = 0.002) and Thursday 
(36.9 ± 8.9, p = 0.026).  
 There was a significant difference between days in the percentage of waking hours 
accumulated in sedentary behaviour 0 steps/min (p = 0.044) (Figure  5-6). Post-hoc 
analyses revealed that the percentage of waking hours accumulated in sedentary 
behaviour on Friday (68.0 ± 9.5) was higher than that measured on Sunday (62.6 ± 
9.3, p = 0.046), Monday (62.8 ± 9.5, p = 0.028), Tuesday (62.6 ± 11.1, p = 0.017), 
Wednesday (60.3 ± 10.7, p = 0.002) and Thursday (63.5 ± 8.1, p = 0.040).  
No differences were observed between total daily step counts between days 
(Table  5-2). When walking based activity was divided into cadence bands and 
expressed in minutes (Table  5-3) or percentage of total wear time (Figure  5-7 and 
Figure  5-8), there was no difference between days (p > 0.05). 
There were no differences between days in the average bout duration for time spent 
in walking based activity ((p > 0.05); Figure  5-9), the average bout duration for time 
spent in sedentary behaviour (p > 0.05; Figure  5-9) peak cadence (p > 0.05; 
Figure  5-9) or the average 30-minute peak cadence (p > 0.05; Figure  5-9). 
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Given that there were very few differences between days, and that those differences 
which were demonstrated were small, these variables were averaged across days.
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Table ‎5-3: Time spent in walking based activity and sedentary behaviour across each day that the Stepwatch
TM
 Activity Monitor 
was worn, expressed in minutes, for healthy controls (n = 29). 
Data are presented as mean ± standard deviation or *median (inter quartile range). min: minutes; SD: standard deviation.
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Figure ‎5-6: Time spent in walking based activity and sedentary behaviour 
across each day that the SAM was worn, expressed as a percentage of total wear 
time, for healthy controls A) walking based activity and B) sedentary behaviour. 
Data are expressed as mean ± standard deviation. *Statistically significant 
difference (p < 0.05).   
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Figure ‎5-7: Time spent in walking based activity cadence of A) 1 to 19, B) 20 to 
39 and C) 40 to 59 steps/day across each day that the SAM was worn, expressed 
as a percentage of total wear time, for healthy controls. Data are expressed as 
mean ± standard deviation.
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Figure ‎5-8: Time spent in walking‎based‎activity‎cadence‎of‎A)‎60‎to‎79,‎B)‎80‎to‎99,‎C)‎100‎to‎119‎and‎D)‎≥‎120‎steps/day‎across‎
each day that the SAM was worn, expressed as a percentage of total wear time, for healthy controls. Data are expressed as mean 
± standard deviation.
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Figure ‎5-9: (A) Average bout durations for walking based activity and 
sedentary behaviour and (B) the peak and average 30-minute peak cadence 
across each day that the SAM was worn for healthy controls. Data are 
expressed as mean ± standard deviation. 
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5.4.4 Comparisons between participants with COPD and healthy controls of 
variables related to walking based activity and sedentary behaviour, 
averaged across the days that Stepwatch
TM
 Activity Monitor data were 
available  
5.4.4.1 Time spent in walking based activity and sedentary behaviour 
Table  5-4 presents the average total time spent in walking based activity (≥ 1 
step/min) and sedentary behaviour (0 steps/min) by participants with COPD and 
healthy controls expressed as minutes. Figure  5-10 presents the average total time 
spent in walking based activity (≥ 1 steps/min) and sedentary behaviour (0 steps/min) 
by participants with COPD and healthy controls, expressed as a percentage of 
waking hours. Compared with healthy controls, participants with COPD spent less 
time in walking based activity (37 ± 7% versus 22 ± 8% of waking hours; p < 0.001). 
This difference was equivalent to 15 ± 12% of waking hours, or 131 ± 105 minutes 
(p < 0.001).  
Compared with healthy controls, participants with COPD spent more time in 
sedentary behaviour (63 ± 6% versus 78 ± 8% of waking hours; p < 0.001). This 
difference was equivalent to 15 ± 13% of waking hours, or 109 ± 103 minutes (p < 
0.001). 
5.4.4.2 Average daily step count 
Compared to healthy controls, males with COPD accumulated fewer daily steps 
(7,472 ± 2,258 versus 4,124 ± 2,039 steps/day; p < 0.001). 
5.4.4.3 Time spent in walking based activity undertaken at different cadences  
Table  5-4 presents the average total time spent in walking based activity undertaken 
at the different cadence bands. Compared with healthy controls, participants with 
COPD spent fewer minutes (Table  5-4) and a lower percentage of waking hours 
(Figure  5-10) in walking based activity at all cadence bands < 100 steps/min. No 
differences were seen between participants with COPD and healthy controls in the 
time spent at cadence bands ≥ 100 steps/min, expressed as minutes (Table  5-4) or as 
a percentage of waking hours (Figure  5-10) (p > 0.05). 
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Table ‎5-4: Comparison of walking based activity, divided into cadence bands in 
both participants with COPD and healthy controls, expressed in minutes. 
Data are presented as mean ± standard deviation. min: minutes; SD: standard 
deviation. * Significant difference between groups.
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Figure ‎5-10: Comparison of A) walking based activity and sedentary behaviour 
and B) walking based activity, divided into cadence bands in both participants 
with COPD and healthy controls, expressed as a percentage of waking hours. 
Data are expressed as mean ± standard deviation. *Statistically significant 
difference (p < 0.05).  
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5.4.5 Patterns of accumulation for both walking based activity and sedentary 
behaviour 
Figure  5-11 illustrates the average duration of bouts for walking based activity and 
sedentary behaviour in participants with COPD and healthy controls. Compared with 
healthy controls, participants with COPD accumulated time in walking based activity 
in shorter bouts (6 ± 1 versus 3 ± 1 min/day; p < 0.01) and sedentary behaviour in 
longer bouts (9 ± 2 versus 12 ± 2 min/day; p < 0.01). 
5.4.6 Peak and 30-minute peak cadences for walking based activity 
Figure  5-11 demonstrates the peak and average 30-minute peak cadence in 
participants with COPD and healthy controls. The peak cadence was lower in 
participants with COPD than healthy controls (76 ± 13 versus 93 ± 13 steps/min; p < 
0.01). The average 30-minute peak cadence was lower in participants with COPD 
compared with healthy controls (47 ± 11 versus 62 ± 9 steps/min; p < 0.01). 
5.4.7 The proportion of participants who met the criteria for participating in 
sufficient walking based activity  
Compared with healthy controls, the proportion of participants with COPD who met 
the criteria for participating in sufficient walking based activity (7,000 steps per day 
for five or more days) was lower (34 % versus 7%; p < 0.001). 
5.4.8 Associations between the components of Dyspnoea-12 questionnaire with 
time spent in walking based activity and sedentary behaviour 
Moderate associations were demonstrated between the score for the quality 
component of the D-12 and time spent in walking based activity, expressed as 
minutes and percentage of waking hours (all r ≥ -0.52, p < 0.01). Similarly, moderate 
associations were demonstrated between the score for the quality component of the 
D-12 and time spent in sedentary behaviour, expressed as minutes and percentage of 
waking hours (all r ≥ 0.46, p < 0.01). Strong associations were revealed between the 
score of the emotional response component of the D-12 and time (expressed as 
minutes and percentage of waking hours) spent in walking based activity (all r ≥ -
0.63, p < 0.01) and sedentary behaviour (all r ≥ 0.66, p < 0.01). The total scores of 
the D-12 were strongly associated with time (expressed as and minutes and 
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percentage of waking hours) spent in walking based activity (all r ≥ -0.72, p < 0.01) 
and sedentary behaviour (all r ≥ 0.66, p < 0.01).
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Figure ‎5-11: Comparison of the bout duration for walking based activity and 
sedentary behaviour in both participants with COPD and healthy controls. Data 
are expressed as mean ± standard deviation. *Statistically significant difference 
(p < 0.05). 
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Figure ‎5-12: Comparison of the peak and average peak 30-minute cadences in 
both participants with COPD and healthy controls. Data are expressed as mean 
± standard deviation. *Statistically significant difference (p < 0.05).     
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5.5 Discussion 
This study demonstrated several differences between males with COPD and healthy 
controls in Saudi Arabia in terms of time spent in walking based activity and 
sedentary behaviour, total daily steps count, the duration of bouts spent in walking 
based activity and sedentary behaviour as well as peak intensity of walking based 
activity. The results demonstrate that males with COPD spent less of their waking 
hours in walking based activity and more time in sedentary behaviour when 
compared with healthy controls. In addition, males with COPD accumulated fewer 
steps in their daily life compared to healthy controls. Further, males with COPD, on 
average, accumulated walking based activity in shorter bouts and sedentary 
behaviour in longer bouts when compared with healthy controls. The highest peak 
and average 30-minute cadences were lower in males with COPD compared to that 
observed in the healthy controls. The results of this study also demonstrated that the 
proportion of males with COPD who participated in sufficient physical activity was 
lower than that seen in healthy controls. In addition, this study demonstrated 
moderate to strong associations between the quality and emotional response 
components of the D-12 with time spent in walking based activity and sedentary 
behaviour in COPD.  
5.5.1 Walking based activity and sedentary behaviour 
Earlier work reported that two days of measurement (weekdays only) were sufficient 
to reliably assess daily physical activity, defined as an intra-class coefficient ≥ 0.7 
(56). Subsequent studies have suggested that the minimum number of wear days 
depends on factors such as disease severity (82, 85). Watz et al (85) demonstrated 
that up to five days of measurement was necessary for reliable results of physical 
activity in people with mild COPD, while those with more severe COPD required 
only two to three days. Given that the participants in the present study had moderate 
to very severe COPD, a minimum of five days of wear time was required to include 
the data in this study’s analyses. 
This is the first study to report data on walking based activity and sedentary 
behaviour in males with COPD in Saudi Arabia, and to compare it with healthy 
controls in Saudi Arabia. The current study demonstrated that, compared to healthy 
Chapter 5: Physical activity and sedentary behaviour 
157 
controls, males with COPD spent 15 ± 12% less of their waking hours in walking 
based activity and 15 ± 13% more of their waking hours in sedentary behaviour. 
These findings correspond to previously reported work conducted in Belgium and 
Brazil (56, 57). The number of daily steps found in this study for males with COPD 
(4,124 ± 2,039 steps/day) was similar to that reported in people with COPD from 
Canada (4,378 ±2,105 steps/day) (463) and the Netherlands (4,472 ±2,716 steps/day) 
(464). Moy et al (465) showed that, people with COPD who did not walk much had 
an increased risk of acute exacerbations of COPD and hospital admission. Thus, the 
implications of the results of this study, whereby low levels of physical activity were 
seen, are that these males with COPD may be at higher risk of acute exacerbation 
and hospitalisation.  
This is the first study to report the proportion of males with COPD and healthy 
controls in Saudi Arabia who met the criteria for participating in sufficient walking 
based activity. Compared to healthy controls, the proportion of males with COPD 
(7%) who accumulated an average of ≥ 7,000 in five or more days was lower than 
that for healthy controls (34%). These findings increase the importance of designing 
interventions aiming at increasing daily steps in males with COPD to meet the 
recommended amount of physical activity necessary to promote and maintain health.   
Males with COPD in this study were more sedentary, with a higher proportion (78%) 
of their waking hours spent in sedentary behaviour, than that reported in people with 
COPD from Belgium (64%) and Brazil (56%) (56, 57). The discrepancy between the 
present study and the previous studies in terms of the percentage of waking hours 
spent in sedentary behaviour may reflect ethnic, geographical, environmental, 
cultural and lifestyle factors unique to Saudi Arabia that can impact participation in 
physical activity. In addition, it is important to note that the discrepancy may also 
have been due to the use of different activity monitors between the studies as well as 
different definitions used for sedentary behaviour (56, 57). In the present study, the 
SAM was used to measure steps count and a pragmatic cut-off of 0 steps/min was 
defined as sedentary behaviour. In the studies on people with COPD from Belgium 
and Brazil (56, 57), the Dynaport accelerometer (McRoberts BV, The Hague, 
Netherlands) was used to quantify the time spent in sedentary behaviour which was 
defined as the time spent in a sitting or reclining posture (56, 57). Notwithstanding 
Chapter 5: Physical activity and sedentary behaviour 
158 
these differences, the magnitude of difference between males with COPD and 
healthy controls from Saudi Arabia in terms of the percentage of waking hours spent 
in sedentary behaviour (15%) was similar to that reported in Belgium in those with 
COPD (18%) when compared to their healthy controls (56). The findings of this 
study reinforce the importance of implementing interventions aim at increasing time 
spent in walking based activity by decreasing time in sedentary behaviour in males 
with COPD.   
In the present study, there were differences across days in the percentage of wear 
time spent in walking based activity and sedentary behaviour by healthy controls. 
These differences were revealed between Friday and the other days of the week. This 
discrepancy could be explained as Friday is considered a holy day for Muslims and 
they spend much of their time in the mosque reading and praying. 
5.5.1.1 Time spent in walking based activity undertaken at different cadences  
This is also the first study to report data on the time spent walking at different 
cadences by males with COPD. In the current study, males with COPD spent less 
time (expressed as a percentage of waking hours and minutes) walking at cadences < 
100 steps/min, when compared to healthy controls. High cadences (≥ 100 steps/min) 
have been considered the threshold for moderate intensity physical activity in adults 
(466). Therefore, it is important to spend time in accumulating steps at cadences ≥ 
100 steps/min, as moderate physical activity is recommended by the ACSM 
guidelines to optimise health benefits such as reductions in the risk of cardiovascular 
and metabolic disease (54). However, neither males with COPD nor the healthy 
controls in this study participated in walking based activity at cadences ≥ 100 
steps/min, which explains the lack of differences between these two groups at high 
cadences. These findings suggest that males with COPD as well as healthy controls 
in Saudi Arabia may be at greater risk of developing chronic diseases, such as 
cardiovascular and metabolic diseases, as they do not spend time participating in 
daily moderate intensity physical activity (54). Therefore, in Saudi Arabia, awareness 
of the benefits of walking at a moderate intensity needs to be promoted among the 
general public as well as males with COPD. Studies that reported changes in physical 
activity in people with COPD have frequently used individual goal setting, collection 
of objective physical activity data in order to place goals and/or provide feedback, 
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overcome barriers, encourage adherence, motivational interviewing and regular 
contact with healthcare professionals to increase motivation (467-472). Therefore, 
these approaches need to be considered, in Saudi nationals, when implementing 
interventions to increase time of participation in physical activity and reduce time in 
sedentary behavior. 
In a comparison with data reported by the NHANES (67) on time spent (expressed as 
a percentage of waking hours) at different cadences by healthy males from the 
United States of America, healthy males in this study spent less time at both 
cadences < 100 steps/min (21% versus 67%) and ≥ 100 steps/min (1% versus 6%). 
Furthermore, healthy controls in the present study were more sedentary, with a 
higher proportion of their waking hours (63%) spent in sedentary behaviour than that 
(34%) reported by the NHANES (67). The discrepancy between the present study 
and the NHANES in terms of the percentage of waking hours spent in walking based 
activity at different cadences and in sedentary behaviour may reflect ethnic, 
geographical, environmental, cultural and lifestyle factors unique to Saudi Arabia 
that can influence participation in physical activity. 
5.5.2 Patterns of accumulation for walking based activity and sedentary 
behaviour  
This study is the first to report data on bout durations for walking based activity and 
sedentary behaviour in males with COPD in Saudi Arabia, and to compare this with 
healthy controls. The present study demonstrated that, compared to healthy controls, 
males with COPD accumulated time in walking based activity in shorter bouts and 
sedentary behaviour in longer bouts. The ACSM guidelines recommend that physical 
activity should be accrued in bouts of at least 10 minutes duration to optimise health 
benefits (54). However, the results of this study demonstrated that, on average, males 
with COPD did not meet these recommendations as they performed their activities in 
shorter bouts (≤ 3 min). This contrasts with earlier work by Donaire-Gonzalez et al 
(446), who investigated the pattern of accumulation of physical activity in 177 (94% 
males) people with COPD (age 71 ± 8 years; FEV1 52 ± 16% predicted). The authors 
found that a relatively high proportion (60%) of people with COPD performed their 
physical activity in bouts ≥ 10 minutes. However, the study by Donaire-Gonzalez et 
al (446) used different methods than those used in the current study in terms of an 
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activity monitor and bout definition. They used a metabolic monitor (SenseWear
®
 
Pro2 Armband) that estimates energy expenditure, and defined physical activity 
bouts as any period ≥10 minutes at an intensity ≥ 1.5 METs per minute each day. 
Whereas, the present study used the SAM and defined walking based activity bouts 
as any period of time accrued in cadences ≥ 1 steps/min each day. Therefore, due to 
different methods, it is difficult to compare the results of this study with those 
reported by Donaire-Gonzalez et al (446). 
In the present study, the bout duration for sedentary behaviour in males with COPD 
was longer than that seen in healthy controls. Longer duration in sedentary behaviour 
has been associated with deleterious health outcomes such as an increased risk of 
developing cardiovascular and metabolic diseases (401). Therefore, the clinical 
recommendation that can be taken for this is that people with COPD need to break up 
their sedentary behaviour with light intensity physical activity (e.g. standing up) 
more often. The bout durations in the present study for males with COPD and 
healthy controls were heavily influenced by a large number of bouts equal to one 
minute in duration. Despite this limitation, a difference in bout durations between 
males with COPD and healthy controls was evident.  
It is likely that the impairment in exercise capacity demonstrated in people with 
COPD(56) affects the way they accumulate time in both walking and sedentary 
behaviour, such that they accumulate time in these domains in short bouts for 
walking based activity and long bouts for sedentary behaviours. These findings 
highlight the importance to educate males with COPD to spend a longer time in 
bouts of physical activity and a shorter time in bouts of sedentary behaviour for the 
purpose of health benefits such as reducing the risk of developing cardiovascular and 
metabolic disease (54, 61, 359). 
5.5.3 Peak intensity of walking based activity 
The peak and average 30-minute peak cadences were lower in males with COPD 
when compared to their healthy controls. This reduction in peak intensity of walking 
based activity in males with COPD may reflect their limitation of peak aerobic 
capacity (463). In addition, these findings suggest that males with COPD may have 
less capacity to walk at moderate intensity. A recent study in young adults (aged 22 ± 
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3 years) demonstrated that an average 30-minute peak cadence ≥ 102 steps/min was 
associated with better leg vascular compliance (473). Thus, if these results can be 
extrapolated to males with COPD, as in the present study, they may be at risk of 
developing leg vascular stiffness as they had a low average 30-minute peak cadence 
(47 steps/min).  
In the present study, the average 30-minute peak cadence accrued by healthy controls 
in this study is somewhat lower than obtained for males in the United States of 
America (62 versus 74 steps/min) (462). This difference in the average 30-minute 
peak cadence of walking based activity due to variations in geographical location, 
ethnicity and lifestyle factors between populations. In addition, these differences 
demonstrate the importance of obtaining local ‘healthy’ control data. 
5.5.4 Associations between the quality and emotional response components of 
the Dyspnoea-12 questionnaire and time spent in sedentary behaviour 
and walking based activity 
Associations of moderate strength were demonstrated between the quality component 
of the D-12 with the time spent in walking based activity (r ≥ -0.52) and sedentary 
behaviour (r ≥ 0.46). However, the emotional response component of the D-12 
yielded somewhat stronger associations with the time accumulated in walking based 
activity (r ≥ -0.63) and sedentary behaviour (r ≥ 0.66). The results of this study 
extend the validity of the Arabic language version of the D-12 in people with COPD 
(presented in Chapter 3) by showing the associations between the perception of 
dyspnoea and time spent in physical activity and sedentary behaviour. The 
associations found in this study indicate that males who spend a low proportion of 
their time in walking based activity also experience a greater emotional response to 
dyspnoea. This finding highlights the importance of targeting interventions that aim 
to minimise the emotional response to dyspnoea, as a strategy to optimise 
participation in physical activity and reduce the time spent in sedentary behaviour. 
Alternatively, interventions that optimise participation in physical activity may have 
a favourable impact on the emotional response to dyspnoea. However, the coefficient 
of determination for the association between emotional response to dyspnoea and the 
time spent in walking based activity (R
2
 = 0.40) or sedentary behaviour (R
2
 = 0.44) 
demonstrates that, at most , only 44% of variance in either time spent in walking 
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based activity or sedentary behaviour is explained by the emotional repose to 
dyspnoea. Therefore, this finding suggests that other important factors contribute to 
how males with COPD spend their daily time in walking based activity and sedentary 
behaviour. 
5.6 Limitations 
This study had a number of limitations which need to be considered. This study 
included a small sample and only recruited at a single location in Riyadh, Saudi 
Arabia. However, adequate power was used in this study and the minimum number 
of participants for completing this study was obtained for both groups. In addition, 
since the sample only included males, the results cannot be generalised to the female 
population. A large sample including males and females from different regions in 
Saudi Arabia is highly recommended to measure the level of physical activity and 
sedentary behaviour in Saudi nationals with COPD and their healthy controls. The 
cadence bands used in this study, which proposed by the NHANES (67), could be 
consider a limitation as it has not been validated in COPD population. However, 
these cadence bands, albeit somewhat arbitrary, appear to be appropriate to use in 
people with COPD. This can be stated because studies that have measured step 
counts in people with COPD, after instruction to walk at a medium pace, have 
recorded step counts between 73 and 79 steps/min (373, 377). Likewise, step counts 
for people after instruction to walk at slow pace have recorded step counts between 
85 and 96 steps/min (377) and these cadences were similar to those used by the 
NHANES (67).  Another limitation was that the present study only measured 
walking based activity and there are other forms of physical activity such as cycling, 
although cycling is uncommon in Saudi Arabia (474). However, walking is 
considered fundamental to human functioning and mobility. Furthermore, walking 
continues to be the most commonly reported leisure time physical activity (475). 
5.7 Conclusions 
Compared to healthy controls, males with COPD: (i) spent a lower proportion of 
their time in walking based activity and a higher proportion of their time in sedentary 
behaviour, (ii) spent shorter bouts in walking based activity and longer bouts in 
sedentary behaviour, (iii) accumulated fewer daily steps, (iv) had a lower proportion 
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meeting the criteria for participating in sufficient walking based activity and (v) had 
lower peak and average 30-minute peak cadences. The quality and emotional 
response components of the D-12 were associated with walking based and sedentary 
behaviour activity in males with COPD. In Saudi Arabia, there is a need to promote 
awareness of the health benefits of walking at moderate intensity among the general 
public as well as in males with COPD. In addition, strategies aimed at minimising 
the severity of dyspnoea and the emotional response to the sensation may reduce the 
time spent in sedentary behaviour and optimise participation in daily life activity in 
COPD. Alternatively, strategies aimed at increasing physical activity may reduce the 
severity of dyspnoea and the emotional response to dyspnoea in people with COPD. 
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CHAPTER 6  
SUMMARY AND CONCLUSIONS 
There were three studies undertaken in this program of research. Study 1 (chapter 3) 
sought to answer the following question;  
Is the Arabic version of Dyspnoea-12 questionnaire (D-12) reliable and valid 
in Saudi nationals with chronic obstructive pulmonary disease (COPD)?  
Study 2 (chapter 4) sought to answer the following question: 
Do the quality and emotional response components of the D-12 differ 
between periods of with an acute exacerbation of COPD (AECOPD) and 
periods of clinical stability? 
Study 3 (chapter 5) sought to answer the following questions:  
1. Do physical activity and sedentary behaviour in males with COPD differ 
from those of healthy controls? 
2. Are the quality and emotional response components of the D-12 associated 
with physical activity and sedentary behaviour in males with COPD?    
This chapter synthesises the novel findings from this body of work, describes the 
clinical implications and suggests areas for further work. 
6.1 The Arabic language version of the Dyspnoea-12 questionnaire: 
a reliable, valid and responsive measure of dyspnoea for use in 
the Gulf region 
This program of research has translated the D-12 into the Arabic language. This is 
important given that there is little work on the measurement of dyspnoea of people 
with COPD in Saudi Arabia. The work completed in the program of research will 
facilitate the use of the D-12 and provide clinicians and researchers with a way of 
evaluating dyspnoea in people with COPD who speak in the Arabic language. This 
may lead to greater advocacy for programs such as pulmonary rehabilitation which 
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aim to reduce dyspnoea in people with COPD. The Arabic version of the D-12 can 
be used by researchers in those with asthma, and interstitial lung disease (ILD), 
populations for whom the D-12 has been previously validated in the English 
language (40, 41). However, this may require further studies to confirm the 
measurement properties of the D-12 in those populations who speak the Arabic 
language.  
Data presented across the three studies completed in the program of research 
contribute novel information pertaining to the measurement properties of Arabic 
language version of the D-12. This is summarised below. 
6.1.1 Reliability 
Data presented in Chapter 3 demonstrated that the D-12 was reliable when 
administered on two occasions, separated by two weeks. This was demonstrated by 
the high intraclass correlation coefficient (ICC) (0.94) and excellent weighted kappa 
score (0.83). The reliability of the Arabic version of the D-12 were consistent with 
what were demonstrated in an English language in people with COPD (23). In 
addition, the total scores for 10 of the D-12 items were no different between the two 
administrations and the scores for the remaining two D-12 items differed by less than 
one point. Further, the scores obtained on the D-12 for people who were grouped 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
grades were reliable, as indicated by the ICC values ≥ 0.85 for GOLD grades 2 to 4. 
This is the first study to demonstrate the D-12 provided a stable measure of dyspnoea 
for people with moderate to very severe COPD. 
6.1.2 Validity 
The Arabic version of the D-12 presented in Chapter 3 was valid in a population of 
Saudi nationals with COPD, as significant associations were revealed between the D-
12 components and its total score with the scores of questionnaire-based 
assessments. Specifically, a moderate to strong association was demonstrated 
between the D-12 total score and the score of COPD Assessment Test (CAT) 
questionnaire, which assessed health status, the total score of the Chronic Respiratory 
Disease Questionnaire (CRDQ), which assessed health-related quality of life, (all r ≥ 
0.50; p < 0.01). These data were consistent with early work in people with COPD 
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(23). In addition, data supporting the validity of the D-12 was also presented in 
Chapter 5, which demonstrated a moderate to strong association between the quality 
and emotional response components of the D-12 as well as the total score of the D-12 
with time spent in walking based activity and the accumulation of time spent in 
sedentary behaviour (r = -0.52 and 0.46, respectively, all p < 0.01). This is the first 
study to report associations between the D-12 and a common form of physical 
activity, such as walking, and sedentary behaviour in people with COPD. People 
with COPD become more sedentary and less physically active and the main reason 
for that is dyspnoea during exertion. Therefore, it is expected that dyspnoea has a 
relationship with physical activity and sedentary behaviour. These findings may 
stimulate future research into ameliorating the emotional response of dyspnoea, 
which appears to have the greatest adverse effect on participation in physical activity 
and the accumulation of time in sedentary behaviour. 
The findings of this research also reported data showing the capacity of the D-12 to 
discriminate between people grouped according to their disease severity (Chapters 3 
and 4). Data presented in Chapter 3 demonstrated the capacity of the D-12 to 
discriminate between people with moderate and very severe COPD. These findings 
were confirmed and expanded in Chapter 4. Data in Chapter 4 demonstrated that the 
D-12 has the capacity to discriminate between people with moderate and very severe 
COPD during hospitalisation for an acute exacerbation of COPD and when they had 
returned to clinical stability. These findings provide additional evidence of the 
validity of the D-12, as dyspnoea has been shown previously to worsen with 
advancing disease (476). 
6.1.3 Responsiveness 
Data presented in Chapter 4 demonstrated that the D-12 was responsive to change in 
dyspnoea. Of note, this is the first study to explore and demonstrate the 
responsiveness of the D-12 in any language in terms of interventions or changes in 
clinical status. Specifically, the quality and emotional response components of the D-
12 were responsive to a change in clinical status. This was indicated by the large 
effect sizes (≥ 1.6) that were obtained for the components and the total score of the 
D-12 between periods of an AECOPD and clinical stability. The responsiveness of 
the D-12 was less that of the CAT (effect sizes 2.1 versus 3.0). The most reason for 
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that is the CAT comprises items related to a broad range of factors that are likely to 
be adversely impacted during an AECOPD such as sleep quality and energy levels, 
rather than just dyspnoea. However, the responsiveness of the D-12 was similar to 
that of the dyspnoea domain of the CRDQ (effect size of 2.5). 
This also is the first study to assess the responsiveness of the Arabic versions of the 
CRDQ and CAT as well as the first to report they are responsive to change following 
an AECOPD. These findings support the utilisation of the CRDQ and CAT in COPD 
population in the clinical and research settings in Saudi Arabia as well as in Arabic 
Gulf countries, as they were highly responsive questionnaires.  
Further research with a larger sample of both genders from different regions in Saudi 
Arabia to investigate the measurement properties of the D-12 in the Arabic COPD 
population is required in order to increase its generalisability. Developing an 
interviewer-administrated version of the D-12 is recommended in order to increase 
the utilisation of the D-12 for those people with COPD who are not able to read or 
write. In addition, further studies are needed to evaluate the capacity of the D-12 to 
change in response to interventions such as pulmonary rehabilitation and oxygen 
therapy. Furthermore, further work is needed to determine the threshold for the 
minimal clinical important difference of the D-12. 
6.2 Characteristics of those hospitalised with a severe AECOPD in 
Riyadh and the time course of their recovery 
Although there was no specific research question around determining the 
characteristics of those hospitalised with a severe AECOPD in Riyadh, the data 
presented in Chapter 4 present novel information in this regard. Specifically, there no 
other studies have reported the length of stay or characteristics of people hospitalised 
for a severe AECOPD in Saudi Arabia. Data presented in Chapter 4 demonstrated 
that the people (of whom 25 males, 86%) who averaged 65 years of age and had a 
moderate severity had the median of six days for length of stay in hospital. This 
median of length of stay in hospital was consistent with that reported in 19 
Australian people (of whom seven males, 37%) who averaged 70 years of age and 
had a moderate severity (length of stay was six days) (477). The results of this study 
demonstrated that the recovery of dyspnoea following a severe AECOPD can take up 
Chapter 6: Summary and conclusions 
168 
to 70 days from hospitalisation. The prolonged recovery period presented in this 
study was consistent with earlier work (477). The findings are important for clinical 
practice as they will allow health professionals to provide Saudis who have been 
hospitalised with a severe AECOPD, and their families, information regarding the 
time course recovery.  
Further work is required to determine the time course recovery of a mild to moderate 
AECOPD in Saudi with COPD for providing patients and their families information 
on the time course recovery for dyspnoea. 
6.3 Physical activity and sedentary behaviour in Saudi nationals 
with COPD 
The study presented in Chapter 5 is the first to provide a detailed description of the 
differences between males with COPD and healthy controls in Saudi Arabia in terms 
of time spent in walking based activity and sedentary behaviour, the duration of 
bouts spent in walking based activity and sedentary behaviour as well as peak 
stepping cadence. The study demonstrated that, compared with healthy controls, 
males with COPD spent 15 ± 12%  less of their waking hours in walking based 
activity (defined as 1 ≥ steps/minute). In addition, when compared with healthy 
controls, males with COPD spent 15 ± 13% more of their waking hours in sedentary 
behaviour (defined as 0 steps/minutes). In keeping with these data was the finding 
that the proportion of males with COPD  who accumulated ≥ 7,000 steps per day (the 
recommended amount of walking based activity to produce health benefits according 
to the guidelines of the American College of Sports Medicine (54)), was lower than 
that for healthy controls (7% versus 34%). These findings increase the importance of 
designing interventions aiming at increasing daily steps in males with COPD to meet 
the recommended amount of physical activity necessary to promote and maintain 
health.   
When walking based activity was divided into intensity bands according to cadences 
described by the National Health and Nutrition Examination Survey (67), males with 
COPD spent less time in cadence bands equivalent to < 100 steps/min than healthy 
controls. However, there were no differences in high cadences ≥ 100 steps/min (a 
threshold equivalent moderate intensity physical activity) as neither group performed 
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any steps at these high cadences bands. These findings suggest that males with 
COPD as well as health controls are at greater risk of developing chronic diseases, 
such as cardiovascular and metabolic diseases, as they did not spend time 
participating in moderate intensity physical activity (54). Therefore, in Saudi Arabia, 
awareness of the health benefits of walking at moderate intensity needs to be 
promoted among the general public as well as males with COPD. However, the 
finding that both the peak and average 30-minute peak cadences were lower in males 
with COPD compared to that measured in the healthy controls suggests that males 
with COPD may have less capacity to walk at a moderate intensity. 
Data presented in Chapter 5 also demonstrated that, compared with healthy controls, 
males with COPD, on average, accumulated walking based activity in shorter bouts 
and sedentary behaviour in longer bouts. These findings provide novel targets for 
patient education regarding participation in walking based activity and the way in 
which time is accumulated in sedentary behaviour. Specifically, data from this study 
suggest that males with COPD should be encouraged to accumulate time in walking 
in longer bouts and time in sedentary behaviour in shorter bouts for the purpose of 
health benefits such as reducing the risk of developing cardiovascular and metabolic 
disease (54, 61, 359). In addition, the 
It is important to note that both Saudi males with COPD and healthy controls 
appeared to be physically less active than those from different countries such as 
Belgium and Brazil (56, 57). Reliance on cars instead of walking for short-distance 
travel, lack of quality physical education programs and facilities, poor air quality in 
many cities, and bad weather have been reported as the major barriers for Saudi 
males being physically active (73, 74, 474).  
Studies that demonstrated changes in physical activity in people with COPD and 
other population have often used individual goal setting, collection of objective 
physical activity data in order to place goals and/or provide feedback, overcome 
barriers, encourage age adherence, motivational interviewing and regular contact 
with healthcare professionals to increase motivation (467-472). Therefore, these 
approaches need to be considered, in Saudi nationals, when implementing 
interventions to increase time of participation in physical activity and reduce time in 
sedentary behavior. 
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Data on physical activity and sedentary behaviour of Saudi females were not 
collected in this study. Several studies from different countries have reported that 
males were more physically active than females (447-451). Similar findings were 
also reported  between males and females in Saudi Arabia (74, 453). However, those 
studies that quantified physical activity in the Saudi population used subjective 
methods (i.e. questionnaires). These methods have been reported to provide 
inaccurate information (361). Therefore, in Saudi Arabia, studies including large 
samples of both males and females with COPD and their healthy controls to measure 
physical activity and sedentary behavior, using objective measures, with 
consideration of sociocultural factors that limit their physical activity are required to 
understand the lifestyle adopted by the patients and healthy controls. 
Finally, data presented in chapter 5 demonstrated moderate to strong associations 
between the components of D-12 and both time spent in walking based activity and 
sedentary behaviour. Of note, the associations between time in walking based 
activity and sedentary behaviour were stronger with the emotional response 
component of the D-12 (r = ≥ -0.63 and r = ≥ 0.66, respectively) than the quality 
component of the D-12 (r = ≥ -0.52 and r = ≥ 0.46, respectively). These findings 
indicate that males with COPD who experience a greater emotional response to 
dyspnoea than the quality of the sensation spend less time of waking hours in 
walking based activity and more time in sedentary behaviour. These findings suggest 
that interventions, such as cognitive behavioural therapy, which aim to minimise the 
emotional response to dyspnoea, may assist to increase the levels of physical activity 
and reduce sedentary behaviour in males COPD. However, the coefficient of 
determination for the association between emotional response to dyspnoea and time 
spent in walking based activity (R
2
 = 0.40) or sedentary behaviour (R
2
 = 0.44) 
demonstrates that, at most, only 44% of variance in either time spent in walking 
based activity or sedentary behaviour is explained by the emotional repose to 
dyspnoea. Therefore, this finding suggests that other important factors contribute to 
how males with COPD spent their daily time in walking based activity and sedentary 
behaviour such as lower exercise capacity, and a higher number of exacerbations in 
the past year (59).  
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The findings from this PhD study highlighted that further research is required to 
identify factors other than dyspnoea that contribute to the time spent in physical 
activity and sedentary behaviour by males with COPD, in Saudi Arabia. In addition, 
research is also needed to investigate if there are health benefits associated with the 
time spent in physical activity at different cadence bands by males with COPD as 
well as healthy males. 
 
 172 
REFERENCES 
1. Tageldin MA, Nafti S, Khan JA, Nejjari C, Beji M, Mahboub B, et al. 
Distribution of COPD-related symptoms in the Middle East and North Africa: results 
of the BREATHE study. Respiratory Medicine. 2012;106:25-32. 
2. Al Ghobain M, Al-Hajjaj MS, Wali SO. Prevalence of chronic obstructive 
pulmonary disease among smokers attending primary healthcare clinics in Saudi 
Arabia. Annals of Saudi Medicine. 2011;31(2):129-33. 
3. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, Pehlivan E. 
Prevalence of COPD: first epidemiological study of a large region in Turkey. 
European Journal of Internal Medicine. 2008;19(7):499-504. 
4. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen 
RL, et al. COPD prevalence in Salzburg, Austria: results from the Burden of 
Obstructive Lung Disease (BOLD) study. Chest. 2007;131(1):29-36. 
5. Vanfleteren LE, Franssen FM, Wesseling G, Wouters EF. The prevalence of 
chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respiratory 
Medicine. 2012;106(6):871-4. 
6. Idolor LF, De Guia TS, Francisco NA, Roa CC, Ayuyao FG, Tady CZ, et al. 
Burden of obstructive lung disease in a rural setting in the Philippines. Respirology. 
2011;16(7):1111-18. 
7. Danielsson P, Ólafsdóttir IS, Benediktsdóttir B, Gíslason T, Janson C. The 
prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden–the Burden 
of Obstructive Lung Disease (BOLD) study: cross‐sectional population‐based study. 
The clinical respiratory journal. 2012;6(2):120-7. 
8. Toelle BG, Xuan W, Bird TE, Abramson MJ, Atkinson DN, Burton DL, et al. 
Respiratory symptoms and illness in older Australians. Medical Journal of Australia. 
2013;198(3):144-8. 
9. Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of 
chronic obstructive pulmonary disease in China: a large, population-based survey. 
American Journal of Respiratory and Critical Care Medicine. 2007;176(8):753-60. 
10. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for 
the diagnosis, management, and prevention of chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine. 
2014;163(5):1256-76. 
11. Khattab A, Javaid A, Iraqi G, Alzaabi A, Ben Kheder A, Koniski M-L, et al. 
Smoking habits in the Middle East and North Africa: results of the BREATHE study. 
Respiratory Medicine. 2012;106:S16-S24. 
12. Waness A, EL‐SAMEED YA, Mahboub B, Noshi M, AL‐JAHDALI H, Vats M, 
et al. Respiratory disorders in the Middle East: a review. Respirology. 
 173 
2011;16(5):755-66. 
13. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau 
J, et al. An official American Thoracic Society statement: update on the mechanisms, 
assessment, and management of dyspnea. American Journal of Respiratory and 
Critical Care Medicine. 2012;185(4):435-52. 
14. Schlecht N, Schwartzman K, Bourbeau J. Dyspnea as clinical indicator in 
patients with chronic obstructive pulmonary disease. Chronic Respiratory Disease. 
2005;2(4):183-91. 
15. Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ. 
Understanding breathlessness: cross-sectional comparison of symptom burden and 
palliative care needs in chronic obstructive pulmonary disease and cancer. Journal of 
Palliative Medicine. 2010;13(9):1109-18. 
16. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to 
measure breathlessness in palliative care? A systematic review. Palliative Medicine. 
2007;21(3):177-91. 
17. Borg GA. Psychophysical bases of perceived exertion. Medicine and Science in 
Sports and Exercise. 1982;14(5):377-81. 
18. Gift AG. Visual analogue scales: measurement of subjective phenomena. Nursing 
Research. 1989;38(5):286-7. 
19. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. Significance of respiratory 
symptoms and the diagnosis of chronic bronchitis in a working population. British 
Medical Journal. 1959;2(5147):257. 
20. Mahler D, Weinberg D, Wells C, Feinstein A. The measurement of dyspnea. 
Contents, interobserver agreement, and physiologic correlates of two new clinical 
indexes. Chest. 1984;85(6):751-8. 
21. Lareau SC, Meek PM, Roos PJ. Development and testing of the modified version 
of the pulmonary functional status and dyspnea questionnaire (PFSDQ-M). Heart 
AND Lung: The Journal of Acute and Critical Care. 1998;27(3):159-68. 
22. Guyatt G, Townsend M, Keller J, Slnger J, Nogradi S. Measuring functional 
status in chronic lung disease: conclusions from a randomized control trial. 
Respiratory Medicine. 1991;85:17-21. 
23. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using 
descriptors: development and initial testing of the Dyspnoea-12. Thorax. 
2010;65(1):21-6. 
24. Parker C, Voduc N, Aaron S, Webb K, O'Donnell D. Physiological changes 
during symptom recovery from moderate exacerbations of COPD. European 
Respiratory Journal. 2005;26(3):420-8. 
25. Seemungal  TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time 
course and recovery of exacerbations in patients with chronic obstructive pulmonary 
 174 
disease. American Journal of Respiratory and Critical Care Medicine. 
2000;161(5):1608-13. 
26. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year 
survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434-
40. 
27. von Leupoldt A, Dahme B. Experimental comparison of dyspnea and pain. 
Behavior Research Methods. 2007;39(1):137-43. 
28. Gracely RH, Undem BJ, Banzett RB. Cough, pain and dyspnoea: similarities and 
differences. Pulmonary Pharmacology and Therapeutics. 2007;20(4):433-37. 
29. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger 
SE. Distinguishable types of dyspnea in patients with shortness of breath. American 
Review of Respiratory Disease. 1990;142(5):1009-14. 
30. Scano G, Stendardi L, Grazzini M. Understanding dyspnoea by its language. 
European Respiratory Journal. 2005;25(2):380-5. 
31. Williams M, Cafarella P, Olds T, Petkov J, Frith P. Affective descriptors of the 
sensation of breathlessness are more highly associated with severity of impairment 
than physical descriptors in people with COPD. Chest. 2010;138(2):315-22. 
32. Wilcock A, Crosby V, Hughes A, Fielding K, Corcoran R, Tattersfield AE. 
Descriptors of breathlessness in patients with cancer and other cardiorespiratory 
diseases. Journal of Pain and Symptom Management. 2002;23(3):182-9. 
33. Mahler DA, Harver A, Lentine T, Scott JA, Beck K, Schwartzstein RM. 
Descriptors of breathlessness in cardiorespiratory diseases. American Journal of 
Respiratory and Critical Care Medicine. 1996;154(5):1357-63. 
34. O'Donnell DE, Bertley JC, Chau L, Webb KA. Qualitative aspects of exertional 
breathlessness in chronic airflow limitation: pathophysiologic mechanisms. 
American Journal of Respiratory and Critical Care Medicine. 1997;155(1):109-15. 
35. Banzett RB, Dempsey JA, O'Donnell DE, Wamboldt MZ. Symptom perception 
and respiratory sensation in asthma. American Journal of Respiratory and Critical 
Care Medicine. 2000;162(3):1178-82. 
36. O'Donnell D. Breathlessness in patients with chronic airflow limitation 
mechanisms and management. Chest. 1994;106:904-12. 
37. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise 
intolerance in chronic obstructive pulmonary disease. American Journal of 
Respiratory and Critical Care Medicine. 2001;164(5):770-7. 
38. Bailey PH. The dyspnea-anxiety-dyspnea cycle—COPD patients’ stories of 
breathlessness:“It’s scary/when you can’t breathe”. Qualitative Health Research. 
2004;14(6):760-8. 
39. von Leupoldt A, Taube K, Henkhus M, Dahme B, Magnussen H. The impact of 
 175 
affective states on the perception of dyspnea in patients with chronic obstructive 
pulmonary disease. Biological Psychology. 2010;84(1):129-34. 
40. Yorke J, Russell A-M, Swigris J, Shuldham C, Haigh C, Rochnia N, et al. 
Assessment of dyspnea in asthma: validation of the dyspnea-12. Journal of Asthma. 
2011;48(6):602-8. 
41. Yorke J, Swigris J, Russell A-M, Moosavi SH, Kwong GNM, Longshaw M, et 
al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with 
interstitial lung disease. Chest. 2011;139(1):159-64. 
42. Yorke J, Armstrong I. The assessment of breathlessness in pulmonary arterial 
hypertension: reliability and validity of the Dyspnoea-12. European Journal of 
Cardiovascular Nursing. 2014;13(6):506-14. 
43. Lee BY, Lee S, Lee JS, Song JW, Lee S-D, Jang SH, et al. Validity and 
reliability of CAT and Dyspnea-12 in bronchiectasis and tuberculous destroyed lung. 
Tuberculosis and Respiratory Diseases. 2012;72(6):467-74. 
44. Taguchi Y, Tanaka E, Hashimoto S, Yasuda T, Kaji Y, Yasuda I, et al. Clinical 
utility of Japanese version of the Dyspnea-12 questionnaire for evaluating 
breathlessness in patients with COPD. American Journal of Respiratory and Critical 
Care Medicine. 2015;191:A3423. 
45. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary 
rehabilitation for chronic obstructive pulmonary disease. Cochrane Database 
Systematic Reviews. 2015(2). 
46. Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long‐term 
effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. 
European Respiratory Journal. 1999;13(1):125-32. 
47. Boyd G, Morice A, Pounsford J, Siebert M, Peslis N, Crawford C. An evaluation 
of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). 
European Respiratory Journal. 1997;10(4):815-21. 
48. Eiser N, Willsher D, Dore C. Reliability, repeatability and sensitivity to change 
of externally and self-paced walking tests in COPD patients. Respiratory Medicine. 
2003;97(4):407-14. 
49. Al Moamary MS. Health care utilization among chronic obstructive pulmonary 
disease patients and the effect of pulmonary rehabilitation. Medical Principles and 
Practice. 2010;19(5):373-8. 
50. Silins R, Marlin G. Evaluation of domiciliary treatment with terbutaline by wet 
nebulisation in patients with chronic bronchitis and emphysema. Australian and New 
Zealand Journal of Medicine. 1985;15(2):230-4. 
51. Wilson R, Connellan S. Domiciliary nebulised salbutamol solution in severe 
chronic airway obstruction. Thorax. 1980;35(11):873-6. 
52. Shah S, Johnston D, Woodcock A, Johnson M, Geddes D. Breathlessness and 
 176 
exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly 
salbutamol by inhalation. Current Medical Research and Opinion. 1983;8(5):345-9. 
53. Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, et al. 
Measurement of short-term changes in dyspnea and disease-specific quality of life 
following an acute COPD exacerbation. Chest. 2002;121(3):688-96. 
54. Garber CE, Blissmer B, Deschenes MR, Franklin B, Lamonte MJ, Lee I-M, et al. 
American College of Sports Medicine position stand. Quantity and quality of 
exercise for developing and maintaining cardiorespiratory, musculoskeletal, and 
neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. 
Medicine and Science in Sports and Exercise. 2011;43(7):1334-59. 
55. Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, et al. 
Physical inactivity in patients with COPD, a controlled multi-center pilot-study. 
Respiratory Medicine. 2010;104(7):1005-11. 
56. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. 
Characteristics of physical activities in daily life in chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine. 
2005;171(9):972-77. 
57. Hernandes NA, Teixeira DdC, Probst VS, Brunetto AF, Ramos EMC, Pitta F. 
Profile of the level of physical activity in the daily lives of patients with COPD in 
Brazil. Jornal Brasileiro de Pneumologia. 2009;35(10):949-56. 
58. Vorrink SN, Kort HS, Troosters T, Lammers J. Level of daily physical activity in 
individuals with COPD compared with healthy controls. Respiratory Research. 
2011;12(33):4-8. 
59. Hartman JE, Boezen HM, de Greef MH, ten Hacken NH. Physical and 
psychosocial factors associated with physical activity in patients with chronic 
obstructive pulmonary disease. Expert Review of Respiratory Medicine. 
2013;4(6):735-45. 
60. Healy GN, Wijndaele K, Dunstan DW, Shaw JE, Salmon J, Zimmet PZ, et al. 
Objectively measured sedentary time, physical activity, and metabolic risk: the 
Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Diabetes Care. 
2008;31(2):369-71. 
61. Healy GN, Dunstan DW, Salmon J, Cerin E, Shaw JE, Zimmet PZ, et al. 
Objectively measured light-intensity physical activity is independently associated 
with 2-h plasma glucose. Diabetes Care. 2007;30(6):1384-9. 
62. Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M, et al. 
Translating physical activity Rrcommendations into a pedometer-based step goal: 
3000 steps in 30 minutes. American Journal of Preventive Medicine. 
2009;36(5):410-15. 
63. Rowlands AV, Stone MR, Eston RG. Influence of speed and step frequency 
during walking and running on motion sensor output. Medicine and Science in Sports 
and Exercise. 2007;39(4):716. 
 177 
64. Tudor-Locke C, Sisson SB, Collova T, Lee SM, Swan PD. Pedometer-
determined step count guidelines for classifying walking intensity in a young 
ostensibly healthy population. Canadian Journal of Applied Physiology. 
2005;30(6):666-76. 
65. Rowe D, Welk G, Heil D, Mahar M, Kemble C, Calabro M, et al. Stride rate 
recommendations for moderate-intensity walking. Medicine and Science in Sports 
and Exercise. 2011;43(2):312-8. 
66. Abel M, Hannon J, Mullineaux D, Beighle A. Determination of step rate 
thresholds corresponding to physical activity intensity classifications in adults. 
Journal of Physical Activity and Health. 2011;8(1):45-51. 
67. Tudor-Locke C, Camhi SM, Leonardi C, Johnson WD, Katzmarzyk PT, Earnest 
CP, et al. Patterns of adult stepping cadence in the 2005–2006 NHANES. Preventive 
Medicine. 2011;53(3):178-81. 
68. Pate RR, O'Neill JR, Lobelo F. he evolving definition of "sedentary". Exercise 
and Sport Sciences Reviews. 2008;36(4):173-8. 
69. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. 
Sedentary time and its association with risk for disease incidence, mortality, and 
hospitalization in adults: a systematic review and meta-analysis. Annals of Internal 
Medicine. 2015;162(2):123-32. 
70. Hill K, Gardiner P, Cavalheri V, Jenkins S, Healy G. Physical activity and 
sedentary behaviour: applying lessons to chronic obstructive pulmonary disease. 
Internal Medicine Journal. 2015;45(5):474-82. 
71. Healy GN, Dunstan DW, Salmon J, Cerin E, Shaw JE, Zimmet PZ, et al. Breaks 
in sedentary time beneficial associations with metabolic risk. Diabetes Care. 
2008;31(4):661-6. 
72. Al-Hazzaa HM. Health-enhancing physical activity among Saudi adults using the 
International Physical Activity Questionnaire (IPAQ). Public health nutrition. 
2007;10(1):59-64. 
73. Al-Rafaee S, Al-Hazzaa HM. Physical activity profile of adult males in Riyadh 
City. Saudi Medical Journal. 2001;22(9):784-9. 
74. Al-Nozha MM, Al-Hazzaa HM, Arafah MR, Al-Khadra A, Al-Mazrou YY, Al-
Maatouq MA, et al. Prevalence of physical activity and inactivity among Saudis aged 
30-70 years: a population-based cross-sectional study. Saudi Medical Journal. 
2007;28(4):559-68. 
75. Bonnefoy M, Normand S, Pachiaudi C, Lacour JR, Laville M, Kostka T. 
Simultaneous validation of ten physical activity questionnaires in older men: a 
doubly labeled water study. Journal of the American Geriatrics Society. 
2001;49(1):28-35. 
76. Eliason G, Zakrisson A-B, Piehl-Aulin K, Hurtig-Wennlöf A. Physical activity 
patterns in patients in different stages of chronic obstructive pulmonary disease. 
 178 
COPD: Journal of Chronic Obstructive Pulmonary Disease. 2011;8(5):369-74. 
77. Kawagoshi A, Kiyokawa N, Sugawara K, Takahashi H, Sakata S, Miura S, et al. 
Quantitative assessment of walking time and postural change in patients with COPD 
using a new triaxial accelerometer system. International Journal of COPD. 
2013;8:397-404. 
78. Lores V, García-Río F, Rojo B, Alcolea S, Mediano O. Recording the daily 
physical activity of COPD patients with an accelerometer: an analysis of agreement 
and repeatability. Archivos de Bronconeumología ((English Edition)). 
2006;42(12):627-32. 
79. Tudorache V, Oancea C, Avram C. Changes in physical activity in healthy 
people and COPD patients. Wiener klinische Wochenschrift. 2014;126(1-2):30-5. 
80. Walker PP, Burnett A, Flavahan PW, Calverley PM. Lower limb activity and its 
determinants in chronic obstructive pulmonary disease. Thorax. 2008;8(63):683-9. 
81. Pitta F, Breyer M-K, Hernandes NA, Teixeira D, Sant'Anna TJ, Fontana AD, et 
al. Comparison of daily physical activity between COPD patients from Central 
Europe and South America. Respiratory Medicine. 2009;103(3):421-6. 
82. Steele BG, Holt L, Belza B, Ferris S, Lakshminaryan S, Buchner DM. 
Quantitating physical activity in COPD using a triaxial accelerometer. Chest. 
2000;117(5):1359-67. 
83. Lemmens K, Nieboer A, Huijsman R. Designing patient-related interventions in 
COPD care: empirical test of a theoretical model. Patient Education and Counseling. 
2008;72(2):223-31. 
84. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, López-Collazo E, et al. 
Daily physical activity in patients with chronic obstructive pulmonary disease is 
mainly associated with dynamic hyperinflation. American Journal of Respiratory and 
Critical Care Medicine. 2009;180(6):506-12. 
85. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with 
COPD. European Respiratory Journal. 2009;33(2):262-72. 
86. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, et al. 
Physical activity monitoring in COPD: Compliance and associations with clinical 
characteristics in a multicenter study. Respiratory Medicine. 2012;106(4):522-30. 
87. Salam AA. Population and Household Census, Kingdom of Saudi Arabia 2010: 
Facts and Figures. International Journal of Humanities and Social Science. 
2013;3(16). 
88. KFMC.  [cited 2016 April 18]. Available from: www.kfmc.med.sa. 
89. Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic 
obstructive pulmonary disease. Respiration. 2012;84(2):89-97. 
90. Rodriguez-Roisin R, Drakulovic M, Rodríguez DA, Roca J, Barbera JA, Wagner 
 179 
PD. Ventilation-perfusion imbalance and chronic obstructive pulmonary disease 
staging severity. Journal of Applied Physiology. 2009;106(6):1902-8. 
91. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship between 
exacerbation frequency and lung function decline in chronic obstructive pulmonary 
disease. Thorax. 2002;57(10):847-52. 
92. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. 
Effect of exacerbation on quality of life in patients with chronic obstructive 
pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 
1998;157(5):1418-22. 
93. Døssing M, Khan J, Al-Rabiah F. Risk factors for chronic obstructive lung 
disease in Saudi Arabia. Respiratory Medicine. 1994;88(7):519-22. 
94. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramirez-Sarmiento A, Anto J, Gea 
J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. 
European Respiratory Journal. 2006;27(3):542-6. 
95. Willemse B, Postma D, Timens W, Ten Hacken N. The impact of smoking 
cessation on respiratory symptoms, lung function, airway hyperresponsiveness and 
inflammation. European Respiratory Journal. 2004;23(3):464-76. 
96. de Serres FJ, Blanco I, Fernández-Bustillo E. Estimating the risk for alpha-1 
antitrypsin deficiency among COPD patients: evidence supporting targeted 
screening. COPD: Journal of Chronic Obstructive Pulmonary Disease. 
2006;3(3):133-9. 
97. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et 
al. International variation in the prevalence of COPD (the BOLD Study): a 
population-based prevalence study. The Lancet. 2007;370(9589):741-50. 
98. Akl EA, Gunukula SK, Aleem S, Obeid R, Jaoude PA, Honeine R, et al. The 
prevalence of waterpipe tobacco smoking among the general and specific 
populations: a systematic review. BMC Public Health. 2011;11(1):244. 
99. Knishkowy B, Amitai Y. Water-pipe (narghile) smoking: an emerging health risk 
behavior. Pediatrics. 2005;116(1):e113-e9. 
100. Sa’ed H, Al-Jabi SW, Sweileh WM. Bibliometric analysis of scientific 
publications on waterpipe (narghile, shisha, hookah) tobacco smoking during the 
period 2003-2012. Tobacco Induced Diseases. 2014;12(1):12-7. 
101. Akl EA, Gaddam S, Gunukula SK, Honeine R, Jaoude PA, Irani J. The 
effects of waterpipe tobacco smoking on health outcomes: a systematic review. 
International Journal of Epidemiology. 2010;39(3):834-57. 
102. Al-Mulla A, Bener A. Cigarette smoking habits among Qatari population. 
Public Health Medicine. 2003;4(3):77-80. 
103. Al-Houqani M, Ali R, Hajat C. Tobacco smoking using midwakh is an 
emerging health problem – evidence from a large cross-sectional survey in the 
 180 
United Arab Emirates. PloS One. 2012;7(6):e39189. 
104. Al Riyami A, Afifi M. Smoking in Oman: prevalence and characteristics of 
smokers. East Mediterranean Health Journal. 2004;10(4-5):600-9. 
105. Al Ghobain M, Alhamad E, Alorainy H, Al Kassimi F, Lababidi H, Al-Hajjaj 
M. The prevalence of chronic obstructive pulmonary disease in Riyadh, Saudi 
Arabia: a BOLD study. The International Journal of Tuberculosis and Lung Disease. 
2015;19(10):1252-7. 
106. Mannino DM, Meilan K, van der Molen T, Ichinose M, Oh Y-M, Davis KJ. 
Continuing to Confront COPD International Patient Survey: methods, COPD 
prevalence, and disease burden in 2012–2013. International Journal of COPD. 
2014;9:597-611. 
107. Al Zaabi A, Asad F, Abdou J, Al Musaabi H, Al Saiari MB, Mohammed 
Buhussien AS, et al. Prevalence of COPD in Abu Dhabi, United Arab Emirates. 
Respiratory Medicine. 2011;105(4):566-70. 
108. Benediktsdóttir B, Gudmundsson G, Jörundsdóttir K, Vollmer W, Gíslason T. 
Prevalence of COPD in Iceland--the BOLD study. Laeknabladid. 2007;93(6):471-7. 
109. Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist A, et al. 
The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. 
Results of the BOLD study. Deutsche Medizinische Wochenschrift. 
2008;133(50):2609-14. 
110. Jansson S-A, Backman H, Stenling A, Lindberg A, Rönmark E, Lundbäck B. 
Health economic costs of COPD in Sweden by disease severity – has it changed 
during a ten years period? Respiratory Medicine. 2013;107(12):1931-8. 
111. Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic 
obstructive pulmonary disease among managed care patients. International Journal of 
Chronic Obstructive Pulmonary Disease. 2010;5:341-9. 
112. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic 
impact of exacerbations of chronic obstructive pulmonary disease and exacerbation 
definition: a review. COPD: Journal of Chronic Obstructive Pulmonary Disease. 
2010;7(3):214-28. 
113. Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive 
pulmonary disease: a review of the economic burden on employers and individuals in 
the United States. International Journal of Chronic Obstructive Pulmonary Disease. 
2014;9:289. 
114. Figueiredo D, Gabriel R, Jácome C, Cruz J, Marques A. Caring for relatives 
with chronic obstructive pulmonary disease: how does the disease severity impact on 
family carers? Aging and Mental Health 2014;18(3):385-93. 
115. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. 
Extrapulmonary effects of chronic obstructive pulmonary disease on physical 
activity: a cross-sectional study. American Journal of Respiratory and Critical Care 
 181 
Medicine. 2008;177(7):743-51. 
116. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting 
in the vastus lateralis of patients with COPD is associated with disease severity: a 
systematic review and meta-analysis. Thorax. 2007;62(11):944-9. 
117. Woo K. A pilot study to examine the relationships of dyspnoea, physical 
activity and fatigue in patients with chronic obstructive pulmonary disease. Journal 
of Clinical Nursing. 2000;9(4):526-33. 
118. Engström C-P, Persson L-O, Larsson S, Sullivan M. Health-related quality of 
life in COPD: why both disease-specific and generic measures should be used. 
European Respiratory Journal. 2001;18(1):69-76. 
119. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly 
patients with chronic obstructive pulmonary disease. Age and Ageing. 
2006;35(5):457-9. 
120. Elnady M, El-Din MS, Amin Y, El-Hindawy A. Pathological changes in the 
skeletal muscles in COPD patients. European Respiratory Journal. 2011;38(Suppl 
55):p4063. 
121. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of 
comorbidities in a cohort of patients with COPD undergoing pulmonary 
rehabilitation. Thorax. 2008;63(6):487-92. 
122. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic 
obstructive pulmonary disease. Proceedings of the American Thoracic Society. 
2006;3(2):180-4. 
123. Cooper CB. The connection between chronic obstructive pulmonary disease 
symptoms and hyperinflation and its impact on exercise and function. The American 
Journal of Medicine. 2006;119(10):21-31. 
124. Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom 
distress and quality of life in patients with advanced chronic obstructive pulmonary 
disease. Journal of Pain and Symptom Management. 2009;38(1):115-23. 
125. Baltzan MA, Scott AS, Wolkove N, Bailes S, Bernard S, Bourbeau J, et al. 
Fatigue in COPD: Prevalence and effect on outcomes in pulmonary rehabilitation. 
Chronic Despiratory Disease. 2011;8:119-28. 
126. Paddison JS, Effing TW, Quinn S, Frith PA. Fatigue in COPD: association 
with functional status and hospitalisations. European Respiratory Journal. 
2013;41(3):565-70. 
127. Katsura H, Yamada K, Wakabayashi R, Kida K. The impact of dyspnoea and 
leg fatigue during exercise on health‐related quality of life in patients with COPD. 
Respirology. 2005;10(4):485-90. 
128. Nici L. Mechanisms and measures of exercise intolerance in chronic 
obstructive pulmonary disease. Clinics in Chest Medicine. 2000;21(4):693-704. 
 182 
129. O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic 
airflow limitation. American Review of Respiratory Disease. 1993;148:1351-7. 
130. Pinto-Plata V, Cote C, Cabral H, Taylor J, Celli B. The 6‐min walk distance: 
change over time and value as a predictor of survival in severe COPD. European 
Respiratory Journal. 2004;23(1):28-33. 
131. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors 
related to mortality in chronic obstructive pulmonary disease: role of exercise 
capacity and health status. American Journal of Respiratory and Critical Care 
Medicine. 2003;167(4):544-9. 
132. Miyamoto S, Nagayan N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. 
Clinical correlates and prognostic significance of six-minute walk test in patients 
with primary pulmonary hypertension: comparison with cardiopulmonary exercise 
testing. American Journal of Respiratory and Critical Care Medicine. 
2000;161(2):487-92. 
133. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular 
physical activity reduces hospital admission and mortality in chronic obstructive 
pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772-8. 
134. Jehn M, Schindler C, Meyer A, Tamm M, Schmidt-Trucksäss A, Stolz D. 
Daily walking intensity as a predictor of quality of life in patients with chronic 
obstructive pulmonary disease. Medicine and Science in Sports and Exercise. 
2012;44(7):1212-18. 
135. Jones P. Health status measurement in chronic obstructive pulmonary disease. 
Thorax. 2001;56(11):880-7. 
136. Stavem K, Boe J, Erikssen J. Health status, dyspnea, lung function and 
exercise capacity in patients with chronic obstructive pulmonary disease. The 
International Journal of Tuberculosis and Lung Disease. 1999;3(10):920-6. 
137. van Manen JG, Bindels PJ, Dekker FW, Bottema BJ, van der Zee JS, 
Ijzermans CJ, et al. The influence of COPD on health-related quality of life 
independent of the influence of comorbidity. Journal of Clinical Epidemiology. 
2003;56(12):1177-84. 
138. Schlenk EA, Erlen JA, Dunbar-Jacob J, McDowell J, Engberg S, Sereika SM, 
et al. Health-related quality of life in chronic disorders: a comparison across studies 
using the MOS SF-36. Quality of Life Research. 1997;7(1):57-65. 
139. Arne M, Janson C, Janson S, Boman G, Lindqvist U, Berne C, et al. Physical 
activity and quality of life in subjects with chronic disease: chronic obstructive 
pulmonary disease compared with rheumatoid arthritis and diabetes mellitus. 
Scandinavian Journal of Primary Health Care. 2009;27(3):141-7. 
140. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T. Stages of disease 
severity and factors that affect the health status of patients with chronic obstructive 
pulmonary disease. Respiratory Medicine. 2000;94(9):841-46. 
 183 
141. Putman-Casdorph H, McCrone S. Chronic obstructive pulmonary disease, 
anxiety, and depression: state of the science. Heart & Lung: The Journal of Acute 
and Critical Care. 2009;38(1):34-47. 
142. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly 
outpatients with chronic obstructive pulmonary disease: prevalence, and validation of 
the BASDEC screening questionnaire. International Journal of Geriatric Psychiatry. 
2000;15(12):1090-6. 
143. Peruzza S, Sergi G, Vianello A, Pisent C, Tiozzo F, Manzan A, et al. Chronic 
obstructive pulmonary disease (COPD) in elderly subjects: impact on functional 
status and quality of life. Respiratory Medicine. 2003;97(6):612-7. 
144. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the 
disease and its burden to society. Proceedings of the American Thoracic Society. 
2006;3(7):619-23. 
145. Macintyre NR. Muscle dysfunction associated with chronic obstructive 
pulmonary disease. Respiratory Care. 2006;51(8):840-52. 
146. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness 
contributes to exercise limitation in COPD. American Journal of Respiratory and 
Critical Care Medicine. 1996;153(3):976-80. 
147. Serres I, Gautier V, Prefaut C, Varray A. Impaired Skeletal Muscle 
Endurance Related to Physical Inactivity and Altered Lung Function in COPD 
Patients Chest. 1998;113(4):900-5. 
148. Couillard A, Koechlin C, Cristol J, Varray A, Prefaut C. Evidence of local 
exercise-induced systemic oxidative stress in chronic obstructive pulmonary disease 
patients. European Respiratory Journal. 2002;20(5):1123-9. 
149. Mador MJ, Deniz O, Aggarwal A, Kufel TJ. Quadriceps fatigability after 
single muscle exercise in patients with chronic obstructive pulmonary disease. 
American Journal of Respiratory and Critical Care Medicine. 2003;168(1):102-8. 
150. Hamilton AL, Killian KJ, Summers E, Jones NL. Symptom intensity and 
subjective limitation to exercise in patients with cardiorespiratory disorders. Chest. 
1996;110(5):1255-63. 
151. Whittom F, Jobin J, Simard P-M, Leblanc P, Simard C, Bernard S, et al. 
Histochemical and morphological characteristics of the vastus lateralis muscle in 
patients with chronic obstructive pulmonary disease. Medicine and Science in Sports 
and Exercise. 1998;30(10):1467-74. 
152. Maltais F, Sullivan M, LeBlanc P, Duscha B, Schachat F, Simard C, et al. 
Altered expression of myosin heavy chain in the vastus lateralis muscle in patients 
with COPD. European Respiratory Journal. 1999;13(4):850-4. 
153. Maltais F, Simard A-A, Simard C, Jobin J, Desgagnés P, LeBlanc P. 
Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in 
normal subjects and in patients with COPD. American Journal of Respiratory and 
 184 
Critical Care Medicine. 1996;153(1):288-93. 
154. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy 
for the diagnosis, management, and prevention of chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine. 2012;163(5). 
155. Kinnunen T, Säynäjäkangas O, Tuuponen T, Keistinen T. Impact of 
comorbidities on the duration of COPD patients' hospital episodes. Respiratory 
Medicine. 2003;97(2):143-6. 
156. G Tsiligianni I, Kosmas E, Van der Molen T, Tzanakis N. Managing 
comorbidity in COPD: a difficult task. Current Drug Targets. 2013;14(2):158-76. 
157. Barnes P, Celli B. Systemic manifestations and comorbidities of COPD. 
European Respiratory Journal. 2009;33(5):1165-85. 
158. Agusti A, Calverley P, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. 
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory 
Research. 2010;11(1):122. 
159. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the 
patient. Respiratory Medicine. 2005;99:11-8. 
160. Meek PM, Lareau SC. Critical outcomes in pulmonary rehabilitation: 
assessment and evaluation of dyspnea and fatigue. Journal of Rehabilitation Research 
and Development. 2003;40(5; SUPP/2):13-24. 
161. O Donnell D, Webb K. Mechanisms of dyspnea in COPD. Lung Biology in 
Health Disease. 2005;208:29. 
162. Hill K, Jenkins SC, Hillman DR, Eastwood PR. Dyspnoea in COPD: Can 
inspiratory muscle training help? Australian Journal of Physiotherapy. 
2004;50(3):169-80. 
163. O'Donnell D, Laveneziana P. Physiology and consequences of lung 
hyperinflation in COPD. European Respiratory Review. 2006;15(100):61-7. 
164. Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and 
dyspnea during exacerbations of chronic obstructive pulmonary disease. American 
Journal of Respiratory and Critical Care Medicine. 2005;172(12):1510-6. 
165. Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, et al. 
Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. 
International Journal of Chronic Obstructive Pulmonary Disease. 2014;9:187. 
166. Gea J, Casadevall C, Pascual S, Orozco-Levi M, Barreiro E. Respiratory 
diseases and muscle dysfunction. Expert Review of Respiratory Medicine. 
2012;6(1):75-90. 
167. O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: 
mechanical factors. COPD: Journal of Chronic Obstructive Pulmonary Disease. 
2007;4(3):225-36. 
 185 
168. O'Donnell D. Breathlessness in Patients With Chronic Airflow Limitation: 
Mechanisms and Management. Journal of Cardiopulmonary Rehabilitation and 
Prevention. 1995;15(3):236. 
169. DE OD. Exercise and dyspnoea. European Respiratory Journal. 2002;12:36-
8. 
170. Marchand E, Decramer M. Respiratory muscle function and drive in chronic 
obstructive pulmonary disease. Clinics in Chest Medicine. 2000;21(4):679-92. 
171. Rochester D. Effects of COPD on the respiratory muscles. Chronic 
Obstructive Pulmonary Disease Philadelphia, Londres: Saunders Co. 1991:134-57. 
172. Barberà JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. 
Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild 
chronic obstructive pulmonary disease. American Journal of Respiratory and Critical 
Care Medicine. 1994;149(2):423-9. 
173. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, 
Gandevia SC, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary 
disease: a roundtable. Proceedings of the American Thoracic Society. 2007;4(2):145-
68. 
174. Gorini M, Misuri G, Corrado A, Duranti R, Iandelli I, De Paola E, et al. 
Breathing pattern and carbon dioxide retention in severe chronic obstructive 
pulmonary disease. Thorax. 1996;51(7):677-83. 
175. O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnia 
in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. 
American Journal of Respiratory and Critical Care Medicine. 2002;166(5):663-8. 
176. Bégin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia 
in chronic obstructive pulmonary disease. American Review of Respiratory Disease. 
1991;143(5 Pt 1):905-12. 
177. Killian K, Summers E, Basalygo M, Campbell E. Effect of frequency on 
perceived magnitude of added loads to breathing. Journal of Applied Physiology. 
1985;58(5):1616-21. 
178. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of 
exertional breathlessness during hyperoxia in chronic airflow limitation. American 
Journal of Respiratory and Critical Care Medicine. 1997;155(2):530-5. 
179. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et 
al. Improvements in symptom-limited exercise performance over 8 h with once-daily 
tiotropium in patients with COPD. Chest. 2005;128(3):1168-78. 
180. Man WD-C, Soliman MG, Gearing J, Radford SG, Rafferty GF, Gray BJ, et 
al. Symptoms and quadriceps fatigability after walking and cycling in chronic 
obstructive pulmonary disease. American Journal of Respiratory and Critical Care 
Medicine. 2003;168(5):562-7. 
 186 
181. Eakin EG, Sassi-Dambron DE, Ries AL, Kaplan RM. Reliability and validity 
of dyspnea measures in patients with obstructive lung disease. International Journal 
of Behavioral Medicine. 1995;2(2):118-34. 
182. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison 
of the level of dyspnea vs disease severity in indicating the health-related quality of 
life of patients with COPD. Chest. 1999;116(6):1632-37. 
183. Liang L, Lin Y, Yang T, Zhang H, Li J, Wang C. Determinants of health-
related quality of life worsening in patients with chronic obstructive pulmonary 
disease at one year. Chinese Medical Journal. 2014;127(1):4-10. 
184. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al. 
Chronic obstructive pulmonary disease stage and health-related quality of life. 
Annals of Internal Medicine. 1997;127(12):1072-9. 
185. Mahler DA, Mackowiak JI. Evaluation of the short-form 36-item 
questionnaire to measure health-related quality of life in patients with COPD. Chest. 
1995;107(6):1585-9. 
186. Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with 
COPD. European Respiratory Review. 2014;23(133):345-9. 
187. Gift A, Cahill C. Psychophysiologic aspects of dyspnea in chronic obstructive 
pulmonary disease: a pilot study. Heart & Lung: the Journal of Critical Care. 
1990;19(3):252-7. 
188. Brenes GA. Anxiety and chronic obstructive pulmonary disease: prevalence, 
impact, and treatment. Psychosomatic Medicine. 2003;65(6):963-70. 
189. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression in chronic 
respiratory impairment. General Hospital Psychiatry. 1992;14(1):20-8. 
190. Borges-Santos E, Wada J, Cano D, Paisani D, da Silva CM, Cukier A, et al. 
Relationship between psychosocial factors, dyspnea and thoracoabdominal 
mechanics in COPD patients. European Respiratory Journal. 2013;42(Suppl 
57):P1379. 
191. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. 
Validity and responsiveness of the self-administered computerized versions of the 
baseline and transition dyspnea indexes. Chest. 2007;132(4):1283-90. 
192. Mahler D, Faryniarz K, Tomlinson D, Colice GL, Robins A, Olmstead EM, 
et al. Impact of dyspnea and physiologic function on general health status in patients 
with chronic obstructive pulmonary disease. Chest. 1992;102(2):395-401. 
193. Mahler DA, Ward J, Fierro-Carrion G, Waterman LA, Lentine TF, Mejia-
Alfaro R, et al. Development of self-administered versions of modified baseline and 
transition dyspnea indexes in COPD. COPD: Journal of Chronic Obstructive 
Pulmonary Disease. 2004;1(2):165-72. 
194. Bessa E, Torres G, Rufino R, Costa C, Faria A. Correlation Between The 
 187 
Scales Of Dyspnea And Fev1% In COPD Patients. American Journal of Respiratory 
and Critical Care Medicine. 2013;187:A2948. 
195. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary 
rehabilitation on physiologic and psychosocial outcomes in patients with chronic 
obstructive pulmonary disease. Annals of Internal Medicine. 1995;122(11):823-32. 
196. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, et al. 
Role of inspiratory capacity on exercise tolerance in COPD patients with and without 
tidal expiratory flow limitation at rest. European Respiratory Journal. 
2000;16(2):269-75. 
197. Yan S, Kaminski D, Sliwinski P. Reliability of inspiratory capacity for 
estimating end-expiratory lung volume changes during exercise in patients with 
chronic obstructive pulmonary disease. American Journal of Respiratory and Critical 
Care Medicine. 1997;156(1):55-9. 
198. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in 
exercise performance after anticholinergic therapy in chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine. 
1999;160(2):542-9. 
199. Almagro P, Martinez-Camblor P, Soriano JB, Marin JM, Alfageme I, 
Casanova C, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year 
survival in COPD patients: the COCOMICS study. PloS One. 2014;9(2):e89866. 
200. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson I. Measurement of 
breathlessness in advanced disease: a systematic review. Respiratory Medicine. 
2007;101(3):399-410. 
201. Bausewein C, Booth S, Higginson IJ. Measurement of dyspnoea in the 
clinical rather than the research setting. Current Opinion in Supportive and Palliative 
Care. 2008;2(2):95-9. 
202. Mahler DA, Jones PW. Measurement of dyspnea and quality of life in 
advanced lung disease. Clinics in Chest Medicine. 1997;18(3):457-69. 
203. Crisafulli E, Clini EM. Measures of dyspnea in pulmonary rehabilitation. 
Multidisciplinary Respiratory Medicine. 2010;5(3):202. 
204. Silverman M, Barry J, Hellerstein H, Janos J, Kelsen S. Variability of the 
perceived sense of effort in breathing during exercise in patients with chronic 
obstructive pulmonary disease. American Review of Respiratory Disease. 
1988;137(1):206-9. 
205. Gigliotti F, Coli C, Bianchi R, Romagnoli I, Lanini B, Binazzi B, et al. 
Exercise training improves exertional dyspnea in patients with COPD: evidence of 
the role of mechanical factors. Chest. 2003;123(6):1794-802. 
206. Cohen J. Statistical power analysis for the behavioral sciences (rev: Lawrence 
Erlbaum Associates, Inc; 1977. 
 188 
207. Wilson RC, Jones P. A comparison of the visual analogue scale and modified 
Borg scale for the measurement of dyspnoea during exercise. Clinical Science. 
1989;76(3):277-82. 
208. Muza SR, Silverman MT, Gilmore GC, Hellerstein HK, Kelsen SG. 
Comparison of scales used to quantitate the sense of effort to breathe in patients with 
chronic obstructive pulmonary disease. American Review of Respiratory Disease. 
1990;141(4 Pt 1):909-13. 
209. De Torres JP, Pinto-Plata V, Ingenito E, Bagley P, Gray A, Berger R, et al. 
Power of outcome measurements to detect clinically significant changes in 
pulmonary rehabilitation of patients with COPD. Chest. 2002;121(4):1092-8. 
210. Alvisi V, Mirkovic T, Nesme P, Guérin C, Milic-Emili J. Acute effects of 
hyperoxia on dyspnea in hypoxemia patients with chronic airway obstruction at rest. 
Chest. 2003;123(4):1038-46. 
211. Reardon J, Awad E, Normandin E, Vale F, Clark B, ZuWallack RL. The 
effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest. 
1994;105(4):1046-52. 
212. Wilcock A, Crosby V, Clarke D, Tattersfield A. Repeatability of 
breathlessness measurements in cancer patients. Thorax. 1999;54(4):374. 
213. Ries AL. Minimally clinically important difference for the UCSD shortness 
of breath questionnaire, Borg Scale, and Visual Analog Scale. COPD: Journal of 
Chronic Obstructive Pulmonary Disease. 2005;2(1):105-10. 
214. Wewers ME, Lowe NK. A critical review of visual analogue scales in the 
measurement of clinical phenomena. Research in Nursing and Health. 
1990;13(4):227-36. 
215. McGavin C, Artvinli M, Naoe H, McHardy G. Dyspnoea, disability, and 
distance walked: comparison of estimates of exercise performance in respiratory 
disease. British Medical Journal. 1978;2(6132):241. 
216. Ambrosino N, Scano G. Measurement and treatment of dyspnoea. 
Respiratory Medicine. 2001;95(7):539-47. 
217. Mahler D, Wells CK. Evaluation of clinical methods for rating dyspnea. 
Chest. 1988;93(3):580-6. 
218. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones 
NL, et al. How should we measure function in patients with chronic heart and lung 
disease? Journal of Chronic Diseases. 1985;38(6):517-24. 
219. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, 
et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index 
in chronic obstructive pulmonary disease. New England Journal of Medicine. 
2004;350(10):1005-12. 
220. Mahler D, Rosiello R, Harver A, Lentine T, McGovern J, Daubenspeck J. 
 189 
Comparison of clinical dyspnea ratings and psychophysical measurements of 
respiratory sensation in obstructive airway disease. The American Review of 
Respiratory Disease. 1987;135(6):1229-33. 
221. Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: 
the role of dyspnea. The American Journal of Medicine. 2006;119(10):12-20. 
222. Witek T, Mahler D. Minimal important difference of the transition dyspnoea 
index in a multinational clinical trial. European Respiratory Journal. 2003;21(2):267-
72. 
223. Ferrari K, Goti P, Misuri G, Amendola M, Rosi E, Grazzini M, et al. Chronic 
exertional dyspnea and respiratory muscle function in patients with chronic 
obstructive pulmonary disease. Lung. 1997;175(5):311-19. 
224. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. 
Validity and responsiveness of the self-administered computerized versions of the 
baseline and transition dyspnea indexes. Chest Journal. 2007;132(4):1283-90. 
225. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a 
new dyspnea measure the UCSD shortness of breath questionnaire. Chest. 
1998;113(3):619-24. 
226. Lareau SC, Carrieri-Kohlman V, Janson-Bjerklie S, Roos PJ. Development 
and testing of the Pulmonary Functional Status and Dyspnea Questionnaire 
(PFSDQ). Heart and lung: the Journal of Critical Care. 1993;23(3):242-50. 
227. Bowen J, Thrall R, ZuWallack R, Votto J. Long-term benefits of short-stay 
inpatient pulmonary rehabilitation in severe chronic obstructive pulmonary disease. 
Monaldi Archives for Chest Disease Archivio Monaldi per Le Malattie Del Torace. 
1999;54(2):189-92. 
228. Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW. The affective 
dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. 
American Journal of Respiratory and Critical Care Medicine. 2008;177(12):1384-90. 
229. Banzett RB, O'Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, 
Meek PM, et al. Multidimensional Dyspnea Profile: an instrument for clinical and 
laboratory research. European Respiratory Journal. 2015;45:1681-91. 
230. Elliott MW, Adams L, Cockcroft A, Macrae KD, Murphy K, Guz A. The 
language of breathlessness: use of verbal descriptors by patients with 
cardiopulmonary disease. American Review of Respiratory Disease. 
1991;144(4):826-32. 
231. Parshall MB. Psychometric characteristics of dyspnea descriptor ratings in 
emergency department patients with exacerbated chronic obstructive pulmonary 
disease. Research in Nursing and Health. 2002;25(5):331-44. 
232. Wade JB, Dougherty LM, Archer C, Price DD. Assessing the stages of pain 
processing: a multivariate analytical approach. Pain. 1996;68(1):157-67. 
 190 
233. Harkins SW, Price DD, Braith J. Effects of extraversion and neuroticism on 
experimental pain, clinical pain, and illness behavior. Pain. 1989;36(2):209-18. 
234. Laviolette L, Laveneziana P. Dyspnoea: a multidimensional and 
multidisciplinary approach. European Respiratory Journal. 2014;43(6):1750-62. 
235. Meek PM, Banzett R, Parshall MB, Gracely RH, Schwartzstein RM, Lansing 
R. Reliability and validity of the multidimensional dyspnea profile. Chest. 
2012;141(6):1546-53. 
236. Streiner DL, Norman GR, Cairney J. Health measurement scales: a practical 
guide to their development and use: Oxford University Press, USA; 2014. 
237. Yorke J, Savin C. Evaluating tools that can be used to measure and manage 
breathlessness in chronic disease. Nursing Times. 2010;106(17):10, 3. 
238. Puhan MA, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, et al. 
Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges 
Respiratory Questionnaire and four other health-related quality of life instruments for 
patients with chronic lung disease. Respiratory Medicine. 2007;101(2):308-16. 
239. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A 
measure of quality of life for clinical trials in chronic lung disease. Thorax. 
1987;42(10):773-8. 
240. Jones PW. Issues concerning health-related quality of life in COPD. Chest. 
1995;107(5):187S-93S. 
241. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD. Development of a 
self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax. 
2001;56(12):954-9. 
242. Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Austin P, 
et al. A comparison of the original chronic respiratory questionnaire with a 
standardized version. Chest. 2003;124(4):1421-9. 
243. Wijkstra P, TenVergert E, Van Altena R, Otten V, Postma D, Kraan J, et al. 
Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax. 
1994;49(5):465-7. 
244. Martin LL. Validity and Reliability of a Quality-of-Life Instrument The 
Chronic Respiratory Disease Questionnaire. Clinical Nursing Research. 
1994;3(2):146-56. 
245. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining 
the minimal clinically important difference. Controlled Clinical Trials. 
1989;10(4):407-15. 
246. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete 
measure of health status for chronic airflow limitation: the St. George's Respiratory 
Questionnaire. American Review of Respiratory Disease. 1992;145(6):1321-7. 
 191 
247. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with 
salmeterol. American Journal of Respiratory and Critical Care Medicine. 
1997;155(4):1283-9. 
248. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. 
Comparison of discriminative properties among disease-specific questionnaires for 
measuring health-related quality of life in patients with chronic obstructive 
pulmonary disease. Journal of Cardiopulmonary Rehabilitation and Prevention. 
1999;19(4):265-6. 
249. Jones PW. St. George's respiratory questionnaire: MCID. COPD: Journal of 
Chronic Obstructive Pulmonary Disease. 2005;2(1):75-9. 
250. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional 
oxygen of limited benefit in patients with chronic obstructive pulmonary disease and 
mild hypoxemia. American Journal of Respiratory and Critical Care Medicine. 
1995;152(5):1616-19. 
251. Woodcock A, Gross E, Geddes D. Oxygen relieves breathlessness in" pink 
puffers". The Lancet. 1981;317(8226):907-9. 
252. Killen J, Corris P. A pragmatic assessment of the placement of oxygen when 
given for exercise induced dyspnoea. Thorax. 2000;55(7):544-6. 
253. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, Marcello J, et 
al. Effect of palliative oxygen versus room air in relief of breathlessness in patients 
with refractory dyspnoea: a double-blind, randomised controlled trial. The Lancet. 
2010;376(9743):784-93. 
254. Somfay A, Porszasz J, Lee S, Casaburi R. Dose-response effect of oxygen on 
hyperinflation and exercise endurance in nonhypoxaemic COPD patients. European 
Respiratory Journal. 2001;18(1):77-84. 
255. Swinburn C, Wakefield J, Jones P. Relationship between ventilation and 
breathlessness during exercise in chronic obstructive airways disease is not altered by 
prevention of hypoxaemia. Clinical Science. 1984;67(5):515-9. 
256. Harris P, Barnes R. The uses of helium and xenon in current clinical practice. 
Anaesthesia. 2008;63(3):284-93. 
257. Eves ND, Petersen SR, Haykowsky MJ, Wong EY, Jones RL. Helium-
hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine. 
2006;174(7):763-71. 
258. Laude EA, Duffy NC, Baveystock C, Dougill B, Campbell MJ, Lawson R, et 
al. The effect of helium and oxygen on exercise performance in chronic obstructive 
pulmonary disease: a randomized crossover trial. American Journal of Respiratory 
and Critical Care Medicine. 2006;173(8):865-70. 
259. Marciniuk DD, Butcher SJ, Reid JK, MacDonald GF, Eves ND, Clemens R, 
et al. The effects of helium-hyperoxia on 6-min walking distance in COPD: a 
 192 
randomized, controlled trial. Chest. 2007;131(6):1659-65. 
260. Oelberg DA, Kacmarek RM, Pappagianopoulos PP, Ginns LC, Systrom DM. 
Ventilatory and cardiovascular responses to inspired He-O2 during exercise in 
chronic obstructive pulmonary disease. American Journal of Respiratory and Critical 
Care Medicine. 1998;158(6):1876-82. 
261. Gerbeaux P, Gainnier M, Boussuges A, Rakotonirina J, Nelh P, Torro D, et 
al. Use of heliox in patients with severe exacerbation of chronic obstructive 
pulmonary disease. Critical Care Medicine. 2001;29(12):2322-24. 
262. Palange P, Valli G, Onorati P, Antonucci R, Paoletti P, Rosato A, et al. Effect 
of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity 
in COPD patients. Journal of Applied Physiology. 2004;97(5):1637-42. 
263. Wigmore T, Stachowski E. A review of the use of heliox in the critically ill. 
Critical Care and Resuscitation. 2006;8:64-72. 
264. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis 
JR, et al. American College of Chest Physicians consensus statement on the 
management of dyspnea in patients with advanced lung or heart disease. Chest. 
2010;137(3):674-91. 
265. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. 
Randomised, double blind, placebo controlled crossover trial of sustained release 
morphine for the management of refractory dyspnoea. BMJ Case Reports. 
2003;327(7414):523-8. 
266. Johnson M, Woodcock A, Geddes D. Dihydrocodeine for breathlessness in" 
pink puffers". BMJ. 1983;286(6366):675-7. 
267. Jennings A, Davies A, Higgins J, Gibbs J, Broadley K. A systematic review 
of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-44. 
268. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, et al. 
Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice 
guidelines. Chest. 2007;131:4-42. 
269. Bianchi R, Gigliotti F, Romagnoli I, Lanini B, Castellani C, Binazzi B, et al. 
Impact of a rehabilitation program on dyspnea intensity and quality in patients with 
chronic obstructive pulmonary disease. Respiration. 2010;81(3):186-95. 
270. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, 
Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive 
pulmonary disease. Cochrane Database Syst Rev. 2011;10(10):1-39. 
271. Franssen FM, Broekhuizen R, Janssen PP, Wouters EF, Schols AM. Effects 
of whole-body exercise training on body composition and functional capacity in 
normal-weight patients with COPD. Chest. 2004;125(6):2021-8. 
272. Spruit M, Gosselink R, Troosters T, De Paepe K, Decramer M. Resistance 
versus endurance training in patients with COPD and peripheral muscle weakness. 
 193 
European Respiratory Journal. 2002;19(6):1072-8. 
273. Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise 
training decreases ventilatory requirements and exercise-induced hyperinflation at 
submaximal intensities in patients with COPD. Chest. 2005;128(4):2025-34. 
274. O'Donnell DE, Mcguire M, Samis L, Webb KA. General exercise training 
improves ventilatory and peripheral muscle strength and endurance in chronic 
airflow limitation. American Journal of Respiratory and Critical Care Medicine. 
1998;157(5):1489-97. 
275. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important 
difference in symptoms: a comparison of two techniques. Journal of Clinical 
Epidemiology. 1996;49(11):1215-19. 
276. Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, et al. Long-
term controlled trial of nocturnal nasal positive pressure ventilation in patients with 
severe COPD. Chest. 2000;118(6):1582-90. 
277. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner C, et al. The Italian 
multicentre study on noninvasive ventilation in chronic obstructive pulmonary 
disease patients. European Respiratory Journal. 2002;20(3):529-38. 
278. Borel J-C, Verges S, Pepin J-L, Vivodtzev I, Levy P, Wuyam B. Home 
exercise training with non-invasive ventilation in thoracic restrictive respiratory 
disorders: a randomised study. Respiratory Physiology & Neurobiology. 
2009;167(2):168-73. 
279. Keilty S, Ponte J, Fleming T, Moxham J. Effect of inspiratory pressure 
support on exercise tolerance and breathlessness in patients with severe stable 
chronic obstructive pulmonary disease. Thorax. 1994;49(10):990-4. 
280. Sapey E, Stockley R. COPD exacerbations· 2: Aetiology. Thorax. 
2006;61(3):250-8. 
281. Pauwels R, Calverley P, Buist A, Rennard S, Fukuchi Y, Stahl E, et al. COPD 
exacerbations: the importance of a standard definition. Respiratory Medicine. 
2004;98(2):99-107. 
282. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and 
prevention. The Lancet. 2007;370(9589):786-96. 
283. Rohde G, Wiethege A, Borg I, Kauth M, Bauer T, Gillissen A, et al. 
Respiratory viruses in exacerbations of chronic obstructive pulmonary disease 
requiring hospitalisation: a case-control study. Thorax. 2003;58(1):37-42. 
284. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message 
S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute 
exacerbations and stable chronic obstructive pulmonary disease. American Journal of 
Respiratory and Critical Care Medicine. 2001;164(9):1618-23. 
285. Mallia P, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental 
 194 
model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a 
pilot study. Respiratory Research. 2006;7(1):116. 
286. Hurst J, Donaldson G, Wilkinson T, Perera W, Wedzicha J. Epidemiological 
relationships between the common cold and exacerbation frequency in COPD. 
European Respiratory Journal. 2005;26(5):846-52. 
287. Seemungal T, Harper‐Owen R, Bhowmik A, Jeffries D, Wedzicha J. 
Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive 
pulmonary disease. European Respiratory Journal. 2000;16(4):677-83. 
288. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha 
JA. Effect of interactions between lower airway bacterial and rhinoviral infection in 
exacerbations of COPD. Chest. 2006;129(2):317-24. 
289. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation 
and bronchial bacterial colonization in chronic obstructive pulmonary disease. 
American Journal of Respiratory and Critical Care Medicine. 2006;173(9):991-8. 
290. Zhang M, Li Q, Zhang X-Y, Ding X, Zhu D, Zhou X. Relevance of lower 
airway bacterial colonization, airway inflammation, and pulmonary function in the 
stable stage of chronic obstructive pulmonary disease. European Journal of Clinical 
Microbiology and Infectious Diseases. 2010;29(12):1487-93. 
291. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway 
bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. 
American Journal of Respiratory and Critical Care Medicine. 2007;176(4):356-61. 
292. Ko FW, Ip M, Chan PK, Fok JP, Chan MC, Ngai JC, et al. A 1-year 
prospective study of the infectious etiology in patients hospitalized with acute 
exacerbations of COPD. Chest. 2007;131(1):44-52. 
293. Patel I, Seemungal T, Wilks M, Lloyd-Owen S, Donaldson G, Wedzicha J. 
Relationship between bacterial colonisation and the frequency, character, and 
severity of COPD exacerbations. Thorax. 2002;57(9):759-64. 
294. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic 
determinants of exacerbation in chronic obstructive pulmonary disease. Archives of 
Internal Medicine. 2005;165(8):891-7. 
295. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, 
et al. Infections and airway inflammation in chronic obstructive pulmonary disease 
severe exacerbations. American Journal of Respiratory and Critical Care Medicine. 
2006;173(10):1114-21. 
296. Anderson H, Spix C, Medina S, Schouten J, Castellsague J, Rossi G, et al. Air 
pollution and daily admissions for chronic obstructive pulmonary disease in 6 
European cities: results from the APHEA project. European Respiratory Journal. 
1997;10(5):1064-71. 
297. Yang C-Y, Chen C-J. Air pollution and hospital admissions for chronic 
obstructive pulmonary disease in a subtropical city: Taipei, Taiwan. Journal of 
 195 
Toxicology and Environmental Health, Part A. 2007;70(14):1214-9. 
298. Gouveia N, Freitas CUd, Martins LC, Marcilio IO. Respiratory and 
cardiovascular hospitalizations associated with air pollution in the city of São Paulo, 
Brazil. Cadernos de Saúde Publica. 2006;22(12):2669-77. 
299. Sunyer J, Saez M, Murillo C, Castellsague J, Martinez F, Anto JM. Air 
pollution and emergency room admissions for chronic obstructive pulmonary 
disease: a 5-year study. American Journal of Epidemiology. 1993;137(7):701-5. 
300. Donaldson G, Seemungal T, Patel I, Lloyd-Owen S, Wilkinson T, Wedzicha 
J. Longitudinal changes in the nature, severity and frequency of COPD 
exacerbations. European Respiratory Journal. 2003;22(6):931-36. 
301. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on 
patients’ health status following early identification of a COPD exacerbation. 
European Respiratory Journal. 2007;30(5):907-13. 
302. Carr SJ, Goldstein RS, Brooks D. Acute exacerbations of COPD in subjects 
completing pulmonary rehabilitation. Chest. 2007;132(1):127-34. 
303. Baghai-Ravary R, Quint JK, Goldring JJ, Hurst JR, Donaldson GC, Wedzicha 
JA. Determinants and impact of fatigue in patients with chronic obstructive 
pulmonary disease. Respiratory Medicine. 2009;103(2):216-23. 
304. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. 
Physical activity and hospitalization for exacerbation of COPD. Chest. 
2006;129(3):536-44. 
305. Patel A, Kowlessar B, Mackay A, Singh R, Donaldson G, Wedzicha J, et al. 
Exercise Capacity In COPD Patients During Exacerbation Recovery. American 
Journal of Respiratory and Critical Care Medicine. 2013;187:A1441. 
306. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-
centered outcomes. Chest. 2007;131(3):696-704. 
307. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An 
official European Respiratory Society/American Thoracic Society technical standard: 
field walking tests in chronic respiratory disease. European Respiratory Journal. 
2014;44(6):1428-46. 
308. Yilmaz D, Dodd J, Shrikrishna D, Hopkinson N, Jones P. Physical activity 
and sleep duration following hospitalisation with exacerbation of COPD vs. stable 
COPD & age matched controls. European Respiratory Journal. 2012;40(Suppl 
56):P613. 
309. AlAhmari A, Patel A, Kowlessar B, Mackay A, Singh R, Allinson J, et al. 
Decline of daily activity in COPD patients with frequent and infrequent 
exacerbations. European Respiratory Journal. 2013;42(Suppl 57):P2162. 
310. Borges RC, Carvalho CRF. Physical activity in daily life in Brazilian COPD 
patients during and after exacerbation. COPD: Journal of Chronic Obstructive 
 196 
Pulmonary Disease. 2012;9(6):596-602. 
311. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala J, Masa F, et al. 
Effect of exacerbations on quality of life in patients with chronic obstructive 
pulmonary disease: a 2 year follow up study. Thorax. 2004;59(5):387-95. 
312. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations 
on pulmonary function, health status and clinical outcomes. International Journal of 
Chronic Obstructive Pulmonary Disease. 2009;4:245-51. 
313. Soler JJ, Sánchez L, Rom n P, Mart  nez M , Perpi   M. Risk factors of 
emergency care and admissions in COPD patients with high consumption of health 
resources. Respiratory Medicine. 2004;98(4):318-29. 
314. Spencer S, Jones PW. Time course of recovery of health status following an 
infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589-93. 
315. Laurin C, Moullec Gg, Bacon SL, Lavoie KL. Impact of anxiety and 
depression on chronic obstructive pulmonary disease exacerbation risk. American 
Journal of Respiratory and Critical Care Medicine. 2012;185(9):918-23. 
316. Pooler A, Beech R. Examining the relationship between anxiety and 
depression and exacerbations of COPD which result in hospital admission: a 
systematic review. International Journal of Chronic Obstructive Pulmonary Disease. 
2014;9:315-30. 
317. Thompson J, Ng C, Dickinson R, Morjaria J. Do Admissions With Acute 
Exacerbations Of COPD Influence Anxiety And Depression? American Journal of 
Respiratory and Critical Care Medicine. 2014;189:A5820. 
318. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha J. Relationship 
between depression and exacerbations in COPD. European Respiratory Journal. 
2008;32(1):53-60. 
319. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas N, Milic 
Emili J, et al. Exacerbations and lung function decline in COPD: new insights in 
current and ex-smokers. Respiratory Medicine. 2007;101(6):1305-12. 
320. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et 
al. Effect of pharmacotherapy on rate of decline of lung function in chronic 
obstructive pulmonary disease: results from the TORCH study. American Journal of 
Respiratory and Critical Care Medicine. 2008;178(4):332-8. 
321. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote 
FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive 
pulmonary disease: results from the lung health study. American Journal of 
Respiratory and Critical Care Medicine. 2001;164(3):358-64. 
322. Connors Jr AF, Dawson NV, Thomas C, Harrell Jr FE, Desbiens N, 
Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic 
obstructive lung disease. The SUPPORT investigators (Study to Understand 
Prognoses and Preferences for Outcomes and Risks of Treatments). American 
 197 
Journal of Respiratory and Critical Care Medicine. 1996;154(4):959-67. 
323. Almagro P, Calbo E, de Echag en AO, Barreiro B, Quintana S, Heredia JL, 
et al. Mortality after hospitalization for COPD. Chest. 2002;121(5):1441-8. 
324. Soler-Cataluna J, Martínez-García MÁ, Sánchez PR, Salcedo E, Navarro M, 
Ochando R. Severe acute exacerbations and mortality in patients with chronic 
obstructive pulmonary disease. Thorax. 2005;60(11):925-31. 
325. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related 
factors after hospitalization for acute exacerbation of COPD. Chest. 
2003;124(2):459-67. 
326. Sprooten R, Slenter R, Kotz D, Wesselig G, Wouters E, Rohde G. Early 
readmission after hospitalization for acute exacerbations of chronic obstructive 
pulmonary disease (AECOPD) is associated with high mortality. European 
Respiratory Journal. 2013;42(Suppl 57):P1528. 
327. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic 
obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 
2012;67(11):957-63. 
328. Andersson F, Borg S, Jansson S-A, Jonsson A-C, ERICSSON Å, Prütz C, et 
al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). 
Respiratory Medicine. 2002;96(9):700-8. 
329. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of 
exacerbations on health care cost and resource utilization in chronic obstructive 
pulmonary disease patients with chronic bronchitis from a predominantly Medicare 
population. International Journal of Chronic Obstructive Pulmonary Disease. 
2012;7:757-64. 
330. Jahnz-Rózyk K, Targowski T, From S. Comparison of outpatient and 
inpatient costs of moderate and severe exacerbations of chronic obstructive 
pulmonary disease in Poland. Pneumonologia i Alergologia Polska. 2008;76(6):426-
31. 
331. Abramson M, Crockett AJ, Dabscheck E, Frith PA, George J, Glasgow N, et 
al. The COPDX Plan: Australian and New Zealand Guidelines for the management 
of chronic obstructive pulmonary disease. The Australian Lung Foundation and 
Thoracic Society of Australia and New Zealand. 2014:Version 2.39. Available from: 
http://www.copdx.org.au/. 
332. Celli B, MacNee W, Agusti A, Anzueto A, Berg B, Buist A, et al. Standards 
for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS 
position paper. European Respiratory Journal. 2004;23(6):932-46. 
333. Selroos O, Borgström L, Ingelf J. Use of dry powder inhalers in acute 
exacerbations of asthma and COPD. Therapeutic Advances in Respiratory Disease. 
2009;3(2):81-91. 
334. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in 
 198 
acute airflow obstruction: a meta-analysis. Archives of Internal Medicine. 
1997;157(15):1736-44. 
335. Ta M, George J. Management of chronic obstructive pulmonary disease in 
Australia after the publication of national guidelines. Internal Medicine Journal. 
2011;41(3):263-70. 
336. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled 
trial of oral prednisone in outpatients with acute COPD exacerbation. American 
Journal of Respiratory and Critical Care Medicine. 1996;154(2):407-12. 
337. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, 
et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive 
pulmonary disease. New England Journal of Medicine. 1999;340(25):1941-47. 
338. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled 
corticosteroids in COPD: systematic review and meta-analysis of randomised 
controlled trials and observational studies. Thorax. 2011;66(8):699-708. 
339. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. 
Global strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease: GOLD executive summary. American Journal of Respiratory and 
Critical Care Medicine. 2013;187(4):347-65. 
340. Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW. Outcomes 
associated with corticosteroid dosage in critically ill patients with acute 
exacerbations of chronic obstructive pulmonary disease. American Journal of 
Respiratory and Critical Care Medicine. 2014;189(9):1052-64. 
341. Quon BS, Gan WQ, Sin DD. Contemporary management of acute 
exacerbations of COPD: a systematic review and metaanalysis. Chest. 
2008;133(3):756-66. 
342. Pavord ID, Jones PW, Burgel P-R, Rabe KF. exacerbations of COPD. 
International Journal of Chronic Obstructive Pulmonary Disease. 2016;11:21-30. 
343. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive 
pressure ventilation to treat respiratory failure resulting from exacerbations of 
chronic obstructive pulmonary disease: Cochrane systematic review and meta-
analysis. British Medical Journal. 2003;326(7382):185. 
344. Meyer TJ, Hill NS. Noninvasive positive pressure ventilation to treat 
respiratory failure. Annals of Internal Medicine. 1994;120(9):760-70. 
345. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. 
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary 
disease. New England Journal of Medicine. 1995;333(13):817-22. 
346. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non‐invasive positive pressure 
ventilation for treatment of respiratory failure due to exacerbations of chronic 
obstructive pulmonary disease. The Cochrane Library. 2004:CD004104. 
 199 
347. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and 
physical fitness: definitions and distinctions for health-related research. Public 
Health Reports. 1985;100(2):126-31. 
348. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et 
al. Compendium of physical activities: an update of activity codes and MET 
intensities. Medicine and Science in Sports and Exercise. 2000;32(9; Suppl 1):S498-
504. 
349. Haskell WL, Lee I-M, Pate RR, Powell KE, Blair SN, Franklin BA, et al. 
Physical activity and public health: updated recommendation for adults from the 
American College of Sports Medicine and the American Heart Association. 
Circulation. 2007;116(9):1081-93. 
350. Barnes J, Behrens TK, Benden ME, Biddle S, Bond D, Brassard P, et al. 
Letter to the Editor: Standardized use of the terms" sedentary" and" sedentary 
behaviours". Applied Physiology Nutrition and Metabolism-Physiologie Appliquee 
Nutrition Et Metabolisme. 2012;37(3):540-2. 
351. Owen N, Healy GN, Matthews CE, Dunstan DW. Too much Sitting: The 
population-Health Science of Sedentary Behavior. Exercise and Sport Sciences 
Reviews. 2010;38(3):105-13. 
352. Voss MW, Carr LJ, Clark R, Weng T. Revenge of the" sit" II: Does lifestyle 
impact neuronal and cognitive health through distinct mechanisms associated with 
sedentary behavior and physical activity? Mental Health and Physical Activity. 
2014;7(1):9-24. 
353. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle 
as a secretory organ. Nature Reviews Endocrinology. 2012;8(8):457-65. 
354. Tudor-Locke C, Leonardi C, Johnson WD, Katzmarzyk PT, Church TS. 
Accelerometer steps/day translation of moderate-to-vigorous activity. Preventive 
Medicine. 2011;53(1):31-3. 
355. Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De 
Bourdeaudhuij I, et al. How many steps/day are enough? For older adults and special 
populations. International Journal of Behavioral Nutrition and Physical Activity. 
2011;8(1):80. 
356. Chau JY, Grunseit A, Midthjell K, Holmen J, Holmen TL, Bauman AE, et al. 
Sedentary behaviour and risk of mortality from all-causes and cardiometabolic 
diseases in adults: evidence from the HUNT3 population cohort. British Journal of 
Sports Medicine. 2013. 
357. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure 
and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular 
disease. Diabetes. 2007;56(11):2655-67. 
358. Levine JA, Miller JM. The energy expenditure of using a “walk-and-work” 
desk for office workers with obesity. British Journal of Sports Medicine. 
2007;41(9):558-61. 
 200 
359. Healy GN, Matthews CE, Dunstan DW, Winkler EA, Owen N. Sedentary 
time and cardio-metabolic biomarkers in US adults: NHANES 2003–06. European 
Heart Journal. 2011;32(5):590-7. 
360. Adamo KB, Prince SA, Tricco AC, Connor‐Gorber S, Tremblay M. A 
comparison of indirect versus direct measures for assessing physical activity in the 
pediatric population: a systematic review. International Journal of Pediatric Obesity. 
2009;4(1):2-27. 
361. Pitta F, Troosters T, Probst V, Spruit M, Decramer M, Gosselink R. 
Quantifying physical activity in daily life with questionnaires and motion sensors in 
COPD. European Respiratory Journal. 2006;27(5):1040-55. 
362. Pitta F, Troosters T, Spruit MA, Decramer M, Gosselink R. Activity 
monitoring for assessment of physical activities in daily life in patients with chronic 
obstructive pulmonary disease. Archives of Physical Medicine and Rehabilitation. 
2005;86(10):1979-85. 
363. Garfield BE, Canavan JL, Smith CJ, Ingram KA, Fowler RP, Clark AL, et al. 
Stanford seven-day physical activity recall questionnaire in COPD. European 
Respiratory Journal. 2012;40(2):356-62. 
364. Prince SA, Adamo KB, Hamel ME, Hardt J, Gorber SC, Tremblay M. A 
comparison of direct versus self-report measures for assessing physical activity in 
adults: a systematic review. International Journal of Behavioral Nutrition and 
Physical Activity. 2008;5(1):56. 
365. Hunt T, Williams MT, Olds TS. Reliability and Validity of the Multimedia 
Activity Recall in Children and Adults (MARCA) in People with Chronic 
Obstructive Pulmonary Disease. PloS One. 2013;8(11):e81274. 
366. Plasqui G, Bonomi A, Westerterp K. Daily physical activity assessment with 
accelerometers: new insights and validation studies. Obesity Reviews. 
2013;14(6):451-62. 
367. Crouter SE, Schneider PL, Karabulut M, Bassett DR. Validity of 10 
electronic pedometers for measuring steps, distance, and energy cost. Medicine and 
Science in Sports and Exercise. 2003;35(8):1455-60. 
368. Schonhofer B, Ardes P, Geibel M, Kohler D, Jones P. Evaluation of a 
movement detector to measure daily activity in patients with chronic lung disease. 
European Respiratory Journal. 1997;10(12):2814-19. 
369. Moy ML, Danilack VA, Weston NA, Garshick E. Daily step counts in a US 
cohort with COPD. Respiratory Medicine. 2012;106(7):962-9. 
370. Wilcox S, Tudor-Lock CE, Ainsworth BE. Physical activity patterns, 
assessment, and motivation in older adults.  Gender, Physical Activity, and Aging 
Boca Raton, FL CRC Press 2002. p. 13-39. 
371. Karabulut M, Crouter SE, Bassett Jr DR. Comparison of two waist-mounted 
and two ankle-mounted electronic pedometers. European Journal of Applied 
 201 
Physiology. 2005;95(4):335-43. 
372. Storti KL, Pettee KK, Brach JS, Talkowski JB, Richardson CR, Kriska AM. 
Gait speed and step-count monitor accuracy in community-dwelling older adults. 
Medicine and Science in Sports and Exercise. 2008;40(1):59. 
373. Furlanetto KC, Bisca GW, Oldemberg N, Sant'Anna TJ, Morakami FK, 
Camillo CA, et al. Step Counting and Energy Expenditure Estimation in Patients 
With Chronic Obstructive Pulmonary Disease and Healthy Elderly: Accuracy of 2 
Motion Sensors Archives of Physical Medicine and Rehabilitation. 2010;91(2):261-
7. 
374. Zabatiero J, Kovelis D, Furlanetto KC, Mantoani LC, Proença M, Pitta F. 
Comparison of Two Strategies Using Pedometers to Counteract Physical Inactivity in 
Smokers. Nicotine and Tobacco Research. 2014;16(5):562-8. 
375. Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, et al. 
Pedometers to enhance physical activity in COPD: a randomised controlled trial. 
European Respiratory Journal. 2014:erj00845-2014. 
376. Fulk GD, Combs SA, Danks KA, Nirider CD, Raja B, Reisman DS. 
Accuracy of 2 Activity Monitors in Detecting Steps in People With Stroke and 
Traumatic Brain Injury. Physical Therapy. 2014;94(2):222-9. 
377. Cindy Ng LW, Jenkins S, Hill K. Accuracy and responsiveness of the 
stepwatch activity monitor and ActivPAL in patients with COPD when walking with 
and without a rollator. Disability and Rehabilitation. 2012;34(15):1317-22. 
378. Cavanaugh JT, Coleman KL, Gaines JM, Laing L, Morey MC. Using Step 
Activity Monitoring to Characterize Ambulatory Activity in Community‐Dwelling 
Older Adults. Journal of the American Geriatrics Society. 2007;55(1):120-4. 
379. Cohen MD, Cutaia M. A novel approach to measuring activity in chronic 
obstructive pulmonary disease: using 2 activity monitors to classify daily activity. 
Journal of Cardiopulmonary Rehabilitation and Prevention. 2010;30(3):186-94. 
380. Murphy SL. Review of physical activity measurement using accelerometers 
in older adults: considerations for research design and conduct. Preventive Medicine. 
2009;48(2):108-14. 
381. Butte NF, Ekelund U, Westerterp KR. Assessing physical activity using 
wearable monitors: measures of physical activity. Medicine and Science in Sports 
and Exercise. 2012;44(1 Suppl 1):5-12. 
382. Singh S, Morgan MD. Activity Monitors Can Detect Brisk Walking in 
Patients With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary 
Rehabilitation and Prevention. 2001;21(3):143-8. 
383. Sallis JF. Measuring Physical Activity Environments: A Brief History. 
American Journal of Preventive Medicine. 2009;36(4):86-92. 
384. Ainslie PN, Reilly T, Westerterp KR. Estimating Human Energy 
 202 
Expenditure. Sports Medicine. 2003;33(9):683-98. 
385. Andre D, Wolf DL. Recent Advances in Free-Living Physical Activity 
Monitoring: A Review. Journal of Diabetes Science and Technology. 2007;1(5):760-
7. 
386. Trost SG, McIver KL, Pate RR. Conducting accelerometer-based activity 
assessments in field-based research. Medicine and Science in Sports and Exercise. 
2005;11Suppl(37):531-43. 
387. Masse LC, Fuemmeler BF, Anderson CB, Matthews CE, Trost SG, Catellier 
DJ, et al. Accelerometer data reduction: a comparison of four reduction algorithms 
on select outcome variables. Medicine and Science in Sports and Exercise. 
2005;37(11):S544-54. 
388. Hart TL, Swartz AM, Cashin SE, Strath SJ. How many days of monitoring 
predict physical activity and sedentary behaviour in older adults. International 
Journal of Behavioral Nutrition and Physical Activity. 2011;8:62. 
389. Matthews CE, Ainsworth BE, Thompson RW, Bassett Jr DR. Sources of 
variance in daily physical activity levels as measured by an accelerometer. Medicine 
and Science in Sports and Exercise. 2002;34(8):1376-81. 
390. Sewell L, Singh SJ, Williams JE, Morgan MD. Seasonal Variations Affect 
Physical Activity and Pulmonary Rehabilitation Outcomes. Journal of 
Cardiopulmonary Rehabilitation and Prevention. 2010;30(5):329-33. 
391. Kang M, Bassett DR, Barreira TV, Tudor-Locke C, Ainsworth B, Reis JP, et 
al. How many days are enough? A study of 365 days of pedometer monitoring. 
Research Quarterly for Exercise and Sport. 2009;80(3):445-53. 
392. Strycker LA, Duncan SC, Chaumeton NR, Duncan TE, Toobert DJ. 
Reliability of pedometer data in samples of youth and older women. International 
Journal of Behavioral Nutrition and Physical Activity. 2007;4(1):4. 
393. Rowe DA, Kemble CD, Robinson TS, Mahar MT. Daily Walking in Older 
Adults: Day-to-Day Variability and Criterion-Referenced Validity of Total Daily 
Step Counts. Journal of Physical Activity and Health. 2007;4(4):434-46. 
394. Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R. Are 
patients with COPD more active after pulmonary rehabilitation? Chest. 
2008;134(2):273-80. 
395. Jehn M, Schmidt-Trucksäss A, Meyer A, Schindler C, Tamm M, Stolz D. 
Association of daily physical activity volume and intensity with COPD severity. 
Respiratory Medicine. 2011;105(12):1846-52. 
396. Hartman JE, Boezen HM, de Greef MH, Bossenbroek L, ten Hacken NH. 
Consequences of physical inactivity in chronic obstructive pulmonary disease. 
Expert Review of Respiratory Medicine. 2010;4(6):735-45. 
397. Maltais F, LeBlanc P, Jobin J, Casaburi R. Peripheral Muscle Dysfunction in 
 203 
Chronic Obstructive Pulmonary Disease Clinics in Chest Medicine. 2000;21(4):665-
77. 
398. Casaburi R. Impacting patient-centred outcomes in COPD: deconditioning. 
European Respiratory Review. 2006;15(99):42-6. 
399. Katz P, Chen H, Omachi TA, Gregorich SE, Julian L, Cisternas M, et al. The 
role of physical inactivity in increasing disability among older adults with obstructive 
airway disease. Journal of Cardiopulmonary Rehabilitation and Prevention. 
2011;31(3):193-7. 
400. Waschki B, Kirsten A, Holz O, MÃžller K-C, Meyer T, Watz H, et al. 
Physical activity is the strongest predictor of all-cause mortality in patients with 
COPDPhysical activity and all-cause mortality in COPDA prospective Cohort Study. 
Chest. 2011;140(2):331-42. 
401. Wilmot E, Edwardson C, Achana F, Davies M, Gorely T, Gray L, et al. 
Sedentary time in adults and the association with diabetes, cardiovascular disease 
and death: systematic review and meta-analysis. Diabetologia. 2012;55(11):2895-
905. 
402. Black A, Coward W, Cole T, Prentice A. Human energy expenditure in 
affluent societies: an analysis of 574 doubly-labelled water measurements. European 
Journal of Clinical Nutrition. 1996;50(2):72-92. 
403. Eisner MD, Iribarren C, Blanc PD, Yelin EH, Ackerson L, Byl N, et al. 
Development of disability in chronic obstructive pulmonary disease: beyond lung 
function. Thorax. 2011;66(2):108-14. 
404. Garcia-Aymerich J, Félez MA, Escarrabill J, Marrades RM, Morera J, Elosua 
R, et al. Physical activity and its determinants in severe chronic obstructive 
pulmonary disease. Medicine and Science in Sports and Exercise. 2004;36(10):1667-
73. 
405. Coronado M, Janssens J-P, de Muralt B, Terrier P, Schutz Y, Fitting J-W. 
Walking Activity Measured by Accelerometry During Respiratory Rehabilitation. 
Journal of Cardiopulmonary Rehabilitation and Prevention. 2003;23(5):357-64. 
406. Ilgin D, Ozalevli S, Kilinc O, Sevinc C, Cimrin AH, Ucan ES. Gait speed as a 
functional capacity indicator in patients with chronic obstructive pulmonary disease. 
Annals of Thoracic Medicine. 2011;6(3):141-6. 
407. Park SK, Larson JL. The relationship between physical activity and metabolic 
syndrome in people with chronic obstructive pulmonary disease. The Journal of 
cardiovascular nursing. 2013;29(6):499-507. 
408. Benzo RP, Chang C-C, Farrell MH, Kaplan R, Ries A, Martinez FJ, et al. 
Physical activity, health status and risk of hospitalization in patients with severe 
chronic obstructive pulmonary disease. Respiration. 2010;80(1):10-8. 
409. Esteban C, Arostegui I, Aburto M, Moraza J, Quintana JM, Aizpiri S, et al. 
Influence of changes in physical activity on frequency of hospitalization in chronic 
 204 
obstructive pulmonary disease. Respirology. 2014;19(3):330-8. 
410. Vaes AW, Garcia-Aymerich J, Marott JL, Benet M, Groenen MT, Schnohr P, 
et al. Changes in physical activity and all-cause mortality in COPD. European 
Respiratory Journal. 2014:erj00232-2014. 
411. Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, et al. 
Prognostic Value of the Objective Measurement of Daily Physical Activity in 
Patients With COPDPhysical Activity and COPD Prognostic Measures. Chest. 
2012;142(2):338-46. 
412. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, 
Bourbeau J, et al. An official American Thoracic Society statement: update on the 
mechanisms, assessment, and management of dyspnea. American Journal of 
Respiratory and Critical Care Medicine. 2012;185(4). 
413. Gracely RH, Undem BJ, Banzett RB. Cough, pain and dyspnoea: similarities 
and differences. Pulmonary Pharmacology and Therapeutics. 2007;20(4):433-7. 
414. von Leupoldt A, Balewski S, Petersen S, Taube K, Schubert-Heukeshoven S, 
Magnussen H, et al. Verbal descriptors of dyspnea in patients with COPD at different 
intensity levels of dyspnea. Chest. 2007;132(1):141-47. 
415. Mador MJ, Kufel TJ. Reproducibility of visual analog scale measurements of 
dyspnea in patients with chronic obstructive pulmonary disease. American Review of 
Respiratory Disease. 1992;146(1):82-7. 
416. Alyami MM, Jenkins SC, Lababidi H, Hill K. Reliability and validity of an 
arabic version of the dyspnea-12 questionnaire for Saudi nationals with chronic 
obstructive pulmonary disease. Annals of Thoracic Medicine. 2015;10(2):112-17. 
417. Puhan MA, Behnke M, Frey M, Grueter T, Brandli O, Lichtenschopf A, et al. 
Self-administration and interviewer-administration of the German Chronic 
Respiratory Questionnaire: instrument development and assessment of validity and 
reliability in two randomised studies. Health and quality of life outcomes. 
2004;2(1):1. 
418. Tsuda T, Suematsu R, Kamohara K, Kurose M, Arakawa I, Tomioka R, et al. 
Development of the Japanese version of the COPD Assessment Test. Respiratory 
investigation. 2012;50(2):34-9. 
419. Jones P, Harding G, Berry P, Wiklund I, Chen W, Leidy NK. Development 
and first validation of the COPD Assessment Test. European Respiratory Journal. 
2009;34(3):648-54. 
420. Al-Moamary MS, Al-Hajjaj MS, Tamim HM, Al-Ghobain MO, Al-Qahtani 
HA, Al-Kassimi FA. The reliability of an Arabic translation of the chronic 
obstructive pulmonary disease assessment test. Saudi Medical Journal. 
2011;32(10):1028-33. 
421. Al Moamary MS, Tamim HM. The reliability of an arabic version of the self-
administered standardized chronic respiratory disease questionnaire (CRQ-SAS). 
 205 
BMC Pulmonary Medicine. 2011;11(1):21. 
422. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. 
Standardisation of spirometry. European Respiratory Journal. 2005;26(2):319-38. 
423. Al Ghobain MO, Alhamad EH, Alorainy HS, Al Hazmi M, Al Moamary MS, 
Al‐Hajjaj MS, et al. Spirometric reference values for healthy nonsmoking Saudi 
adults. The clinical respiratory journal. 2014;8(1):72-8. 
424. Jenkins S, Cecins NM. Six‐minute walk test in pulmonary rehabilitation: Do 
all patients need a practice test? Respirology. 2010;15(8):1192-6. 
425. Casanova C, Celli B, Barria P, Casas A, Cote C, De Torres J, et al. The 6-min 
walk distance in healthy subjects: reference standards from seven countries. 
European Respiratory Journal. 2011;37(1):150-6. 
426. Chinn S. Statistics in respiratory medicine. 2. Repeatability and method 
comparison. Thorax. 1991;46(6):454-6. 
427. Lee S, Lee JS, Song JW, Choi C-M, Shim TS, Kim TB, et al. Validation of 
the Korean version of chronic obstructive pulmonary disease assessment test (CAT) 
and Dyspnea-12 questionnaire. Tuberculosis and Respiratory Diseases. 
2010;69(3):171-6. 
428. Yorke J, Swigris J, Russell A-M, Moosavi SH, Kwong GNM, Longshaw M, 
et al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with 
interstitial lung disease. Chest. 2011;139(1):159-64. 
429. Yorke J, Armstrong I. The assessment of breathlessness in pulmonary arterial 
hypertension: reliability and validity of the Dyspnoea-12. European Journal of 
Cardiovascular Nursing. 2013:1474515113514891. 
430. Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression 
in patients with chronic obstructive pulmonary disease (COPD). A review. Nordic 
Journal of Psychiatry. 2004;58(1):65-70. 
431. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR. 
BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air 
hunger. Journal of Neurophysiology. 2002;88(3):1500-11. 
432. Tageldin MA, Nafti S, Khan JA, Nejjari C, Beji M, Mahboub B, et al. 
Distribution of COPD-related symptoms in the Middle East and North Africa: results 
of the BREATHE study. Respiratory medicine. 2012;106:S25-S32. 
433. Osman I, Godden D, Friend J, Legge J, Douglas J. Quality of life and hospital 
re-admission in patients with chronic obstructive pulmonary disease. Thorax. 
1997;52(1):67-71. 
434. Wijkstra P, Van Altena R, Kraan J, Otten V, Postma D, Koeter G. Quality of 
life in patients with chronic obstructive pulmonary disease improves after 
rehabilitation at home. European Respiratory Journal. 1994;7(2):269-73. 
 206 
435. Puhan MA, Behnke M, Laschke M, Lichtenschopf A, Brändli O, Guyatt GH, 
et al. Self-administration and standardisation of the chronic respiratory questionnaire: 
a randomised trial in three German-speaking countries. Respiratory Medicine. 
2004;98(4):342-50. 
436. Jones PW, Tabberer M, Chen W-H. Creating scenarios of the impact of 
COPD and their relationship to COPD Assessment Test (CAT™) scores. BMC 
Pulmonary Medicine. 2011;11(1):42. 
437. Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R, et al. Tests of 
the Responsiveness of the COPD Assessment Test Following Acute Exacerbation 
and Pulmonary RehabilitationCOPD Assessment Test Responsiveness. Chest. 
2012;142(1):134-40. 
438. Yorke J. 2011. 
439. Wassertheil-Smoller S. Biostatistics and epidemiology: a primer for health 
professionals. 2nd ed. Bronx: Springer Science & Business Media; 2013. 
440. Agustí A, Soler JJ, Molina J, Muñoz MJ, García-Losa M, Roset M, et al. Is 
the CAT questionnaire sensitive to changes in health status in patients with severe 
COPD exacerbations? COPD: Journal of Chronic Obstructive Pulmonary Disease. 
2012;9(5):492-8. 
441. Singh S, Sodergren S, Hyland M, Williams J, Morgan M. A comparison of 
three disease-specific and two generic health-status measures to evaluate the 
outcome of pulmonary rehabilitation in COPD. Respiratory Medicine. 
2001;95(1):71-7. 
442. Cohen J. Statistical power analysis for the behavioral sciences: Routledge 
Academic; 2013. 
443. He M, Yu S, Wang L, Lv H, Qiu Z. Efficiency and Safety of Pulmonary 
Rehabilitation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. 
Medical science monitor: international medical journal of experimental and clinical 
research. 2015;21:806-12. 
444. Chang C, Guo Z, Shen N, He B, Yao W, Zhu H, et al. Dynamics of 
inflammation resolution and symptom recovery during AECOPD treatment. 
Scientific Reports. 2014;4:1-5. 
445. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. 
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to 
evaluate severity of COPD exacerbations. American Journal of Respiratory and 
Critical Care Medicine. 2012;185(11):1218-24. 
446. Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, Rodríguez DA, Farrero 
E, de Batlle J, et al. Physical activity in COPD patients: patterns and bouts. European 
Respiratory Journal. 2013;42(4):993-1002. 
447. Macera C, Jones D, Yore M, Ham S, Kohl H, Kimsey Jr C, et al. Prevalence 
of physical activity, including lifestyle activities among adults-United States, 2000-
 207 
2001. Morbidity and Mortality Weekly Report. 2003;52(32):764, 6-9. 
448. Pitsavos C, Panagiotakos DB, Lentzas Y, Stefanadis C. Epidemiology of 
leisure-time physical activity in socio-demographic, lifestyle and psychological 
characteristics of men and women in Greece: the ATTICA Study. BMC Public 
Health. 2005;5(1):1. 
449. Teh K, Ong V. Physical activity patterns of Singaporeans in 2001. Singapore 
Medical Journal. 2004;45(11):517. 
450. Ham S, Yore M, Fulton J, Kohl III H. Prevalence of no leisure-time physical 
activity-35 states and the District of Columbia, 1988-2002. Morbidity and Mortality 
Weekly Report. 2004;53(4):82-6. 
451. Forrest K, Bunker CH, Kriska AM, Ukoli F, Huston SL, Markovic N. 
Physical activity and cardiovascular risk factors in a developing population. 
Medicine and Science in Sports and Exercise. 2001;33(9):1598-604. 
452. Al-Hamdan N, Kutbi A, Choudhry A, Nooh R, Shoukri M, Mujib S. WHO 
stepwise approach to NCD surveillance country-specific standard report Saudi 
Arabia. Organization WH (ed) WHO Stepwise Approach WHO: Geneva. 2005. 
453. Al-Zalabani AH, Al-Hamdan NA, Saeed AA. The prevalence of physical 
activity and its socioeconomic correlates in Kingdom of Saudi Arabia: A cross-
sectional population-based national survey. Journal of Taibah University Medical 
Sciences. 2015;10(2). 
454. Mabry R, Reeves M, Eakin E, Owen N. Evidence of physical activity 
participation among men and women in the countries of the Gulf Cooperation 
Council: a review. Obesity Reviews. 2010;11(6):457-64. 
455. Amin TT, Suleman W, Ali A, Gamal A, Al Wehedy A. Pattern, prevalence, 
and perceived personal barriers toward physical activity among adult Saudis in Al-
Hassa, KSA. J Phys Act Health. 2011;8(6):775-84. 
456. Samara A, Nistrup A, AL-Rammah TY, Aro AR. Lack of facilities rather 
than sociocultural factors as the primary barrier to physical activity among female 
Saudi university students. International journal of women's health. 2015;7:279. 
457. Nguyen HQ, Burr RL, Gill DP, Coleman K. Validation of the StepWatch 
device for measurement of free-living ambulatory activity in patients with chronic 
obstructive pulmonary disease. Journal of Nursing Measurement. 2011;19(2):76-90. 
458. Resnick B, Nahm E-S, Orwig D, Zimmerman SS, Magaziner J. Measurement 
of activity in older adults: reliability and validity of the Step Activity Monitor. 
Journal of Nursing Measurement. 2001;9(3):275-90. 
459. Coleman KL, Smith DG, Boone DA, Joseph AW, del Aguila MA. Step 
activity monitor: Long term, continuous recording of ambulatory function. Journal of 
Rehabilitation Research and Development. 1999;36:8-18. 
460. Shepherd EF, Toloza E, McClung CD, Schmalzried TP. Step activity 
 208 
monitor: Increased accuracy in quantifying ambulatory activity. Journal of 
Orthopaedic Research. 1999;17:703-8. 
461. White DK, Tudor‐Locke C, Zhang Y, Fielding R, LaValley M, Felson DT, et 
al. Daily Walking and the Risk of Incident Functional Limitation in Knee 
Osteoarthritis: An Observational Study. Arthritis Care and Research. 
2014;66(9):1328-36. 
462. Tudor-Locke C, Brashear MM, Kotzmarzyk PT, Johnson WD. Peak stepping 
cadence in free-living adults: 2005-2006 NHANES. Journal of Physical Activity and 
Health. 2012;9(8):1125-29. 
463. Hill K, Dolmage TE, Woon L, Coutts D, Goldstein R, Brooks D. Defining the 
relationship between average daily energy expenditure and field-based walking tests 
and aerobic reserve in COPD. Chest. 2012;141(2):406-12. 
464. Zwerink M, van der Palen J, van der Valk P, Brusse-Keizer M, Effing T. 
Relationship between daily physical activity and exercise capacity in patients with 
COPD. Respiratory Medicine. 2013;107(2):242-48. 
465. Moy ML, Teylan M, Weston NA, Gagnon DR, Garshick E. Daily step count 
predicts acute exacerbations in a US cohort with COPD. PloS One. 
2013;8(4):e60400. 
466. Tudor-Locke C, Rowe DA. Using cadence to study free-living ambulatory 
behaviour. Sports Medicine. 2012;42(5):381-98. 
467. Altenburg WA, Duiverman ML, Ten Hacken N, Kerstjens HA, de Greef MH, 
Wijkstra PJ, et al. Changes in the endurance shuttle walk test in COPD patients with 
chronic respiratory failure after pulmonary rehabilitation: the minimal important 
difference obtained with anchor-and distribution-based method. Respiratory 
Research. 2015;16:27. 
468. Kawagoshi A, Kiyokawa N, Sugawara K, Takahashi H, Sakata S, Satake M, 
et al. Effects of low-intensity exercise and home-based pulmonary rehabilitation with 
pedometer feedback on physical activity in elderly patients with chronic obstructive 
pulmonary disease. Respiratory Medicine. 2015;109(3):364-71. 
469. Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, et al. 
Pedometers to enhance physical activity in COPD: a randomised controlled trial. 
European Respiratory Journal. 2015;45(2):347-54. 
470. Moy ML, Weston NA, Wilson EJ, Hess ML, Richardson CR. A pilot study of 
an Internet walking program and pedometer in COPD. Respiratory Medicine. 
2012;106(9):1342-50. 
471. Hospes G, Bossenbroek L, ten Hacken NH, van Hengel P, de Greef MH. 
Enhancement of daily physical activity increases physical fitness of outclinic COPD 
patients: results of an exercise counseling program. Patient Education and 
Counseling. 2009;75(2):274-8. 
472. Wewel AR, Gellermann I, Schwertfeger I, Morfeld M, Magnussen H, Jörres 
 209 
RA. Intervention by phone calls raises domiciliary activity and exercise capacity in 
patients with severe COPD. Respiratory Medicine. 2008;102(1):20-6. 
473. Gonzales JU, Kumar P, Shephard J, Means A. Peak stepping cadence is 
associated with leg vascular compliance in young adults. Journal of Science and 
Medicine in Sport. 2014;17(6):683-7. 
474. Al-Hazzaa HM, Abahussain NA, Al-Sobayel HI, Qahwaji DM, Musaiger 
AO. Physical activity, sedentary behaviors and dietary habits among Saudi 
adolescents relative to age, gender and region. Int J Behav Nutr Phys Act. 
2011;8(1):140. 
475. Ham SA, Kruger J, Tudor-Locke C. Participation by US adults in sports, 
exercise, and recreational physical activities. Journal of physical activity & health. 
2009;6(1):6. 
476. Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S. Palliation 
of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 
2009;64(10):910-15. 
477. Tang CY, Taylor NF, Blackstock FC. Patients admitted with an acute 
exacerbation of chronic obstructive pulmonary disease had positive experiences 
exercising from the beginning of their hospital stay A qualitative analysis. Chronic 
Respiratory Disease. 2013;10(4):197-205. 
 
  
 210 
I would be very pleased to hear from any copyright owner who has been omitted or 
incorrectly acknowledged.  
 211 
APPENDICES 
Appendix A:  Dyspnoea- 12 questionnaire English version  
Dyspnoea-12 
This questionnaire is designed to help us learn more about how your breathing 
is troubling you. 
Please read each item and then tick in the box that best matches your breathing these 
days. 
If you do not experience an item tick the ‘none’ box. Please respond to all items. 
Individual number: .......................                                         Date: ..... /..... /..... 
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Appendix B:  The back- translation version (first independent translator) 
Dyspnoea-12 
This questionnaire is designed to help us learn more about how your breathing 
is troubling you. 
Please read each item and then tick in the box that best matches your breathing these 
days. 
If you do not experience an item tick the ‘none’ box. Please respond to all items. 
Individual number: .......................                                         Date: ..... /..... /..... 
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Appendix C:  The back- translation version (second independent translator) 
Dyspnoea-12 
This questionnaire is designed to help us learn more about how your breathing 
is troubling you. 
Please read each item and then tick in the box that best matches your breathing these 
days. 
If you do not experience an item tick the ‘none’ box. Please respond to all items. 
Individual number: .......................                                         Date: ..... /..... /..... 
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 eriannoitseuq 21-aeonpsyD fo noisrev cibarA ehT  :D xidneppA
 
 ضيق التنفس-۱۲
 
 التنفس ضيق لك يسببه الذي الإزعاج مدى على عرفالت على مساعدتنا بهدف الاستبيان هذا صمم
 لم إذا الايام. هذه تنفسك بحالة يتعلق فيما خيار أفضل مع يتناسب الذي المربع في علامة وضع و فقرة لك قراءة الرجاء
 الفقرات. جميع على الاجابة يرجى (لايوجد). المربع في علامة ضع أدناه المذكورة الحالات أحدى من تعاني تكن
                                                   التاريخ:.../.../...                                       الشخص:.................................. رقم
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Appendix E:  The mean scores for domains of Chronic Respiratory Disease 
Questionnaire for all participants (n = 29) 
 
     
   
Mean scores obtained for: A) fatigue, B) emotional function and C) mastery domains 
of the Chronic Respiratory Disease Questionnaire for all participants as one group. 
Data are mean and standard error. *Statistically significant difference (p < 0.05) 
difference from the final administration (day 98). † No significant difference 
between consecutive administrations.  
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Appendix F:  The mean scores for the domains of the Chronic Respiratory 
Disease Questionnaire for the participant who did not have re-exacerbations (n 
= 22) 
      
 
 
Mean scores obtained for: A) fatigue, B) emotional function and C) mastery domains 
of the Chronic Respiratory Disease Questionnaire for The participant who did not 
have re-exacerbations. Data are mean and standard error. *Statistically significant 
difference (p < 0.05) difference from the final administration (day 98). † No 
significant difference between consecutive administrations.  
